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Abstract	
Previous	work	using	immortalised	cells	transfected	with	a	NF-κB	reporter	and	challenged	with	zymosan,	 to	mimic	 a	 fungal	 infection,	 suggested	 possible	 co-operation	 between	Dectin-1	 and	TLR5	 receptors	 in	 urogenital	 tissues.	 These	 data	 were	 interesting	 as	 research	 describing	Dectin-1R	 functioning	 relates	 specifically	 to	 myeloid	 derived	 cells	 and	 TLR5,	 classically,	 is	known	 to	 function	 as	 a	 homodimer.	 The	 aim	 of	 the	 research	 reported	 in	 this	 thesis	 was	therefore	 to	 focus	 on	 the	 Dectin-1	 and	 TLR5	 receptors	 in	 the	 bladder	 urothelium,	 with	 the	objective	 of	 investigating	Dectin-1	 receptor	 functioning,	 Dectin1/TLR5	 receptor	 co-operation	and	cell	signalling	events	following	a	zymosan	(β-glucan)	challenge.	Western	 analyses	 of	 cell	 lysates	 from	 a	 bladder	 biopsy	 and	 immortalised	 RT4	 bladder	 cells	using	 a	 Dectin-1R	 antibody	 (R&D	 systems,	 AF1859)	 revealed	 the	 synthesis	 of	 proteins	representing	 full-length	 and	 truncated	 (stalk-less)	 Dectin-1	 receptors.	 These	 data	 supported	the	 use	 of	 the	 immortalised	 RT4	 cells	 in	 all	 subsequent	 analyses	 exploring	 Dectin-1R	functioning	 in	 the	 urothelial	 tissues.	 Following	 challenge	 of	 the	 cells	with	 the	 yeast	 cell	wall	extract	 zymosan	 (50ug/ml)	 increased	 synthesis	 of	 an	 array	 of	 host	 defence	 agents	 including	hBD2,	 IL-8	 and	 LCN2	 were	 observed	 (p<0.05).	 Furthermore	 IL-8	 effector	 synthesis	 was	significantly	 reduced	 following	 CLEC7A	 (Dectin-1R)	 gene	 knockdown	 (p<0.05)	 and	 antibody	blocking	 of	 the	 Dectin-1R	 (p<0.01).	 These	 data	 supported	 synthesis	 of	 the	 Dectin-1R	 in	urothelial	cells	and	a	role	in	defending	the	bladder	against	a	fungal	challenge.	Knocking-down	 the	TLR5	 gene	 in	RT4	 cells	 (80%	knockdown)	 and	 challenging	 the	 cells	with	zymosan,	resulted	 in	a	significant	reduction	 in	hBD2,	 IL8	and	LCN2	synthesis	(p<0.05).	These	data	suggested	co-operation	between	the	Dectin-1	and	TLR5	receptors	in	bladder	cells,	which	was	supported	by	 immunostaining	and	a	proximity	 ligation	assay	approach.	 In	addition	these	analyses	supported	clustering	of	the	Dectin-1	and	TLR5	receptors	following	activation.		Experiments	 to	 explore	 roles	 for	 the	 encoded	 Dectin-1	 receptor	 isoforms,	 1,	 2	 and	 4,	 in	 the	TLR5	co-operation	events	involved	engineering	a	suite	of	stable	cell	lines	each	over-expressing	a	 Dectin-1	 receptor	 isoform	 and	 either	 a	 TLR5	 full-length	 or	 TLR5	 truncated	 receptor.	 This	approach	 exploited	 the	 pVitro2-neo-mcs	 vector,	 which	 is	 able	 to	 co-express	 two	 cDNA	sequences	simultaneously.	However,	 the	resultant	cell	 lines	did	not	over-express	the	Dectin-1	and	TLR5	receptors.			It	was	hypothesised	that	the	increased	number	of	receptors	synthesised	by	the	cells	over-loaded	the	urothelial	cell	membranes	causing	gene	silencing	and/or	cell	death.				The	 signalling	 mechanisms	 activating	 the	 transcription	 of	 host	 effector	 genes	 following	 a	zymosan	challenge	of	RT4	bladder	cells	were	explored	using	western	analyses	and	an	antibody	to	 Syk-P	 (Cell	 Signalling,	 C87C1),	 SYK	 gene	 knockdown	 and	 piceatannol	 (100	 ug/ml)	 a	 Syk	inhibitor	 followed	 by	 ELISA	 to	 measure	 LCN2	 and	 IL-8	 media	 concentrations.	 No	phosphorylation	 of	 Syk	 was	 observed	 and	 the	 knock-down/inhibition	 approaches	 had	 no	significant	effects	on	the	media	concentrations	of	either	IL-8	or	LCN2.	However,	knockdown	of	the	RAF1	 gene	 resulted	 in	 decreased	 secretion	 of	 the	 host	 defence	molecules	 LCN2	 and	 IL-8	(p<0.01).	Additionally	western	blot	 analyses	 showed	phosphorylation	and	degradation	of	 the	NF-κB	inhibitor	IκBα.	These	data	suggested	that	Dectin-1R	activation	in	response	to	zymosan	in	bladder	cells	involved	Raf-1	signalling,	which	supported	a	non-canonical	signalling	pathway.		In	summary,	Dectin-1	receptors	were	shown	to	be	synthesized	 in	RT4	bladder	epithelial	cells	and	were	 activated	 in	 response	 to	 zymosan	 (fungal)	 challenge	 resulting	 in	 the	 production	 of	host	 defence	 effector	 molecules.	 Data	 showed	 potential	 co-operation	 between	 Dectin-1	 and	TLR5	receptors	 in	mediating	the	bladder	cell	response.	Dectin-1R	signalling	in	urothelial	cells	was	 also	 orchestrated	 via	 a	 non-canonical	 signalling	 pathway	 involving	 Raf-1.	 These	 data	support	 a	 novel	 host	 defence	mechanism,	 involving	Dectin-1	 and	TLR5	 receptors	 functioning	co-operatively,	to	defend	urothelial	from	fungal	infections.	 	
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Chapter	1 .	Introduction	
The	urinary	 tract	 comprises	 the	kidneys	 and	ureters	 (upper	urinary	 tract)	 and	bladder	 and	 urethra	 (lower	 urinary	 tract)	 and	 its	 key	 function	 is	 to	 remove	metabolites	and	toxic	waste	products	from	the	body,	which	it	does	through	urine	[1].	Urine	 is	produced	 in	 the	kidneys,	of	which	nephrons	are	the	key	 functional	units,	 and	 on	 entering	 the	 ureters	 is	 devoid	 of	 essential	 metabolites	 including	glucose	 and	 amino	 acids,	 but	 high	 in	 organic	 waste	 materials	 including	 urea,	creatinine	and	uric	acid.		Ureters	are	tubes,	20-30	cm	in	length,	comprising	smooth	muscle	material	lined	by	a	specialised	layer	of	epithelial	cells	called	the	urothelium.		The	function	of	the	ureters	is	to	act	as	a	conduit	that	allows	the	continuous	removal	of	urine	from	its	site	of	production,	the	kidney,	to	the	bladder.	A	typical	human	bladder,	which	is	tetrahedral	 in	shape	when	empty	but	ovoid	on	 filling	can	hold	300	–	500	ml	of	urine	 so	 it	 acts	 as	 a	 collecting	vessel	 storing	urine,	until	 its	 expulsion	 from	 the	body.		The	periodic	release	of	urine	or	flushing	of	urine	from	the	bladder	plays	a	key	 role	 in	 protecting	 the	 urinary	 tract	 from	 microbial	 infection.	 This	 is	particularly	 important	as	 the	opening	of	 the	urinary	 tract	 to	 the	exterior	of	 the	body	 is	 sited	 close	 to	 the	 anus,	 which	 means	 the	 urinary	 tract	 is	 constantly	challenged	by	significant	populations	of	gut	and	skin	microbes.		The	 urinary	 tract	 from	 ureters	 to	 urethra	 is	 lined	 by	 a	 specialised	 epithelium	called	the	urothelium,	although	there	is	data	to	suggest	differences	between	the	urothelia	 lining	 the	ureters	and	 the	bladder	 [1].	 In	 fact	 results	of	 tissue	culture	analyses	 support	 the	 ureteral	 urothelium	 to	 contain	 reduced	 amounts	 of	 cell	surface	proteins	called	uroplakins	and	apically	located	membrane	vesicles,	called	fusiform	vesicles,	compared	to	bladder	[2,	3].	This	difference	most	likely	relates	to	 the	embryological	origin	of	 these	 tissues	with	 the	ureteral	urothelium	being	derived	 from	mesoderm	 and	 the	 bladder,	 and	 urethra	 urothelia	 being	 derived	from	the	endoderm	[4,	5].	Studies	 involving	 electron	 microscopy	 and	 immune-histochemical	 analyses	indicate	 the	 urothelium	 to	 be	 composed	 of	 distinct	 layers	 including	 basal,	intermediate	 and	 superficial/umbrella	 layers	 (Figure	 1.1).	 It	 is	 a	 slow	 cycling	
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epithelium	with	 turnover	rates	of	up	 to	200	days,	which	probably	relates	 to	 its	functioning	 as	 a	 highly	 efficient	 permeability	 barrier	 that	 protects	 the	 body	against	 any	 toxic	 materials	 in	 urine	 [6].	 A	 trans-epithelial	 resistance	 of	 up	 to	75,000	Ω/cm2	has	 been	 reported	 making	 it	 a	 more	 efficient	 barrier	 than	 skin	epidermis	[6].	Although	the	turnover	rate	of	the	urothelium	is	slow	it	is	quick	to	regenerate	when	damaged.	For	example	following	the	loss	of	umbrella	cells	due	to	 infection	 and/or	 senescence	 the	 underlying	 intermediate	 cells	 differentiate	into	 umbrella	 cells	 a	 process,	 which	 is	 also	 accompanied	 by	 tight-junction	formation	[7].			
	
Figure	1.1	Structure	of	urinary	bladder.		Urinary	bladder	is	composed	of	basal	urothelial	cell,	intermediate	urothelial	cells	and	superficial	urothelial	cells	[8].		The	urothelium	also	needs	flexibility	so	 it	can	increase	and	decrease	 its	surface	area	during	the	micturition	cycle.	Flexibility	is	achieved	through	the	presence	of	urothelial	plaques,	which	are	concave	structures	that	cover	approximately	90%	of	the	urothelial	apical	surface	(Figure	1.2)	and	are	present	in	fusiform	vesicles	in	the	 cytoplasm	 of	 superficial	 umbrella	 cells.	 The	 plaques	 themselves	 are	composed	 of	 four	 uroplakin	 building	 blocks	 comprising	 uroplakin	 1a	 (27kDa),	uroplakin	 1b	 (28kDa),	 uroplakin	 II	 (15kDa)	 and	 uroplakin	 IIIa	 (47kDa).	 Ion	exchange	 chromatography	 and	 transfection	 studies	 suggest	 these	 proteins	 to	form	 two	 heterodimers,	 UPIa/II	 and	 UPIb/IIIa	 [9].	 The	 importance	 of	 these	heterodimers	in	the	urothelium	has	been	shown	through	mice	transgenic	studies	where	UPII	or	UPIIIa	gene	knock-outs	were	associated	with	the	loss	of	urothelial	
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plaques	 [10].	 In	 addition	 their	 roles	 in	 permeability	were	 confirmed	by	Ussing	chamber	experiments	that	revealed	urothelia	taken	from	knock-out	mice	showed	increased	permeability	to	14C-urea	and	3H	water	[6].			
	
Figure	1.2	Urothelial	plaques.		A:	 Electron	 microscopy	 image	 of	 bladder	 showing	 urothelial	 surface;	 B:	reconstruction	of	urothelial	plaque.	Taken	from	[11].		It	is	also	known	that	a	glycosaminoglycan	(GAG)	layer	lines	the	luminal	surface	of	the	 urinary	 tract.	 GAGs	 are	 polysaccharide	 molecules	 that	 contain	 repeating	disaccharide	 units	 and	 are	 reported	 to	 function	 in	 creating	 an	 impermeable	barrier	 to	 charged	 and	 uncharged	 molecules	 present	 in	 urine,	 and	 inhibiting	bacterial	 attachment	 [12,	 13].	 There	 are	 four	 families	 of	 GAGs	 including	 the	chondroitin	and	dermatan	sulphate	family,	heparin	and	heparan	sulphate	family,	the	 keratan	 sulphate	 family	 and	 hyaluronate.	 The	 presence	 of	 sulphur	 is	associated	 with	 anti-proliferative	 effects	 suggesting	 that	 the	 presence	 of	sulphated	 GAGs	 in	 urothelia	 helps	 maintain	 a	 quiescent	 cell	 phenotype	 [14].	Interestingly,	GAG	instillations	have	been	found	to	be	linked	to	fewer	episodes	of	urinary	tract	infections	in	women	and	longer	periods	between	infections	[15].			
A	 B	
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1.1 Urinary	microbiome	Historically	the	urinary	tract	was	considered	to	be	sterile	in	healthy	individuals.	However,	 the	 use	 of	molecular	 techniques	 including	 16S	RNA	 sequencing	 have	revealed	 the	 urinary	 tract	 to	 be	 colonised	 and	 carry	 a	 natural	 microbiota.		Microbes	 identified	 in	 healthy	 men	 and	 women	 include	 Lactobacillus	 spp,	
Streptococcus	spp,	Prevotella	spp,	Sneathia	spp,	Mycoplasmas,	Ureaplasmas,	 and	
Gardnerella	 spp	 [16,	 17].	 As	 expected	 a	 change	 in	 diversity	 of	 microbiota	 can	correlate	with	some	diseases	[18]	with	key	example	being	the	loss	of	Lactobacilli	during	 the	menopause	associated	with	 increased	 infections	of	 the	urinary	 tract	by	 	 Escherichia	 coli	 [19],	 although	 more	 recent	 work	 has	 challenged	 this	relationship	 [20].	 While,	 lately,	 significant	 research	 has	 focussed	 on	 the	 gut	microbiota	and	its	roles	in	health	and	disease	there	is	in	comparison	little	work	exploring	 the	 role(s)	 of	 the	 microbiota	 in	 the	 urinary	 tract.	 It	 is	 possible	 to	speculate	 however,	 that	 the	 urinary	microbiome	 functions	 similarly	 to	 the	 gut	microbiota	including	priming	the	innate	immune	system	and	creating	a	barrier	to	potential	 pathogenic	 microbes	 from	 the	 faeces	 contaminating	 the	 urethra	 and	ascending	the	urinary	tract.		Initial	 characterisations	 of	 the	 human	 mycobiome	 have	 utilised	 culture	 based	systems	 mainly	 to	 identify	 pathogenic	 species	 including	 Candida	 albicans,	
Aspergillus	 fumigatus	 and	 Coccidiodes	 spp.	 Again	 however,	 new	 non-culture-based	techniques	including	next	generation	sequencing	are	being	used	to	identify	fungal	 species	 or	 the	 mycobiome	 colonising	 the	 urinary	 tract	 [21].	 To	 date,	 a	significant	 diversity	 of	 fungi	 including	 Dothideomycetes,	 Eurotiomycetes,	
Saccharomycetes,	 which	 includes	 Candida	 spp,	 and	 Orbiliomycetes	 (actually	 16	classes	relating	to	12	women	with	no	reported	urinary	issues	were	recorded)	has	been	 revealed	 in	 clean–catch	mid-stream	 urine	 samples,	 of	 which	 no	 one	 taxa	showed	dominance.			
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1.2 Urinary	tract	infections	As	stated	a	diverse	variety	of	microorganisms	can	colonise	the	urinary	tract	and	many	do	 so	without	 causing	 infection.	However,	 infections	 of	 the	 urinary	 tract	are	 common	with	 statistics	 indicating	 that	25	 to	50	%	of	women	will	 suffer	an	urinary	tract	infection	at	least	once	in	their	lifetime	[22].		Female	susceptibility	is	linked	primarily	to	the	female	anatomy	and	shortness	of	the	urethra,	which	is	4-5	cm	in	women	compared	to	approximately	20	cm	in	males	[23].	Additionally	20	to	50	%	 of	 women	 reporting	 an	 UTI	 will	 develop	 recurrent	 UTI	 (rUTI),	 which	 is	characterized	as	 three	or	more	 infections	 in	12	months	or	 two	 infections	 in	six	months	 [24].	 UTIs	 in	men	 and	 children	 are	 observed,	 but	 these	 are	much	 less	prevalent	 at	 0.1	%	 and	 up	 to	 6.4	%	 respectively.	 These	 infections	 are	 often	 a	consequence	of	some	anatomical	disorder	of	 the	urinary	 tract	 [22]	and	as	such	are	described	as	complicated	UTIs.		In	the	majority	of	uncomplicated	UTI	cases	the	predominant	infecting	microbe	is	
Escherichia	 coli,	 which	 originates	 from	 the	 gastro-intestinal	 tract	 and	contaminates	the	urinary	tract	(UT)	via	the	faecal	material.	In	the	urinary	tract	it	is	known	as	uropathogenic	E.	coli	(UPEC).	Figure	1.3	demonstrates	the	mechanism	by	which	E.	coli	infects	the	urinary	tract.	Essentially	 E.	 coli	 (UPEC)	 from	 the	 anus	 colonise	 the	 urethra	 and	 infect	 the	bladder	resulting	in	cystitis	[25].	These	bacteria	can,	 in	certain	individuals,	also	migrate	 through	 ureters	 to	 the	 kidney	 where	 they	 cause	 pyelonephritis	 and	blood	sepsis,	which	can	result	in	death	[26].		UPEC	are	generally	flagellated	and	work	in	mice	has	shown	that	flagella	are	key	virulence	 factors	 that	 allow	 the	 bacteria	 to	 ascend	 and	 infect	 the	 urinary	 tract	[27].	 UPEC	 also	 use	 surface	 adhesins,	 called	 FimH	 proteins,	 to	 interact	 with	uroplakins	UPIa/Ib	on	the	urothelium,	which	prevents	them	from	being	flushed	out	during	micturition.	Murine	studies	have	suggested	UPEC	can	actually	invade	the	urothelial	cells	and	form	intracellular	bacterial	communities	(IBC).	These	IBC	contain	metabolically-active	bacteria	that	are	either	able	to	 infect	adjacent	cells	or	 form	 non-replicating	 quiescent	 intracellular	 reservoirs	 (IQR)	 	 [6].	 It	 is	proposed	 that	 in	 response	 to	a	 stimulus,	potentially	weeks	or	months	after	 the	
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initial	 infection	 and	 probably	 involving	 cell	 turnover	 these	 bacterial	 reservoirs	emerge	to	start	a	new	acute	infection.	Interestingly	although	the	IBC/QIR	model	has	been	demonstrated	in	multiple	mouse	backgrounds	there	is	limited	evidence	to	support	its	functioning	in	humans	[28-30].				
E.	 coli	 accounts	 for	 up	 to	 80%	 of	 non-complicated	 UTIs	 [22].	 Other	 common	species	of	bacteria	linked	to	UTIs	are	Enterococcus	faecalis,	Klebsiella	pneumonia	and	 Proteus	 mirabilis	 [31],	 although	 many	 of	 these	 infections	 are	 classed	 as	complicated	and	involve	catheters	or	a	pathology	such	as	diabetes.		Antibiotic	 treatment	 is	 the	most	 common	method	 to	 treat	 UTIs.	 However,	 the	constant	use	of	antibiotics	is	known	to	promote	antimicrobial	resistance.	This	is	supported	 by	 data	 that	 shows	 35	 to	 75	%	 of	 uropathogenic	E.	 coli	 strains	 are	resistant	 to	 the	antibiotic	 trimethoprim,	which	 is	 commonly	used	 to	 treat	UTIs	[32-34].	In	the	UK	and	Europe	antibiotic	stewardship	and	reduction	of	antibiotic	prescriptions	are	key	political	targets	[35].	This	means	there	is	a	desperate	need	to	 further	 understand	 the	 defences	 of	 the	 urinary	 tract	 to	 help	 develop	 new	therapies	to	either	replace	or	work	alongside	antibiotics	in	the	treatment	of	UTIs.		
Candida	albicans	is	the	most	common	cause	of	fungal	infections	of	the	uro-genital	tract	 [36],	 and,	 interestingly	 is	 often	 associated	 with	 long-term	 antibiotic	therapies.	This	yeast	often	exists	in	the	uro-genital	tract	as	a	commensal,	but	can	become	a	pathogen	especially	in	immunocompromised	individuals	[37].	In	fact	a	one	day	surveillance	in	228	hospitals	from	29	European	countries	indicated	that		9.4%	 of	 UTIs	 were	 caused	 by	 a	 Candida	 fungal	 infection	 [38].	 However,	 these	cases	 mainly	 included	 a	 mix	 of	 immunocompromised,	 diabetes	 and	 renal	transplant	patients,	neonates,	the	elderly,	those	in	burn	and	intensive	care	units	as	well	as	those	on	long-term	antibiotic	therapies.		
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Figure	1.3	Anatomy	of	the	urinary	tract	and	sites	of	infection.		Diagram	adapted	from	Kaper	et	al.	(2004)	[39].	
	
1.3 The	innate	defences	of	the	Urinary	Tract	Protection	 of	 the	 urinary	 tract	 is	 through	 innate	 defence	 mechanisms.	 These	include	the	flushing	action	of	urine	and	the	constitutive	and	regulated	synthesis	of	host	defence	peptides	and	proteins	including	β-defensin-1	(HBD1),	β-defensin-2,	 lipocalin	 2	 (LCN2),	 RNase	 7,	 cathelicidin	 and	 Tamm-Horsfall	 protein,	 all	 of	which	function	to	limit	bacterial	growth	[40,	41].		In	addition	urothelial	detection	of	potential	pathogens	also	 triggers	 the	secretion	of	cytokines	and	chemokines,	including	 IL-8,	 which	 is	 associated	 with	 the	 migration	 of	 macrophages	 and	neutrophils	to	the	infected	site	[42,	43],	and	which	function	to	facilitate	bacterial	clearance	[44,	45].			
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1.4 Defensins			Beta-defensins	are	a	family	of	hydrophobic,	cationic	host	peptides	(3	to	5	kDa	in	size)	 that	 function	by	 forming	pores	 in	prokaryote	membranes	 that	 causes	 cell	lysis.	Their	effectiveness	as	killing	agents	relates	specifically	to	their	charge	and	hydrophobicity,	which	 allows	 them	 to	 target	 and	 kill	 gram-negative	 and	 gram-positive	 bacteria,	 fungi	 as	 well	 as	 enveloped	 viruses	 [46-49].	 Their	 positive	charge	reflects	a	high	number	of	arginine	and	lysine	amino	acids,	which	interact,	through	 electrostatic	 interactions,	 with	 the	 negatively	 charged	 membranes	 of	bacteria.	 Their	 hydrophobicity	 then	 allows	 the	 peptides	 to	 insert	 into	 the	bacterial	 membranes	 creating	 pores	 that	 result	 in	 bacterial	 killing	 [50,	 51].	However,	 membrane	 disruption	 is	 not	 the	 only	 role	 of	 defensins;	 it	 has	 been	shown	that	defensins	can	kill	fungi	by	promoting	ROS	production	and	apoptosis	[49].	The	 defensin	 family	 of	 peptides	 are	 characterised	 by	 six	 conserved	 cysteine	residues,	which	form	three	di-sulfide	bridges.	The	family	in	humans	includes	α-defensins	 and	 β-defensins,	 which	 differ	 in	 their	 di-sulfide	 (C-C)	 bridges	 [52].	Alpha-defensins	 are	 characterised	 by	 C1-C6,	 C2-C5	 and	C3-C4	bridges	while	 β-defensins	are	characterised	by	C1-C5,	C2-C6	and	C3-C4	bridges	(Figure	1.4).	It	is	known	 that	 the	urothelium	synthesises	human	β-defensins	1,	 2	 and	3	 [41,	 53],	with	data	from	clinical	and	in-vitro	studies	identifying	human	β-defensin-2	(hBD-2),	which	is	induced	in	response	to	infection,	as	a	key	antimicrobial	factor	in	the	protection	of	the	urogenital	tract	[54,	55].			
	
Figure	1.4	Di-sulfide	bridges	in	α-defensin	and	β-defensin	peptides.		Di-sulfide	 bonds	 are	 showed	 as	 solid	 lines.	 Diagram	 adapted	 from	 Ganz	 et	 al.	(2003)	[56].		
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1.5 Other	antimicrobial	molecules	in	the	urinary	tract	Another	 key	 molecule	 protecting	 the	 urinary	 tract	 is	 lipocalin	 2	 (LCN2)	 also	known	as	NGAL.	This	molecule	limits	bacterial	growth	by	sequestering	iron	[57],	which	 is	 a	 key	 microbial	 growth	 factor.	 Microbes	 sequester	 iron	 through	synthesis	 of	 siderophores	 [58]	 and	 	 LCN2	 synthesised	 by	 the	 host	 binds	 to	bacterial	siderophores	preventing	iron	uptake	and	limiting	bacterial	infection.	A	specific	 role	 for	 LCN2	 in	 protecting	 against	 fungal	 infections	 has,	 to	 date,	 not	been	 investigated	 extensively.	 However,	 upregulation	 of	 LCN2	 has	 been	demonstrated	following	Candida	infection	[59].	Cathelicidin	 is	 a	 linear	 antibacterial	 peptide	 secreted	 by	 epithelial	 cells.	 It	 is	encoded	 by	 the	 CAMP	 gene	 as	 a	 pro-peptide	 also	 known	 as	 pro-LL-37.	 Once	secreted	 it	 is	cleaved	 into	cathelin	and	LL-37,	both	of	which	have	antimicrobial	and	 antifungal	 properties	 [60-62].	 Like	 the	 defensins	 cathelicidin	 prevents	bacterial	 and	 fungal	 infection	by	pore	 formation	 [63]	 although	 it	has	also	been	shown	to	function	by	inhibiting	bacterial	division	[64].	More	recently	cathelicidin	has	been	described	as	a	potent	immunomodulatory	agent,	including	functioning	to	amplify	TLR9	and	TLR3	activation	[65].	Although	suggested	to	be	a	significant	protector	 of	 the	 urinary	 tract	 from	 bacterial	 infection	 [66]	 laboratory	investigations	 using	RT4	bladder	 cells	 have	 failed	 to	 identify	 expression	 of	 the	
CAMP	gene	(unpublished	data).				RNases	 are	 another	 family	 of	 cationic	 molecules,	 functioning	 to	 defend	 the	urinary	 tract	 from	 infection	 and	 one	 member	 RNase	 7	 is	 synthesised	 by	 the	urothelium	 [67].	 As	 with	 other	 cationic	molecules	 RNase	 7	 is	 proposed	 to	 kill	bacteria	through	targeting	and	disrupting	their	microbial	membrane	[68,	69].	Tamm-Horsfall	 protein	 or	 uromodulin	 is	 an	 abundant	 glycoprotein	 found	 in	urine	and	also	a	key	defender	of	the	urinary	tract.	While	Tamm-Horsfall	proteins	are	found	in	urine,	they	result	from	the	expression	of	the	UMOD	gene	and	protein	synthesis	 in	 the	 kidney	 tissues.	 They	 are	 known	 to	 function	 by	 preventing	bacterial	adhesion	to	uroplakin	receptors	Ia	and	Ib	on	urothelial	cells	[70].		
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1.6 Pathogen	recognition	receptors	Secretion	of	host	defence	peptides	and	proteins	in	the	urinary	tract	is	stimulated	through	the	activation	of	pathogen	recognition	receptors	(PRRs)	including	Toll-like	receptors	 (TLRs)	and	C-type	 lectin	receptors	 [71,	72].	PRRs	are	part	of	 the	host	 innate	 defences	 and	 recognise	 components	 of	 microbes	 called	 pathogen-associated	molecular	patterns	(PAMPs).	These	PPRs	are	expressed	by	epithelial	cells	 as	 well	 as	 antigen	 presenting	 cells,	 including	 dendritic	 cells,	 monocytes,	macrophages	and	neutrophils,	involved	in	the	innate	response	[71,	73].		
1.7 Toll-like	receptors	In	humans	ten	functional	Toll-like	receptors	(TLRs)	have	been	identified	to	date	[74]	although	in	mice	this	number	is	13	with	TLRs	11,	12	and	13	unique	to	the	mouse	[75].	TLRs	are	located	on	the	plasma	membrane	and	in	the	cytoplasm	of	epithelial	and	antigen	presenting	cells,	and	function	to	detect	potential	pathogens	and	activate	a	host	response.		Receptor	recognition	and	binding	of	different	bacterial,	viral	and	fungal	molecules	or	PAMPS	including	lipopolysaccharides,	flagellin,	nucleic	acids	and	peptidoglycans	activates	signalling	pathways	resulting	in	the	expression	of	genes	encoding	an	array	of	host	defence	molecules	including	antimicrobial	peptides	such	as	the	β-defensins	and	pro-inflammatory	proteins	such	as	IL-8	[75].		Table	1.1	lists	the	13	TLRs	and	the	microbial	components	recognised	by	each.	Toll-like	receptors	assemble	into	homo-	or	heterodimers	to	bind	ligands	and	initiate	signalling	cascades	that	result	in	the	host	response.	It	has	been	shown	that	while	TLR-1,	TLR-2,	TLR4	and	TLR-6	operate	as	heterodimers	[76,	77],	TLR-5	functions	only	as	a	homodimer	[78,	79].					
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Table	1.1	Toll-like	receptors	and	their	ligands.			
Receptor	 Localisation	 Ligand	TLR-1	 Plasma	membrane	 Lipoproteins	and	peptidoglycans	TLR-2	 Plasma	membrane	 Peptidoglycans	TLR-3	 Endosome	 Double-stranded	RNA	TLR-4	 Plasma	membrane	 Lipopolysaccharides	TLR-5	 Plasma	membrane	 Flagellin	TLR-6	 Plasma	membrane	 Diacyl	lipoprotein	TLR-7	 Endosome	 Single-stranded	RNA	TLR-8	 Endosome	 Single-stranded	RNA	TLR-9	 Endosome	 Double-stranded	DNA	TLR-10	 Plasma	membrane	 Unknown	TLR-11	 Endosome	 Flagellin	and	profilin	TLR-12	 Endosome	 Profilin	TLR-13	 Endosome	 Ribosomal	RNA		The	 TLRs	 1	 and	 2,	 and	 TLRs	 4	 -	 6	 signal	 via	 the	 intracellular	 MyD88	 protein	(Figure	1.5).	TLR5,	TLR2/TLR1	and	TLR2/TLR6	bind	MyD88	directly	 following	their	 activation,	 while	 TLR4	 induces	 signalling	 through	 the	 adaptor	 molecule	TIRAP.	Activated	MyD88	promotes	complex	formation,	which	involves	the	IRAK4	(Interleukin-1	 receptor-associated	 kinase	 4),	 IRAK1	 and	 IRAK2	 proteins.	 A	consequence	of	the	signalling	cascade	is	the	phosphorylation	and	degradation	of	IκB,	and	the	release	of	NF-κB,	which	translocates	to	the	nucleus	and	induces	the	expression	 of	 genes	 encoding	 cytokines,	 chemokines	 and	 host	 defence	 peptide	molecules.		
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Figure	1.5	Toll-like	receptor	signalling	pathways.		Stimulated	 Toll-like	 receptors	 initiate	 a	 signalling	 cascade	 involving	 MyD88	protein,	IRAK	and	NF-κB	activation.			Using	a	murine	model,	 including	TLR4-/-	mice,	TLR4	has	been	reported	as	a	key	protein	 in	 defending	 the	 bladder	 from	uropathogenic	E.	coli	 infections	 [80-82].	However,	in	vitro	data	has	demonstrated	that	in	the	human,	TLR5	and	not	TLR4	receptors	function	to	protect	tissues	of	the	lower	urinary	tract	from	infection	[83,	84].	As	[84][84][84][84][83][82][81]TLR5	receptors	recognise	flagellin	proteins,	which	 are	 the	 major	 components	 of	 the	 flagella	 that	 facilitate	 uropathogenic	
E.coli	motility,	this	detection	system	allows	the	host	urothelial	tissues	to	quickly	orchestrate	 a	 defence	 response	 (Figure	 1.6A).	 Importantly	 the	 TLR5	polymorphism	 TLR5_C1174T,	 carried	 by	 10	 %	 of	 population,	 results	 in	 the	synthesis	 of	 a	 truncated	 TLR5	 protein	 lacking	 its	 cytoplasmic	 signalling	apparatus	 [40,	 85]	 (Figure	 1.6B)	 and	 carriers	 of	 this	 polymorphism	 are	 more	susceptible	 to	 recurrent	 urinary	 tract	 infections	 [40,	 86].	 In	 vitro,	 in	 vivo	 and	clinical	 data	 from	 our	 laboratory	 have	 also	 shown	 that	 this	 polymorphism	 is	
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linked	 to	 a	 reduction	 in	 the	 production	 of	 HBD2,	 which	 illustrates	 that	 the	reduced	signalling	significantly	impacts	host	defence	mechanisms	[40].	
	
Figure	1.6	Normal	and	defective	TLR5	signalling.		Flagellated	 bacteria	 activate	 TLR5,	 which	 results	 in	 HDP	 production	 including	hBD2	synthesis	(A).	Polymorphism	TLR5_C1174T	leads	to	reduced	signalling	and	reduced	innate	defences	(B).			Essentially	 individuals	 carrying	 the	TLR5_C1174T	polymorphism	are	 unable	 to	clear	 UTIs	 efficiently	 and	 suffer	 from	 recurrent	 UTIs.	 These	 patients	 are	prescribed	 prophylactic	 antibiotic	 treatments	 to	 help	 clear	 the	 infections,	 but	because	 of	 their	 genetic	 defect	 the	 treatment	 does	 not	 cure	 the	 problem	 and	contributes	to	the	development	of	antibiotic	resistant	bacterial	strains.	One	idea	to	help	address	this	problem	is	to	develop	therapies	that	boost	their	urogenital	innate	immune	defences	and	therefore	reduce	the	number	of	infections	and	their	use	of	antibiotics.				
1.8 C-type	Lectin	Receptors		C-type	 lectin	 receptors	 are	 another	 group	 of	 membrane	 bound	 receptors	 that	recognise	 pathogen-associated	 molecular	 patterns	 (PAMPs)	 and	 whose	activation	results	in	a	host	response.	These	receptors,	namely	Dectin-1,	Dectin-2,	
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Mincle	and	DC-SIGN	(Figure	1.7),	each	have	a	carbohydrate-recognition	domain	(CRD)	and	play	important	roles	in	antifungal	immunity	[87].		
	 	
Figure	1.7	Family	of	C-type	lectin	receptors.		Taken	 from	 [88].	 Orange:	 Carbohydrate	 binding	 domain;	 Purple:	 stalk	 region;	Black:	neck	region;	ITAM	and	Y	are	intracellular	signalling	domains.			The	 Dectin-1R	 recognises	 β-1,3-glucans,	 which	 are	 synthesised	 as	 part	 of	 the	fungal	 cell	 wall	 (Figure	 1.8A	 &	 B).	 The	 receptor	 is	 synthesised	 and	 known	 to	function	 in	 myeloid	 derived	 cells	 including	 monocytes,	 macrophages	 and	dendritic	cells	[87],	and	there	are	reports	of	Dectin-1	receptors	in	epithelial	cells	of	 the	 lung,	 cornea	 and	 intestine	 [89-91].	 Interestingly	 previous	 work	 in	 our	laboratory	suggested	that	the	Dectin-1R	is	also	synthesised	in	bladder	(RT4)	and	vaginal	(VK2	E6/7)	cells	[83].	Moreover,	data	from	studies	in	which	vaginal	VK2	E6/7	 cells	 were	 challenged	 with	 zymosan,	 representing	 the	 1-3	 β-glucan	component	 of	 the	 fungal	 cell	 wall,	 supported	 DEFβ4	 expression	 and	 hBD2	synthesis	[83].	
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Figure	1.8	β-glucans	as	components	of	the	fungal	cell	wall.		A:	(1,3)-β-D-glucan	B:	Fungal	cell	wall	components.	Taken	from	[87].		The	Dectin-2	receptor	is	also	found	in	myeloid	derived	cells,	namely	monocytes	and	macrophages,	and	recognises	mannose-capped	structures.	It	does	not	appear	to	 have	 an	 unique	 signalling	 motif	 (Figure	 1.7),	 but	 associates	 with	 the	 Fc	receptor	γ	subunit,	which	has	an	ITAM	signalling	motif	[92].	Similarly	the	Mincle	receptor,	 synthesised	 in	 macrophages,	 dendritic	 cells,	 neutrophils	 and	 B	 cells,	and	which	recognises	glycolipids	also	associates	with	the	Fc	receptor	γ	subunit	[93].		The	 fourth	 member	 of	 the	 group,	 the	 DC-SIGN	 receptor,	 binds	 carbohydrates	containing	mannose	 sugar	 units	 and	 is	 commonly	 found	 in	 dendritic	 cells	 and	macrophages.	Its	known	functions	include	intercellular	adhesion,	antigen	uptake	and	signalling	[94],	and	it	has	also	been	shown	to	modulate	the	immune	response	of	 Toll-like	 receptors	 TLR3,	 TLR4	 and	 TLR5	 [95].	 It	 binds	 ligands	 through	 a	
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carbohydrate	 recognition	 domain	 (CRD)	 [94]	 and	 its	 intracellular	 domain	exhibits	a	YXXF	signalling	motif	[96].			
1.9 Structure	of	the	Dectin-1	Receptor		The	Dectin-1R	is	a	Type	II	transmembrane	receptor,	with	the	extracellular	region	composed	 of	 a	 C-type	 lectin-like	 (CTLD)	 domain	 and	 a	 stalk	 region,	 although	some	 isoforms	 synthesised	 lack	 this	 stalk	 region.	The	 intracellular	 components	include	ITAM-like	and	DED	domains	(Figure	1.9)	[97].	The	ITAM-like	domain	has	only	one	 tyrosine	 (Y)	 residue,	while	 the	 classical	 ITAM	domain	 found	 in	 the	Fc	receptor	 γ	 subunit	 has	 two	 tyrosine	 (Y)	 residues,	 which	 are	 both	 required	 to	activate	 signalling.	 DED	 is	 a	 tri-acidic	 domain,	 which	 can	 participate	 in	intracellular	signalling	independently	of	the	ITAM-like	domain.	Ligand	binding	to	the	Dectin-1R	promotes	 receptor	dimerisation,	phosphorylation	of	 the	 tyrosine	residues	and	activation	of	an	intracellular	signalling	cascade.			
	
Figure	1.9	Structure	of	Dectin-1	receptor.		Full-length	Dectin-1R	(A)	and	truncated	Dectin-1R	(B).		
A	Dec&n-1R	isoform	1	 B	Dec&n-1R	isoform	2	
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The	gene	encoding	the	Dectin-1	receptor	 is	CLEC7A,	which	has	six	exons	and	 is	transcribed	 as	 eight	 different	mRNA	 isoforms	 (Figure	 1.10).	 The	main	 variants	synthesised	in	humans	are	a	full-length	isoform	1	and	a	short	isoform	2	that	lacks	a	 stalk	 region	 [98-100].	 Mice	 macrophages	 have	 similarly	 been	 shown	 to	synthesise	 full-length	 and	 stalk-less	 isoforms	 [101].	 Importantly	 it	 has	 been	shown	that	only	isoforms	A	and	B	(isoform	1	and	2)	can	bind	β-glucans	[102].		
	
Figure	1.10	CLEC7A	gene	and	mRNA	isoforms.		
CLEC7A	gene	encoding	the	Dectin-1R	has	6	exons	and	can	be	spliced	into	8	mRNA	isoforms.	Taken	from	[102].	
	
1.10 	Dectin-1R	activation	and	signalling	pathways	The	research	related	to	Dectin-1R	activation	and	signalling	has	been	performed	using	myeloid	 derived	 cells	 specifically	macrophages,	monocytes	 and	 dendritic	cells.	 Using	 macrophages,	 receptor	 activation	 has	 been	 shown	 to	 result	 in	 a	number	of	outcomes	 including	phagocytosis,	cell	autophagy,	 inflammatory	 lipid	
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production	 and	 the	 expression	 of	 various	 cytokines	 and	 chemokines	 including	TNFα,	 IL-2,	 IL-8,	 IL-10	 and	 IL-12	 [103-106].	 The	 signalling	 cascades	 following	activation	have	been	determined	and	 it	 is	 established	 that	Dectin-1R	 signalling	functions	via	either	the	canonical	spleen	tyrosine	kinase	(Syk)	dependent	or	non-canonical	Syk	independent	pathways	(Figure	1.11).		
	
Figure	1.11	Dectin-1	signalling	pathways.		Dectin-1R	 signalling	 can	 trigger	 Syk	 dependent	 or	 Syk	 independent	 pathways.	Syk	 dependent	 pathways	 involve	 activation	 of	 the	 CARD9	 complex,	 NIK	 and	PLCγ2.	The	Syk	independent	pathway	activates	Raf-1	protein.	All	pathways	result	in	NF-κB	activation.		In	 the	 Syk	 dependent	 pathway	 the	 ITAM-like	motif	 phosphorylates	 Syk,	which	activates	the	CARD9	complex	and	leads	to	IKK	complex	activation.	This	promotes	phosphorylation	and	degradation	of	IκBα,	which	in	turn	releases	NF-κB	allowing	
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it	 to	 translocate	 into	 the	nucleus	 and	activate	 gene	 transcription	 (Figure	1.11).	Phosphorylation	of	 Syk	 can	 also	 activate	 an	NF-κB-inducing	kinase	 (NIK)	 [107,	108],	 which	 in	 turn	 activates	 the	 IKK	 complex	 although	 this	 pathway	 appears	specific	 to	 the	 development	 of	 secondary	 lymphoid	 organs	 and	 lymphocyte	survival	[109].	Additionally,	Syk	activation	can	also	result	in	the	phosphorylation	of	 PLCγ2,	 causing	 an	 influx	 of	 Ca2+	 ions	 into	 the	 cytoplasm,	 which	 through	calcineurin	promotes	NFAT	translocation	to	the	nucleus	and	gene	transcription.	In	dendritic	 cells	 this	pathway	 is	associated	with	 the	 transcription	of	 cytokines	IL-2,	IL-10	and	IL-12	[110].	The	 non-canonical	 pathway	 is	 the	Dectin-1R	 Syk-independent	 pathway.	 In	 this	signalling	 cascade	 it	 is	 proposed	 that	 the	 Raf-1	 signalling	 protein	 is	phosphorylated	 following	 Dectin-1R	 activation,	 and	 the	 consequence	 is	 NF-κB	activation	 and	 gene	 transcription.	 It	 has	 been	 shown	 that	 activation	 of	 this	pathway	 by	 curdlan	 in	 dendritic	 cells	 is	 associated	 with	 IL-12	 expression	 and	differentiation	 of	 T-helper	 cells	 [111].	 To	 date	 the	 intracellular	 signalling	components	of	the	Dectin-1R/Raf-1	signalling	pathway	have	not	been	identified.	It	 has	 however,	 been	 reported	 that	 stimulation	 of	DC-SIGN	with	mannosylated	lipoarabinomannan	activates	Raf-1	signalling	and	that	the	cascade	also	involves	Ras	[95].		
1.11 		Co-operation	of	the	Dectin-1R	and	TLRs	Cross-talk	 between	 receptors	 is	 an	 important	 mechanism	 to	 integrate	 and	amplify	signals	as	well	as	 induce	a	specific	response	[112].	 	Previous	studies	 in	macrophages	 have	 shown	 the	 Dectin-1R	 to	 interact	 with	 Toll-like	 receptors	including	TLR2	and	TLR4	 [104,	113].	 In	 fact	 it	has	been	demonstrated	 that	 the	Dectin-1R,	 in	mouse	macrophages	 and	 dendritic	 cells,	 in	 response	 to	 β-glucan	challenge	 co-operates	with	TLR-2	 to	 stimulate	 production	 of	 pro-inflammatory	molecules	 including	 TNF	 and	 IL-12	 [103,	 104].	 Other	 studies	 involving	macrophages	have	also	shown	Dectin-1R	and	TLR-2	to	co-operate	in	response	to	either	 mycobacteria	 or	 C.	 albicans	 challenges	 [113,	 114].	 Additionally,	 the	 co-operation	 of	Dectin-1R	with	TLR4	was	 demonstrated	 by	 stimulating	 of	murine	
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dendritic	 cells	 with	 curdlan,	 an	 agonist	 of	 Dectin-1R,	 and	 lipopolysaccharide,	resulting	 in	 the	 potentiation	 of	 IL-6	 and	 TGF-α	 production	 [115].	 Further	evidence	of	Dectin-1R	synergy	with	TLR-2	and	TLR-4	has	been	demonstrated	in	human	 primary	 peripheral	 blood	 mononuclear	 cells	 and	 in	 human	 monocyte-derived	 macrophages	 where	 co-operation	 was	 necessary	 for	 IL-10	 and	 TNF-α	production	[116].			
1.12 	Dectin-1R	/TLR5	co-operation	Previous	work	by	Lanz	suggested	possible	co-operation	between	 the	Dectin-1R	and	 TLR5	 receptor	 in	 immortalised	 vaginal	 VK2	 E6/E7	 and	 bladder	 RT4	epithelial	cells	[83].	In	these	experiments,	which	used	cells	transfected	with	a	NF-κB	reporter	and	challenged	with	zymosan,	NF-κB	reporter	activity	was	decreased	in	cells	incubated	with	a	monoclonal	antibody	to	TLR5	(Figure	1.12).	These	data	suggested	 synergy	 of	 the	 TLR5	 and	 Dectin-1R	 receptors	 in	 the	 response	 to	zymosan,	used	to	mimic	a	fungal	challenge.		
	
Figure	1.12	 Inhibition	of	TLR5	 receptor	decreased	 zymosan	activated	NF-
κB	production	in	RT4	(A)	and	VK2	(B)	cells.		Figure	 is	 taken	 from	 Lanz	 (2013)	 [83].	 The	 TLR5	 receptor	 was	 blocked	 with	antibody	 in	RT4	 and	VK2	E6/E7	 cells,	 	 the	 cells	 challenged	with	 the	Dectin-1R	ligand,	zymosan	and		NF-κB	reporter	activity	measured.		To	further	investigate	possible	co-operation	of	the	Dectin-1	and	TLR5	receptors	immunocytochemistry	(ICC)	of	RT4	bladder	cells	following	a	zymosan	challenge	was	 performed	 [117].	 These	 ICC	 data,	 shown	 in	 Figure	 1.13,	 confirmed	 the	
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epithelial	presence	of	the	Dectin-1R	and	TLR5	proteins,	and	the	cyan	colouration	observed	 in	panel	C	 suggested	co-localisation	and	potential	 co-operation	of	 the	two	receptor	proteins	following	a	zymosan	challenge.			
		
Figure	 1.13	 Dectin-1R	 and	 TLR5	 staining	 in	 RT4	 cells	 following	 zymosan	
challenging.		A:	Dectin-1R	 –	 green	 colour;	 B:	 TLR5	 –	 blue	 colour;	 C:	merged	 green	 and	 blue	channels.	Nuclei	are	stained	in	red;	D:	RT4	cells	were	incubated	with	secondary	antibodies	 only.	 Images	 were	 taken	 using	 Zeiss	 Axioimager	 II	 fluorescent	microscope	with	apotome	and	400x	magnification	[117].			Dectin-1R	 is	 classically	 linked	 to	 antifungal	 defence	 while	 TLR5	 is	 associated	with	 an	 antibacterial	 defence.	 These	 data	 therefore	 suggested	 that	 in	 the	urogenital	 tissues,	where	 the	 presence	 of	 fungi	 and	 bacteria	 linked	 to	 the	 gut-faecal	 cycle	 is	 common	co-operation	between	 the	Dectin-1	and	TLR5	 receptors	has	evolved.			Classically	the	TLR5	receptor	is	reported	to	function	as	a	homodimer	[118]	and	receptor	 co-operation	 with	 another	 and	 none	 TLR	 was	 potentially	 novel	 and	
A	 B	
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exciting.	The	aim	of	the	research	reported	in	this	thesis	was	therefore	to	focus	on	the	Dectin-1	and	TLR5	receptors	in	the	bladder	urothelium	with	the	objective	of	investigating	receptor	co-operation	following	a	zymosan	challenge	used	to	mimic	a	fungal	infection.	Using	an	in	vitro	model	namely	the	RT4	bladder	cell	line	the	project	attempted	to:		 1. Investigate	the	gene	expression	and	synthesis	of	the	Dectin-1R	in	bladder	epithelial	cells.	2. Explore	 and	 demonstrate	 co-operation	 between	 the	 Dectin-1	 and	 TLR5	receptors	in	bladder	epithelial	cells	following	β-glucan	challenges.	3. Engineer	 novel	 bladder	 cell	 lines	 to	 further	 investigate	 co-operation	between	different	Dectin-1R	isoforms	and	TLR5	receptors.		4. Investigate	the	Dectin-1R	signalling	pathway	in	bladder	epithelial	cells.		 	
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Chapter	2 .	Materials	and	methods	
 Pathogen-associated	molecular	pattern	s	(PAMPs)	2.1Zymosan,	curdlan,	scleroglucan	and	flagellin	diluted	in	water	described	in	Table	2	were	used	to	stimulate	inflammatory	response	in	cells.			
Table	2	PAMPs	used	to	challenge	the	RT4	cells	PAMP	 Source	 Challenge	conc.	 Stock	conc.	 Supplier	
Zymosan	 S.	cerevisae	 50	 μg/ml	 or	 200	μg/ml	 1	mg/ml	 Sigma	Aldrich	
Curdlan	 A.	faecalis	 50	 μg/ml	 or	 200	μg/ml	 1	mg/ml	 Invivogen	
Scleroglucan	 S.	rolfsii	 50	 μg/ml	 or	 200	μg/ml	 1	mg/ml	 Invivogen	
Flagellin	 E.	coli	 70	 ng/ml	 or	 250	ng/ml	 670	μg/ml	 Lanz	 (2013)	[83]		
 Chemicals	2.2Phosphate	 buffered	 saline	 (PBS)	 tablets,	 TRIS,	 sodium	 chloride,	paraformaldehyde	 (PFA),	 dimethyl	 sulfoxide	 (DMSO),	 Tween	 20,	 acrylamide,	tetramethylethylenediamine	 (Temed),	 APS,	 Tris	 Base,	 sodium	dodecyl	 sulphate	(SDS)	and	bovine	serum	albumin	(BSA)	were	purchased	from	Sigma-Aldrich.		
 Antibodies	2.3Antibodies	 for	 Western	 blot	 included	 primary	 anti-human	 Dectin-1R	 (R&D	systems,	 AF1859),	 TLR2	 (Abcam,	 ab68159),	 Syk	 (Cell	 Signalling,	 D3Z1E),	phospho-Syk	(Cell	Signalling,	C87C1),	IκBα	(Abcam,	ab32518),	and	β-actin	(Santa	Cruz,	SC-1616).	Secondary	antibodies	were	donkey	anti-goat	 IRDye	800CW	(Li-Cor,	925-32214),	goat	anti-rabbit	Alexa	Fluor	680	(Thermo	Fisher,	A-21109)	and	rabbit	anti-mouse	Alexa	Fluor	750	(Abcam,	ab175743)	.		
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Primary	 antibodies	 used	 in	 immunocytochemistry	 were	 anti-human	 Dectin-1R	(R&D	systems,	MAB1859),	anti-human	TLR5	(Abcam,	ab37071),	anti-TLR2,	anti-MPR1.	Secondary	antibodies	were	Alexa	Fluor	350	(Life	technologies,	A-11046)	and	Alexa	Fluor	488	 (Life	Technologies,	A-11059).	Working	 concentrations	 are	shown	in	Tables	3.2	and	3.3.			
Table	 3	 Primary	 antibodies	 used	 in	 western	 blot	 (WB)	 and	
immunocytochemistry	(ICC).	Protein	 Cat	No	 Type	 Conc.	 Procedure	 Supplier	
Dectin-1	 AF1859	 Goat	polyclonal	IgG	 0.4	μg/mL	 WB	 R&D	Systems	
Dectin-1	 MAB1859	 Mouse	monoclonal	IgG2B	 20	μg/mL	 ICC/blocking	 R&D	Systems	
TLR5	 ab37071	 Rabbit	polyclonal	IgG	 20	μg/mL	 ICC	 ABCAM	
TLR2	 ab68159	 Rabbit	monoclonal	IgG	 1:	250/1:500	 ICC/WB	 Abcam	
MPR1	 ab32574	 Mouse	monoclonal	IgG1	 1:25	 ICC	 Abcam	
β-actin	 SC-1616	 Goat	polyclonal	IgG	 1:1000	 WB	 Santa	Cruz	
Syk	 D3Z1E	 Rabbit	monoclonal	IgG	 1:1000	 WB	 Cell	Signalling	
Phospho
-Syk		
C87C1	 Rabbit	monoclonal	IgG	 1:1000	 WB	 Cell	Signalling	
IκBα	 ab32518	 Rabbit	monoclonal	IgG	 1:1000	 WB	 Abcam	
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Table	 4	 Secondary	 antibodies	 used	 in	 western	 blot	 (WB)	 and	
immunocytochemistry	[ICC].	Probe	 Cat	No	 Type	 Conc.	 Procedure	 Supplier	
Alexa	 Fluor	
750	
ab175743	 Rabbit	 anti-Mouse	IgG	 1:5000	 WB	 Abcam	
IRDye	800	 925-32214	 Donkey	 anti-Goat	IgG	 1:5000	 WB	 Li-Cor	
Alexa	 Fluor	
680	
A-21109	 Goat	anti-Rabbit	 1:5000	 WB	 Thermo	Fisher	
Alexa	 Fluor	
488	
A-11059	 Rabbit	 anti-Mouse	IgG	 1:2000	 ICC		 Life	Technologies	
Alexa	 Fluor	
350	
A-11046	 Goat	anti-Rabbit	IgG	 1:1000	 ICC	 Life	Technologies	
Mouse	
IgG2b	
Control	
02-6300	 Mouse	IgG2b	 3	 –	 20	μg/mL	 Blocking	 Invitrogen	
	
 Cell	culture	2.4Immortalised	 bladder	 epithelial	 RT4	 cells	 (ATCC-HTB-2,	 LGC	 Standards,	 UK)	were	 maintained	 in	 RPMI	 1640	 (Sigma)	 growth	 medium	 with	 2	 %	 of	 HEPES	buffer,	 2	 mM	 L-glutamine	 and	 10	 %	 foetal	 calf	 serum	 (FCS).	 The	 cells	 were	cultured	in	75	cm2	culture	flasks	(Corning,	UK)	with	25	ml	of	media	and	passaged	weekly.	 Passaging	 included	 cell	 trypsinisation	 for	 10	minutes	 at	 37°C	 and	5	%	CO2,	 cell	 counting	and	dispensing	 the	appropriate	volume	of	 cell	 suspension	so	that	4x105	of	cells	were	seeded	into	25	ml	of	fresh	growth	media.	Cells	were	used	at	passage	numbers	15	to	25.	Chinese	 hamster	 ovary	 (CHO)	 cells	 were	 cultured	 from	 in	 house	 stocks	 and	maintained	in	DMEM	(Sigma),	2	mM	L-glutamine	supplemented	with	10	%	FCS.	The	cells	were	cultured,	passaged	and	counted	as	described	 for	RT4	cells.	Cells	were	 used	 at	 passage	 numbers	 1	 –	 17,	 where	 1	 was	 the	 first	 passage	 in	 this	laboratory.		
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 Challenging	of	RT4	cells	with	PAMPs		2.5RT4	cells	were	seeded	into	six	well	or	twelve	well	plates	(Corning)	(105	cells/ml),	grown	 for	 48	 h	 to	 confluence	 and	 1ml	 of	 fresh	 media	 added	 24h	 before	challenging	with	zymosan	(50	μg/ml	or	200	μg/ml),	 flagellin	 (70	ηg/ml	or	250	ηg/ml)	or	curdlan	(50	μg/ml	or	200	μg/ml)	for	6,	16	or	24	hours.			
 RNA	isolation		2.6RNA	was	isolated	using	SV	Total	RNA	Isolation	System	(Promega)	as	directed	by	the	manufacturer’s	instructions.	Briefly	175	μl	of	RNA	lysis	buffer	was	added	to	each	well	in	12	well	plate	containing	about	2	million	cells.	The	cells	were	scraped,	transferred	to	a	1.5ml	microfuge	tube	and	RNA	dilution	buffer,	350	μl,	added	to	each	sample.	The	content	in	the	tubes	was	mixed	by	inverting	and	then	the	tubes	were	 centrifuged	 for	 10	 minutes	 at	 13000	 x	 g	 at	 room	 temperature.	 The	supernatant	was	diluted	using	200	μl	of	95	%	ethanol,	centrifuged	for	1	minute	at	13000	 x	 g	 in	 a	 spin	 basket	 and	washed	with	 600	 μl	 of	 RNA	wash	 solution.	 To	remove	residual	DNA	the	sample	was	treated	with	50	μl	of	DNase	incubation	mix	and	the	reaction	stopped	with	200	μl	of	DNase	stop	solution.		After	washing	and	centrifugation	 the	 RNA	was	 eluted	with	 100	 μl	 of	 nuclease-free	water	 and	 the	concentration	measured	using	NanoDrop	2000	(Thermo	Scientific).		
 Isolation	of	genomic	DNA	2.7Genomic	DNA	was	isolated	using	the	PureLink	Genomic	DNA	Mini	Kit	(K1820-00,	Invitrogen).	Medium	bathing	cells	grown	in	12	well	plates,	was	removed,	the	cells	harvested	by	scraping	with	a	pipette	tip,	the	cells	resuspended	in	200	μl	of	PBS	and	 transferred	 to	 the	 tube	 containing	 Proteinase	 K.	 The	 sample	 was	 briefly	vortexed	with	20	μl	 of	RNase	A	 and	 following	 a	2	minute	 incubation	200	μl	 of	Lysis/Binding	buffer	was	added.	The	sample	was	again	vortexed	and	following	a	further	10	min	incubation			at	55°C,	200	μl	of	96-100%	of	ethanol	was	added	and	the	lysate	transferred	to	a	spin	column.	The	column	was	centrifuged	at	10000	x	g	
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for	1	minute	at	room	temperature.	The	spin	column	was	washed	with	500	μl	of	Wash	Buffer	2	at	16000	x	g	for	3	minutes.	The	DNA	was	eluted	with	50	μl	Elution	Buffer	and	stored	at	-20°C.	
	
 cDNA	synthesis	2.8To	quantify	mRNA	 in	samples	cDNA	had	 to	be	synthesised.	Complementary	 (c)	DNA	was	synthesised	using	MMLV	RT	enzyme	(Promega)	as	showen	below:		0.5	μg	 Isolated	RNA	1	μl	 Hexamers	[0.5	mg/ml	(Roche)]	12.5	μl	 Volume	adjusted	using	MilliQ	water		The	 samples	 were	 incubated	 in	 at	 65°C	 for	 5	 min,	 the	 mix	 left	 on	 ice	 for	 2	minutes,	the	following	reagents	added	and	incubated	at	42°C	for	2	hours:	5	μl	 MMLV	Buffer	(Promega)	6.25	μl	 dNTPs	[2mM]	(Promega)		0.25	μl	 RNasin	(Promega)	0.5	μl	 MMLV	RT	enzyme	(Promega)		The	reaction	was	stopped	by	incubating	at	70°C	for	5	minutes	and	cDNA	stored	at	-20°C.		
 End-Point	PCR	2.9End-point	 PCR	 was	 used	 to	 analyse	 expression	 of	 genes	 or	 to	 clone	 genes	 of	interest.	GoTaq	G2	polymerase	(Promega)	was	used	to	synthesise	DNA	fragments	of	interest.	The	reaction	mix	was	as	follows:				
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5	μl	 5x	green	GoTaq	reaction	buffer	(Promega)	2.5	μl	 dNTPs	[10	mM]	(Bioline)	2.5	μl	 Primers	(mix	of	forward	and	reverse	primers,	10	μM	each;	IDT	DNA)	0.2	μl	 GoTaq	G2	DNA	polymerase	(Promega)	1.5	μl	 cDNA		20	μl	 Volume	adjusted	using	MilliQ	water		The	reaction	mix	was	added	to	a	0.2	ml	PCR	tube	(I1402-8100, StarLab).	The	reaction	conditions	were	as	shown	below:		
Polymerase	activation	 95	°C	 2	min	 	Denaturation	 95	°C	 30	sec	 35	cycles	Annealing	 Tm	 30	sec	Extension	 72	°C	 30	sec	Final	extension	 72	°C	 10	min	 		Genes	 for	 cloning	 were	 amplified	 using	 KOD	 Hot	 Start	 DNA	 Polymerase	 kit	(71086-3,	 Novagen).	 All	 the	 components	 except	 primers	 and	 water	 were	contained	within	the	kit.	The	reaction	mix	was	as	follows:	5	μl	 10x	Buffer	for	KOD	Hot	Start	DNA	Polymerase	3	μl	 Mg2SO4	[25	mM]	5	μl	 dNTPs	[2	mM]	1.5	μl	 Forward	Primers	[10	μM]	(IDT	DNA)	1.5	μl	 Reverse	Primers	[10	μM]	(IDT	DNA)	2	μl	 DNA	template	1	μl	 KOD	Hot	Start	DNA	Polymerase	(1	U/	μl)	50	μl	 Volume	adjusted	using	PCR	grade	water				
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The	PCR	conditions:	
Polymerase	activation	 95	°C	 2	min	 	Denaturation	 95	°C	 20	sec	 30	cycles	Annealing	 Tm	 10	sec	Extension	 68	°C	 25	sec	Final	extension	 72	°C	 10	min	 		 	
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Primers	designed	for	qRT-PCR	showed	in	Table	5:	
Table	5	Primers	designed	for	End-Point	PCR.	Gene	 Direction	 Sequence	 Product	size	
Human	
CLEC7A	 (full	
length)	
Forward	 ATGGAATATCATCCTGAT	 744,	 626,	606,	 507	and	487	bp	Reverse	 TTACATTGAAAACTTCTTCTC	
Human	
CLEC7A	
(isoform	1)	
Forward	 TGGAGATCCAATTCAGGAAGCAA	 	372	bp	Reverse	 GAGCCATGGTACCTCAGTCT	
Human	
CLEC7A	
(isoform	2)	
Forward	 TGGGTACCATGGGGGTTCTT	 228	bp	Reverse	 GCCGAGAAAGGCCTATCCAA	
Human	
DEFB4	
Forward	 CAGCCATCAGCCATGAGGGT	 83	bp	Reverse	 CCACCAAAAACACCTGGAAGAGG	
Human	LCN2	 Forward	 CAAAGACCCGCAAAAGATGT	 	126	bp	Reverse	 GGCAACCTGGAACAAAAGTC	
Human	IL6	 Forward	 GGCACTGGCAGAAAACAACC	 85	bp	Reverse	 GCAAGTCTCCTCATTGAATCC	
Human	CXCL8	 Forward	 ATGACTTCCAAGCTGGCCGTGGCT	 292	bp		Reverse	 TCTCAGCCCTCTTCAAAAACTTCTC	
Human	IL10	 Forward	 GGTTGCCAAGCCTTGTCTGA	 101	bp	
	 Reverse	 AGGGAGTTCACATGCGCCT	 	
Human	IL1A	 Forward	 CTTCTGGGAAACTCACGGCA	 162	bp	
	 Reverse	 GTGAGACTCCAGACCTACGC	 	
	Human	IL1B	 Forward	 TGAGCTCGCCAGTGAAATGA	 552	bp	
	 Reverse	 AACACGCAGGACAGGTACAG	 	
pVitro2		
MCS2/CELC7A	
(Primer	1)		
Forward	 CCTCATCCGTCGCTTCATGT	 399	bp	
	 Reverse	 TCCTGGTATTGCTTTGAGAGTCG	 	
pVitro2	
MSC1/TLR5	
(Primer	2)		
Forward	 TCGGGCTTCTTAGCGGTTCA	 347	bp	
	 Reverse	 CAAGGGGGTATACTGGCTCC	 		
		 31	
Agarose	 gel	 electrophoresis	 was	 used	 to	 separate	 and	 analyse	 amplified	 DNA	fragments.	Gels	(1%)	were	prepared	by	dissolving	1g	of	agarose	in	100	μl	Tris-buffer	(50	mM	Tris-Cl,	pH	7.5	and	150	mM	NaCl)	and	5	μl	of	Sybre	Safe	stain	was	added	(Thermo	Fisher).	Samples	and	DNA	markers	were	 loaded	on	the	gel	and	ran	using	electrophoresis	for	1	hour	at	100	V.		
 		qRT-PCR	2.10Quantitative	 PCR	 (qRT-PCR)	 was	 used	 to	 investigate	 relative	 gene	 expression.	RNA	 was	 isolated	 from	 cells	 and	 reverse	 transcribed	 into	 cDNA	 as	 described	(Section	2.6).	The	cDNA	was	diluted	1:3	with	water	for	housekeeping	genes	and	1:2	for	other	genes.	The	diluted	DNA	and	primers	were	mixed	with	reaction	mix	SYBR	Green	(04887352001,	Roche)	as	follows:			 x1	(μl)	SYBR	Green	 5	Primers	 0.5	Water	 2.5		Eight	(8)	μl	of	master	mix	was	pipetted	into	each	well	in	LightCycler	480	96	well	plate	 (04729692001,	Roche)	and	2	μl	of	diluted	cDNA	added	per	well.	Samples	were	analysed	in	duplicate	using	a	Lightcycler	480	(Roche).	Primers	designed	for	qRT-PCR	are	shown	in	Table	2.		 	
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Table	6	Primers	designed	for	qRT-PCR.	Gene	 Direction	 Sequence	 Product	size	
Human	
CLEC7A	
Forward	 GGGGCTCTCAAGAACAATGGAA	 113	bp	Reverse	 CTGAAACAACAGCTATCCTGGT	
Human	
TLR5	
Forward	 AGCATCCCTGGTTTGGTGAC	 91	bp	Reverse	 TGATGTTCATGTTCCTGACACT	
Human	
DEFB4	
Forward	 CAGCCATCAGCCATGAGGGT	 83	bp	Reverse	 CCACCAAAAACACCTGGAAGAGG	
Human	
SYK	
Forward	 TTTTGGAGGCCGTCCACAAC	 222	bp	Reverse	 ATGGGTAGGGCTTCTCTCTG	
Human	
RAF1	
Forward	 TTTCCTGGATCATGTTCCCCT	 153	bp	Reverse	 ACTTTGGTGCTACAGTGCTCA	
Human	
CXCL8	
Forward	 ATGACTTCCAAGCTGGCCGTGGCT	 292	bp		Reverse	 TCTCAGCCCTCTTCAAAAACTTCTC	
Human	
IL1A	
Forward	 CTTCTGGGAAACTCACGGCA	 162	bp	Reverse	 GTGAGACTCCAGACCTACGC	
Human	
LCN2	
Forward	 CAAAGACCCGCAAAAGATGT	 	126	bp	
	 Reverse	 GGCAACCTGGAACAAAAGTC	
Human	
GAPDH	
	 Unknown	(commercial	primers)	 	
Human	
ATP5B	
	 Unknown	(commercial	primers)	 		Commercial	primers	were	used	for	the	reference	genes:	GAPDH	and	ATP5B	HK-SY-hu-1200	(Primerdesign).	Relative	 gene	 expression	 calculations	were	 performed	 using	 standard	 curve.	 A	serially	 diluted	 plasmid	 with	 a	 gene	 of	 interest	 was	 amplified	 by	 qRT-PCR.	Obtained	 cycle	numbers	were	plotted	against	 concentrations	of	 serially	diluted	plasmid	 and	 a	 standard	 curve	 was	 produced.	 Then	 this	 curve	 was	 used	 to	calculate	relative	concentrations	in	samples.		
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 		Protein	extraction	from	RT4	cells	2.11Proteins	were	extracted	from	RT4	bladder	cells	for	western	blot	analyses.	Media	was	removed	from	the	well	and	washed	with	1	ml	of	PBS	twice.	Then	100	μl	of	RIPA	buffer	(R0278-50ML,	Sigma)	was	added	per	well	in	a	12	well	plate	and	the	cells	 were	 scraped.	 The	 lysate	 was	 transferred	 to	 a	 1.5ml	microfuge	 tube	 and	centrifuged	 at	 13000	 x	 g	 at	 4°C	 for	 15	 minutes,	 the	 supernatant	 was	 then	collected	and	stored	at	-80°C.			
 		Determination	of	protein	concentration	2.12Total	protein	concentrations	were	measured	using	the	Bradford	assay.	Briefly	10	μl	of	diluted	sample	in	water	(1:6)	or	standards	(bovine	serum	albumin,	Sigma)	were	 analysed	 in	 duplicate	 using	 a	 96	 well	 plate	 (Thermo	 Fisher).	 To	 each	sample	100	μl	of	Coomassie	Plus	assay	reagent	 (1856210,	Thermo	Fisher)	was	added	and	 the	 absorbance	of	 the	 samples	 read	at	595	nm	using	a	plate	 reader	(FLUOstar	Omega,	BMG	Labtech)	right	away.	Readings	from	the	standards	were	used	to	plot	a	standard	curve	and	this	was	used	to	determine	the	sample	protein	concentrations.		
 		SDS	PAGE	electrophoresis		2.13Reducing	 SDS	 PAGE	 (sodium	 dodecyl	 sulfate–polyacrylamide	 gel	electrophoresis)	was	used	to	separate	proteins	by	mass.	Proteins	were	separated	using	4	-12	%	polyacrylamide	gels.	Recipes	for	separating	and	stacking	parts	of	the	gel	were	as	follows:	
Separating	gel	12%	 	40%	Acrylamide/Bis	Acrylamide	(37.5:1)	 1.75	ml	4x	Separating	Buffer	 1.7	ml	Distilled	Water	 3.48	ml	TEMED	 6	μl	10%	APS	 65	μl		
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Stacking	gel	4%	 	40%	Acrylamide/Bis	Acrylamide	(37.5:1)	 0.3	ml	5x	Stacking	Buffer	 0.6	ml	Distilled	Water	 2	ml	TEMED	 3.75	μl	10%	APS	 27	μl		
4x	Separating	Buffer	 5x	Stacking	Buffer	1.5M	Tris	Base	pH	8.9	 0.3	M	Tris	Base	pH	6.7	0.25%	SDS	 0.5%	SDS		Acrylamide,	TEMED,	APS,	Tris	Base	and	SDS	were	purchased	from	Sigma.	Protein	 samples	 were	mixed	 with	 4X	 NuPAGE	 LDS	 (lithium	 dodecyl	 sulphate)	sample	 buffer	 (Thermo	 Fisher),	 10X	 NuPAGE	 sample	 reducing	 agent	 (Thermo	Fisher)	and	incubated	at	70°C	for	10	minutes.	The	samples	were	electrophoresed	at	 200	 V	 for	 50	 minutes	 in	 1x	 running	 buffer.	 When	 the	 electrophoresis	 was	completed	 the	 gels	 were	 either	 stained	 using	 commassie	 brilliant	 blue	 G250	(Pierce)	or	used	for	western	blot	analyses.	The	recipe	of	the	running	buffer	was	as	follows:	
Running	buffer	5x	1L	 	Tris	Base	 60.6	g	Glycine	 144.1	g	SDS	 5	g		
 Western	blot	2.14Proteins	separated	by	SDS	PAGE	were	transferred	to	a	nitrocellulose	membrane	(Bio-Rad)	using	a	semi-dry	transferring	system	Atto	AE-6675	(Atto)	set	at	15	V	for	50	minutes	and	transfer	buffer.		
Transferring	buffer	50	ml	 	Running	buffer	1x	 40	ml	Methanol	 10	ml		
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The	 resulting	 membrane	 was	 blocked	 for	 1	 hour	 or	 overnight	 at	 room	temperature	using	Odyssey	blocking	buffer	(Li-Cor	Biosciences)	diluted	in	equal	parts	with	PBS-Tween	20	 (0.1%)	(PBST)	or	TBS-Tween	(TBST)	20	 (0.1%),	The	membrane	 was	 incubated	 with	 appropriately	 diluted	 primary	 antibody	 in	 the	same	blocking	buffer	for	either	1	hour	or	overnight	at	room	temperature	or	4°C	respectively.	Following	this	step	the	membrane	was	washed	three	times	in	either	PBST	or	TBST	and	then	incubated	with	appropriately	diluted	secondary	antibody	for	30	minutes	at	room	temperature.	This	incubation	step	was	followed	by	three	PBST	 or	 TBST	washes	 and	 then	 the	membrane	was	 scanned	 using	 an	Odyssey	CLx	infrared	scanner	(Li-Cor	Biosciences).		
 		ELISA	2.15Sandwich	 ELISAs	 were	 used	 to	 quantitate	 the	 protein	 concentrations	 in	 the	media	bathing	the	RT4	cells.	 IL8	and	LCN2	were	measured	using	BD	ELISA	kits	(DY208	and	DY1757,	R&D	Systems).	For	both	analyses	a	96	well	plate	(Thermo	Fisher)	was	coated,	100	μl	per	well,	with	capture	antibody	diluted	in	PBS	to	the	recommended	working	concentration.	The	plate	was	sealed,	incubated	overnight	at	room	temperature	then	each	well	aspirated	and	washed	three	times	with	400	μl	 of	 buffer	 (Tween	0.05%	 in	PBS).	The	wells	were	blocked	with	300	μl	 of	1%	BSA	in	PBS	for	1	hour	at	room	temperature	and	the	washing	steps	repeated.	100	μl	per	well	of	 standards	and	samples	were	added	 in	duplicate	and	 incubated	2	hours	at	room	temperature.	After	washing	100	μl	of	detection	antibody	diluted	in	1%	 BSA	 in	 PBS	 was	 added	 to	 each	 well	 and	 incubated	 2	 hours	 at	 room	temperature.	 The	 washing	 steps	 were	 repeated,	 100	 μl	 of	 Streptavidin-HRP	antibody	diluted	 in	1%	BSA	 in	PBS	added	 to	each	well	 for	20	minutes	at	 room	temperature	and	 the	plate	washed	again.	Finally,	100	μl	of	 a	mixture	of	Colour	reagent	 A/reagent	 B	 (1:1)	 was	 added	 to	 each	 well.	 The	 reaction	 was	 stopped	after	20	minutes	with	50	μl	of	1N	sulphuric	acid.	Absorbance	was	read	with	plate	reader	 (FLUOstar	 Omega,	 BMG	 Labtech)	 set	 at	 450	 nm.	 The	 readings	 were	corrected	by	subtraction	reading	at	540	nm	from	the	readings	at	450	nm	as	said	in	the	instruction	manual	of	the	plate	reader.	
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Human	 BD2	 protein	 was	 measured	 by	 ELISA	 using	 a	 capture	 antibody	(ab109570,	Abcam),	detection	antibody	(ab83509,	Abcam)	and	Streptavidin-HRP	antibody	 (N504,	 Thermo	 Fisher)	 and	 standards	 (G2815,	 PeproTech)	 at	concentration	 recommended	 by	manufacturer.	 The	 protein	was	 detected	 using	100	μl	of	TMB-ELISA	substrate	solution	(34028,	Thermo	Fisher).	All	steps	were	same	as	described	before.			
 		Immunocytochemistry		2.16RT4	 cells	 were	 cultured	 to	 confluence	 on	 13	 mm	 coverslips	 (Deckglaser)	 and	fixed	with	 4	%	 paraformaldehyde	 (PFA)	 (Sigma-Aldrich)	 for	 15	min.	 The	 cells	were	washed	three	times	with	20	mM	NH4Cl,	three	times	with	PBS	and	with	1	%	BSA	in	PBS-Tween	20	(0.1	%)	blocking	buffer	 for	1h	at	room	temperature.	The	cells	 were	 incubated	 with	 either	 primary	 antibodies	 or	 appropriate	 control	antibodies	diluted	in	1	%	BSA	in	PBST	overnight	at	4	°C.	After	incubation	the	cells	were	washed	three	times	 in	PBST	and	 incubated	with	secondary	antibodies	 for	30	min	at	room	temperature.	After	washing	five	times	in	PBST	and	three	times	in	PBS,	 the	 coverslips	were	mounted	on	microscope	 slides	 and	 the	nuclei	 stained	using	 Vectashield	 with	 propidium	 iodide	 or	 DAPI	 (Vectorlabs)	 mounting	medium.	 Images	 were	 taken	 using	 Zeiss	 Axioimager	 II	 fluorescent	 microscope	with	ApoTome	and	ZEN	software.		
 		Proximity	ligation	assay	(Duolink)	2.17Protein-protein	physical	 interaction	was	investigated	using	a	Duolink	proximity	ligation	 assay	 kit	 (Sigma-Aldrich).	 Cells	were	 fixed	with	 4%	 paraformaldehyde	(PFA)	for	15	min	at	room	temperature,	washed	three	times	with	PBS	and	blocked	using	 1%	BSA	 in	 PBS	Tween	0.1%	 for	 two	hours.	 Following	 blocking,	 the	 cells	were	 incubated	 with	 appropriately	 diluted	 ICC	 primary	 antibodies	 or	appropriate	 control	 antibodies	 overnight.	 The	 cells	were	 then	washed	 in	 PBST	2x5	minutes.	Two	PLA	probes	were	diluted	1:5	 in	1%	BSA	in	PBS	Tween	0.1%,	incubated	at	room	temperature	for	20	min	and	25	μl	of	this	solution	added	to	the	
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cells	 on	 each	 coverslip.	 Following	 incubation	 of	 the	 cells	 plus	 probes	 in	 a	humidity	chamber	for	1h	at	37	°C,	the	cells	were	washed	in	1x	Wash	Buffer	A	2	x	5	min	 using	 a	 rocker.	 Ligation	 solution	 comprising	 1:5	 ligation	 stock	 and	 1:40	ligase	diluted	in	water	was	added	to	each	of	the	coverslips	(25	μl	per	coverslip),	incubated	30	min	at	37	°C	and	then	washed	in	Wash	Buffer	A	for	2	x	2	min	on	a	rocker.	 	 Amplification	 stock	 and	 polymerase	 were	 diluted	 1:5	 and	 1:80	respectively	in	water	and	25	μl	of	the	amplification	solution	was	added	to	each	of	the	coverslips	for	100	min	at	37	°C.	In	the	dark	coverslips	were	washed	in	Wash	Buffer	B	for	2	x	10	min	and	then	with	0.01	x	wash	Buffer	B	for	1	min,	dried	and	mounted	 on	 slides	 with	 Duolink	 mounting	 medium.	 Imaging	 of	 the	 cells	 was	using	a	fluorescent	microscope	Zeiss	Axioimager	with	Apotome.		
 		Fluorescent	microscopy	2.18Cells	in	immunocytochemistry	and	proximity	ligation	assay	were	visualised	using	Zeiss	 Axioimager	 microscope	 with	 Apotome.	 The	 images	 were	 obtained	 and	analysed	with	Zeiss	Zen	Blue	software.	
	
 		DNA	Cloning		2.19Dectin-1	 and	 TLR5	 cDNA	 material	 was	 cloned	 into	 plasmid	 pVitro2-neo-msc	(Invitrogen)	 to	 co-express	 the	 proteins	 in	 RT4	 cells	 (Figure	 2.1).	 This	 plasmid	contains	two	multiple	cloning	sites	(MCS)	and	two	promoters	hFerH	and	hFerL.	The	 neo	 gene	 provides	 resistance	 to	 kanamycin	 in	 E.	 coli	 and	 to	 G418	 in	mammalian	cells.			
		 38	
	
Figure	2.1	pVitro2-neo-mcs	plasmid	was	used	to	overexpress	Dectin-1	and	
TLR5	proteins	in	RT4	cells.		The	 plasmid	 possesses	 two	 multiple	 cloning	 sites	 (MCS1	 and	 MCS2)	 and	 two	promoters	(hFerH	and	hFerL).	The	figure	taken	from		[88].		Primers	 to	 amplify	 CLEC7A	 and	 TLR5	 genes	 were	 designed	 and	 included	restriction	fragment	sites	(BglII	and	XhoI	or	SalI	and	BamHI	respectively)	at	their	termini	to	allow	insertion	of	the	products	into	the	plasmid.	The	genes	of	interest	were	amplified	using	KOD	Hot-Start	End-Point	PCR	and	purified	as	described	in	the	 Section	 2.21	 and	 restricted	 as	 described	 in	 the	 Section	 2.20.	 DNA	 was	separated	on	a	1%	agarose	gel,	 the	bands	of	 interest	were	excised	from	the	gel	with	 a	 razor	 blade	 and	 purified	 (Section	 2.21)	 and	 ligated	 into	 the	 plasmid	pVitro2-neo-mcs	 as	 described	 in	 the	 Section	 2.22	 overnight.	 The	 recombinant	plasmid	 was	 transformed	 into	 E.	 coli	 DH5α	 bacteria	 (Section	 2.24),	 and	 the	bacteria	were	plated	on	a	LB	plate	with	antibiotic	kanamycine	overnight.	A	single	colony	 was	 picked,	 grown	 in	 LB	 with	 kanamycine	 overnight	 and	 the	 plasmid	isolated	as	described	in	the	Section	2.25.	
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Table	7	Primers	designed	for	cloning.	Gene	 Direction	 Sequence	 Tm,	°C	 Product	size	
Dectin-1	 all	
isoforms	
Forward	 TAA	GCA	AGA	TCT	ATG	GAA	TAT	CAT	
CCT	GAT	 55	 772,	 654,	630,	 531,	511	bp	Reverse	 TGC	TCA	CTC	GAG	TTA	CAT	TGA	AAA	
CTT	CTT	CTC	
Dectin-1	 all	
isoforms	
Forward	 CGA	GCA	GGA	TCC	ATG	GAA	TAT	
CAT	CCT	GAT	 55	 772,	 654,	630,	 531,	511	bp	Reverse	 TGC	TGC	GTC	GAC	TTA	CAT	TGA	AAA	
CTT	CTT	CTC	
TLR5	WT	 Forward	 CGA	GCA	GGA	TCC	ATG	GGA	GAC	
CAC	CTG	GAC	C	 61	 2601	bp	Reverse	 TGC	TGC	GTC	GAC	TTA	GGA	GAT	
GGT	TGC	TAC	
TLR5	 SNP	
C1174T	
Forward	 CGA	 GCA	 GGA	 TCC	 ATG	 GGA	 GAC	
CAC	CTG	GAC	C	 62	 1197	bp	Reverse	 TGC	TGC	GTC	GAC	TCA	GAG	ATC	CAA	
GGT	CTG		
 		DNA	digestion	2.20The	 purified	 Dectin-1	 and	 TLR5	 DNA	 fragments	 and	 pVitro2	 plasmid	 were	restricted	 with	 enzymes	 in	 preparation	 for	 ligation.	 Dectin-1	 fragments	 were	restricted	 with	 BglII	 and	 XhoI	 (Promega)	 and	 TLR5	 with	 Sall	 and	 BamHI	(Promega).	While	pVitro2	plasmid	was	 restricted	with	either	BglII	 and	XhoI	or	Sall	and	BamHI.	The	following	reaction	mix	was	prepared:		Sterile	water	 17.3	μl	Restriction	Enzyme	buffer	10x	 2	μl	Acetylated	BSA,	10	μg/μl	 0.2	μl	DNA.	1	μg/μl	 1	μl	Restriction	Enzyme,	10	u/μl	 1	μl		The	reaction	mix	was	incubated	for	1	hour	at	room	temperature	and	then	loaded	on	1%	agarose	gel	for	DNA	separation.	All	enzyme	pairs	were	compatible	and	no	double	digestion	was	used.		
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 		DNA	purification	from	agarose	gel	and	PCR	reaction	2.21
mixture	DNA	 from	 an	 agarose	 gel,	 and	 where	 appropriate	 PCR	 mixture,	 was	 purified	using	 the	 Wizard	 SV	 Gel	 and	 PCR	 Clean-Up	 System	 (Promega).	 Briefly	 a	 DNA	band	was	excised	from	agarose	gel,	deposited	 in	to	a	microcentrifuge	tube,	and	10	 μl	 of	 Membrane	 Binding	 Solution	 per	 10	 mg	 of	 gel	 slice	 was	 added.	 The	mixture	was	incubated	at	60°C	for	15	minutes	with	occasional	vortexing.	For	PCR	mixtures	 an	 equal	 volume	 of	 Membrane	 Binding	 Solution	 was	 added.	 The	dissolved	gel	or	PCR	mixture	was	 transferred	 to	 the	SV	Minicolumn,	 inserted	a	into	 collection	 tube	 and	 incubated	 for	 1	 minute.	 Then	 the	 Minicolumn	 was	centrifuged	for	16000	g	for	1	minute.	The	flowthrough	was	discarded,	700	μl	of	Membrane	 Wash	 Solution	 was	 added	 to	 the	 Minicolumn	 and	 centrifuged	 at	16000	g	for	1	minute.	The	previous	step	was	repeated	with	500	μl	of	Membrane	Wash	Solution	and	centrifuged	at	16000	g	 for	5	minutes.	The	 flowthrough	was	discarded	and	empty	Minicolumn	was	centrifuged	at	16000	g	for	1	minutes.	The	Minicolumn	 was	 transferred	 into	 clean	 1.5	 ml	 minicentrifuge	 tube.	 50	 μl	 of	nuclease-free	water	was	added	 into	Minicolumn	and	 incubated	 for	1	minute	at	room	 temperature.	 Then	 the	 Minicolumn	 was	 centrifuged	 at	 16000	 g	 for	 1	minute	and	the	eluted	DNA	stored	at	-20°C.			
 		DNA	ligation	into	plasmid	2.22cDNA	 fragments	 after	 restriction	 digestion	 were	 ligated	 into	 appropriately	restricted	plasmid	vectors	using	Promega	T4	DNA	Ligase	(M180A).	 	Generally	a	molar	 ratio	 of	 1:3	 of	 vector:insert	 was	 used.	 The	 following	 reaction	 mix	 was	prepared	and	incubated	overnight	at	4°C	in	a	cooling	water	bath:	T4	DNA	Ligase	 0.1-1	u	Ligase	buffer	10x	 1	μl	Vector	DNA	 100	ng	Insert	DNA	 X	ng	Nuclease	Free	Water	to	final	volume	of	 10	μl		
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 		Preparation	of	competent	cells		2.23
E.	coli	 DH5α	bacteria	were	 used	 in	 transformation	 procedures.	 A	 single	 colony	was	picked	from	a	fresh	plate	of	E.	coli	DH5α	bacteria	and	grown	overnight	in	10	ml	 of	 LB	medium	 at	 37°C	 in	 shaking	 incubator.	 1	ml	 of	 overnight	 culture	was	transferred	into	a	1L	conical	flask	containing	100	ml	of	LB	medium.	The	bacterial	culture	 was	 grown	 at	 37°C	 in	 a	 shaking	 incubator	 set	 to	 200-250	 rpm	 to	 an	absorbance	at	600	nm	of	between	0.3-0.4.	The	bacterial	culture	was	centrifuged	at	 4000g	 at	 4°C	 for	 5	 minutes,	 the	 supernatant	 discarded	 and	 the	 pellet	resuspended	 in	 10-20	ml	 of	 0.1M	MgCl2.	 After	 recentrifugation	 and	 removal	 of	the	supernatant	 the	pellet	was	resuspended	 in	4	ml	0.1M	CaCl2	and	kept	on	 ice	for	2	hours.	Competent	cells	were	used	fresh.	For	freezing	4	ml	of	these	bacteria	were	 mixed	 with	 4	 ml	 of	 50%	 glycerol	 stock,	 500	 μl	 volumes	 aliquoted	 into	microfuge	tubes	and	stored	at	-80°C.		
 		Plasmid	transformation	into	bacteria	2.24Following	 ligation	 the	 recombinant	 plasmids	 were	 transformed	 into	 the	competent	 bacterial	 cells.	 The	 ligation	 mix	 was	 centrifuged	 briefly	 and	 2	 μl	transferred	to	a	new	1.5	ml	microfuge	tube	pre-cooled	on	ice.	Competent	cells,	50	μl,	were	added	to	the	ligation	mix	and	after	a	gentle	mix	the	tube	was	left	on	ice	for	 20	 minutes.	 The	 bacterial	 mix	 was	 heat	 shocked	 for	 50	 seconds	 at	 42°C,	returned	to	ice	for	2	minutes	and	then	diluted	using	950	μl	of	LB.	This	mix	was	then	 incubated	 for	 1	 hour	 in	 at	 37°C	 with	 shaking	 (200	 rpm).	 Following	 this	incubation	100	μl	aliquots	of	the	mix	were	plated	onto	LB	plates	containing	the	appropriate	 antibiotic	 and	 incubated	 overnight	 at	 37°C.	 Recombinant	 bacterial	colonies	were	selected	for	further	analysis.			
 		Purification	plasmid	from	bacteria	2.25To	 purify	 plasmid	 DNA	 from	 the	 recombinant	 bacteria	 a	 PureYield	 Plasmid	Miniprep	System	(Promega)	was	used.	A	single	bacterial	colony	was	selected	and	
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grown	 in	 3	 ml	 of	 LB	 plus	 appropriate	 antibiotic	 overnight.	 This	 volume	 was	transferred	 into	 tube	 and	 centrifuged	 at	 maximum	 speed	 (17000	 g)	 for	 30	seconds	to	pellet	the	bacteria,	the	supernatant	discarded,	the	pellet	resuspended	in	 600	 μl	 of	 double	 distilled	 (dd)	 sterile	water	 and	 100	 μl	 of	 Cell	 Lysis	 Buffer	added.	The	sample	was	mixed	by	inverting	the	tube	six	times.	Then	350	μl	of	cold	4°C	Neutralisation	Solution	was	added	and	the	sample	again	mixed	by	inverting.	The	mixture	was	microfuged	at	maximum	speed	(17000	g	 )	 for	3	minutes.	The	supernatant	was	 transferred	 to	a	Minicolumn	 that	was	placed	 into	a	Collection	Tube	and	again	microfuged	at	maximum	speed	for	15	seconds.	The	flowthrough	was	 discarded,	 200	 μl	 of	 Endotoxin	 Removal	 Wash	 added	 to	 the	 minicolumn,	which	was	microfuged	as	previously	described.	400	μl	of	Column	Wash	Solution	was	 added	 to	 the	 minicolumn	 and	 the	 centrifugation	 step	 repeated.	 The	minicolumn	 was	 then	 transferred	 to	 clean	 microcentrifuge	 tube	 and	 30	 μl	 of	nuclease	free	water	was	added.	After	1	minute	the	minicolumn	was	centrifuged	(17000	g)	 for	15	seconds	to	elute	plasmid	DNA	solution.	The	plasmid	DNA	was	stored	at	-20°C.		
 		Transfection	of	plasmid	into	mammalian	cells	2.26Plasmid	 was	 transfected	 into	 mamalian	 cells	 using	 the	 transfection	 agent	attractene	 (301005,	 QiGen).	 The	 plasmid	 in	 the	 amounts/volumes	 highlighted	below	was	mixed	with	attractene	and	serum	 free	media	Opti-Mem	(Gibco)	and	incubated	for	20	minutes	at	room	temperature.	The	mix	was	then	added	to	the	media	bathing	 the	RT4	 cells	 (106	 cells/ml)	 grown	on	 the	well	 of	 12	well	 plate.	Amounts/volumes	of	each	component	were	as	follows:	Plasmid	 	 1000	ηg	Attractene	 1.5	μl	Optimem	 245	μl	Media	 750	μl		70	μg/ml	of	antibiotic	G418	 (Geneticin)	 (200049,	Agilent	Technologies)	or	100	μg/ml	of	antibiotic	zeocin	 (Invivogen)	was	used	 to	select	 cells	 transfected	with	pVitro2-neo-mcs	 or	 psiRNA-Dectin-1/Luciferase	 plasmids	 respectively.	 G418	
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concentration	 Cells	 without	 plasmid	 died	 while	 transfected	 cells	 survived	 and	produced	colonies.	The	survived	colonies	were	tripsinised	and	were	grown	in	75	cm3	 culture	 flasks	 (Corning,	 UK).	 When	 the	 cells	 were	 confluent	 they	 were	tripsinised	and	frozen	for	storage	in	liquid	nitrogen	(Section	43).	
 		Freezing	cells	in	liquid	nitrogen	2.27Transfected	 RT4	 cells	 were	 stored	 in	 liquid	 nitrogen.	 Confluent	 cells	 were	trypsinised	and	8	ml	of	cells,	106	cells/ml,	were	gently	mixed	with	1	ml	of	foetal	calf	 serum	 and	 1	ml	 of	 DMSO	 (D8418,	 Sigma).	 One	ml	 aliquots	were	 frozen	 in	liquid	nitrogen.			
 		siRNA	Gene	knockdown		2.28Knockdown	of	Dectin-1	gene	expression	was	performed	with	psiRNA-hDectin-1	plasmid	(InvivoGen),	while	knockdown	of	other	gene	expression	was	performed	using	 siRNA	 primers:	 TLR5	 –S14199	 (Ambion),	 TLR2	 S168	 (Ambion),	 TLR4	S14196	 (Ambion),	 TLR6	 S20215	 (Ambion),	 SYK	 S13679	 (Ambion),	 RAF-1	103578	(Ambion).		Plasmid	psiRNA-hDectin-1	was	transfected	into	RT4	cells	using	the	transfection	protocol	 described	 in	 the	 Section	 2.26.	 To	 select	 stably	 transfected	 cells	 100	μg/ml	of	antibiotic	zeocin	(ant-zn-1,	InvivoGen)	was	used.		To	transfect	RT4	cells	with	siRNA	105	cells/ml	were	grown	to	20	%	confluence	in	each	well	of	a	12	well	plate.	A	10-20%	mix	of	 transfection	agent	Lipofectamine	RNAiMAX	(Thermo	Fisher),	siRNA	and	serum	free	Optimem	media	was	prepared	and	 incubated	 for	 20	 minutes	 at	 room	 temperature.	 The	 reaction	 mix	 was	 as	follows:	Lipofectamine	RNAiMAX	 2	μl		siRNA	 2	μl	Optimem	 196	μl		200	μl	of	this	mix	was	added	to	each	well	and	the	cells	challenged	48	hours	later.		
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 		Blocking	Dectin-1	receptor	(R)	with	antibody	2.29Dectin-1R	was	 blocked	 using	 anti-Dectin-1	 antibody	MAB1859	 (R&D	 Systems).	To	 facilitate	 this	 1	ml	 of	 105	cells/ml	were	 seeded	 in	 to	 each	well	 of	 a	 12	well	plate.	 When	 the	 cells	 were	 100%	 confluent	 6	 or	 3	 μg/ml	 of	 anti-Dectin-1R	antibody	solution	was	added	and	after	two	hours	the	cells	were	challenged	with	zymosan	 ligand.	 As	 a	 control	 6	 μg/ml	 solution	 of	 IGG2B	 antibody	 was	 added	(026300,	Invitrogen).			
 		Syk	Inhibition	using	piceattanol	2.30Syk	protein	 signalling	was	 inhibited	using	piceattanol	 (SC-200610,	 Santa	Cruz)	diluted	 in	 DMSO.	 RT4	 cells	 were	 seeded	 in	 to	 12	 well	 plate.	 When	 100%	confluent	0	μM,	10	μM,	20	μM,	30	μM	and	100	μM,	of	piceattanol	solution	were	added	to	each	well.	After	20	minutes	 incubation	the	cells	were	challenged	with	50	μg/ml	of	zymosan	for	6	h.		
 		Statistical	analysis	2.31Statistical	analyses	were	performed	using	Prism	6.0	(GraphPad	Software).	Data	are	shown	as	mean	±	SD.	One-way	ANOVA	with	post-hoc	Tukey’s	test	was	used	to	determine	 significance	 of	 the	 observed	 differences.	 P	 values	 of	 <0.05	 were	considered	significant.		
 		Ethical	approval		2.32Research	Ethics	(09/H0905/15)	and	Newcastle	upon	Tyne	Hospitals	NHS	Trust	(ID	4841)	allowed	the	collection	of	biopsy	materials.	Written	 informed	consent	was	 obtained	 from	 all	 participants	 and	 all	 methods	 were	 performed	 in	accordance	with	relevant	guidelines	and	regulations.	 	
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Chapter	3 .	Dectin-1	receptor	and	RT4	cells	
The	 expression	 and	 synthesis	 of	 Dectin-1	 receptor	 (Dectin-1R)	 isoforms	 were	explored	previously	in	vivo	using	male	and	female	murine	bladder	tissues	[117].	Using	 tissue	 RNA	 and	 molecular	 analyses	 cDNA	 bands	 of	 450bp	 (strong)	 and	550bp	 (weak)	 were	 detected	 indicative	 of	 two	 major	 transcripts,	 encoding	proteins	 of	 23	 and	 27kDa	 respectively.	 DNA	 sequencing	 and	 BLAST	 analyses	revealed	 the	 450bp	 cDNA	 transcript	 sequence	 encoded	 the	 23	 kDa	 mouse	isoform	 B,	 Dectin-1R	 protein,	 which	 is	 predicted	 to	 be	 stalk	 free	 (Figure	 1.9).	Importantly	 these	 data	 supported	 Dectin-1R	 synthesis	 in	 the	 murine	 bladder,	hence	 urinary	 tract	 tissues.	 However,	 probable	 contamination	 of	 the	 murine	epithelial	tissues	by	antigen	presenting	cells,	such	as	macrophages	meant	it	was	not	possible	to	localise	the	observed	receptors	specifically	to	the	urothelia.	To	 explore	 whether	 Dectin-1R	 is	 also	 expressed	 and	 synthesised	 in	 human	bladder	 epithelia	 in	 vitro	 analyses	 were	 performed.	 Initial	 analyses	 utilised	bladder	 biopsy	 material	 and	 these	 were	 followed	 by	 further	 experiments	exploiting	an	 in	vitro	bladder	cell	model,	 the	 immortalised	RT4	human	bladder	epithelial	cell	line.			
 Expression	of	Dectin-1R	isoforms	in	human	bladder	biopsy	3.1To	 explore	 CLEC7A	 (Dectin-1R)	 expression	 and	 synthesis	 in	 the	 human	urogenital	tract	a	human	bladder	biopsy	sample	(female)	was	used.	A	section	of	the	tissue	was	homogenised,	RNA	extracted	(Section	2.6),	transcribed	into	cDNA	and	the	Dectin-1	gene,	CLEC7A,	amplified	by	end-point	PCR	using	isoform	specific	primers	 (Table	5).	Data	 in	Figure	3.1A	 (lane	1)	 shows	a	 strong	band	at	330	bp	representing	Dectin-1R	isoform	1	(predicted	to	encode	25	kDa	protein)	and	two	weaker	 bands	 at	 250	 bp	 and	 180	 bp.	 These	 smaller	 bands	 represented	 DNA	fragments	amplified	due	to	non-specific	binding	of	primers.		To	 investigate	 Dectin-1R	 protein	 synthesis	 the	 tissue	 was	 homogenised,	 cells	lysed	 with	 RIPA	 buffer,	 proteins	 separated	 by	 SDS-PAGE,	 blotted	 onto	nitrocellulose	 and	 analysed	 using	 anti-Dectin-1R	 abtibody	 (R&D	 systems,	
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MAB1859)	 (Table	 2).	 Data	 in	 Figure	 3.1B	 demonstrated	 bands	 relating	 to	proteins	 of	 20kDa,	 25kDa,	 42kDa	 and	 54kDa	 respectively.	 These	 relate	 to	 the	Dectin-1R	 isoform	1	monomer	 (25	kDa)	and	 isoform	2	monomer	 (20	kDa)	and	potentially	 an	 isoform	 1	 dimer	 (54	 kDa)	 and	 isoform	 2	 dimer	 (42	 kDa).	 The	isoform	2	Dectin-1R	protein	 lacks	a	stalk	region,	which	 is	present	 in	 isoform	1,	although	the	function	of	the	stalk	region	is	not	known.		
	
Figure	 3.1	 Dectin-1R	 mRNA	 expression	 and	 protein	 synthesis	 in	 human	
bladder.		A:	Bladder	RNA	was	analysed	using	end-point	PCR	and	Dectin-1R	primers.	Lane	1	–	the	band	of	330	bp	represents	Dectin-1R	isoform	1,	bands	at	250	bp	and	180	bp	were	amplified	due	 to	nonspecific	primers	binding;	M	–	base	pairs	markers.	B:	Western	blot	analyses	of	bladder	proteins	using	anti-Dectin-1R	antibody	diluted	1:50.	M-	protein	markers;	Lane	1	–	bands	representing	Dectin-1R	isoforms.	The	gels	represent	two	independent	experiments.		
 Expression	of	Dectin-1R	isoforms	in	human	bladder	3.2
epithelial	cells	While	 these	data	confirmed	CLEC7A	 (Dectin-1R)	gene	expression	and	synthesis	in	human	bladder	tissue	again	contamination	of	the	tissue	with	myeloid	derived	cells	 could	not	be	guaranteed.	To	 focus	 therefore	on	epithelial	 tissues	a	human	
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bladder	epithelial	cell	line	was	used	for	all	further	experiments.	The	RT4	bladder	cell	line	was	chosen	as	it	represents	a	robust	urothelial	cell	model	[119].		The	Dectin-1R	gene,	CLEC7A,	was	amplified	using	cDNA	prepared	from	confluent	RT4	cells	and	primers	designed	to	amplify	the	CLEC7A	gene	sequence	(Table	5).	PCR	products	were	analysed	on	a	1%	agarose	gel	and	 the	results	are	shown	 in	Figure	3.2.	A	number	of	cDNA	bands	were	observed	indicating	the	synthesis	of	a	number	of	different	Dectin-1R	protein	isoforms.	Fragment	sizes	1,	2,	3,	4,	5	with	sizes	 of	 744,	 626,	 606,	 507	 and	 487	 bp	 respectively	 align	 to	 the	 Dectin-1R	isoforms	 1,	 2,	 3,	 4,	 and	 5	 [120].	 It	 was	 noted	 however,	 that	 the	 intensity	 of	fragment	(cDNA	band)	4	was	much	stronger	compared	to	those	of	the	other	four	cDNA	bands.		 	
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Figure	3.2	End-Point	PCR	showing	mRNA	expression	of	Dectin-1	isoforms	in	
RT4	cells.		M-	 base	 pairs	markers;	 Lane	 1	 cDNA	 bands	 amplified	 from	 cDNA	 of	 RT4	 cells	with	 CLEC7A	 primers.	 The	 sizes	 of	 the	 bands	 744,	 626,	 606,	 507	 and	 487	 bp	relate	 to	 the	 Dectin-1R	 isoforms	 1,	 2,	 3,	 4	 and	 5.	 The	 gel	 represents	 two	independent	experiments.		To	 confirm	 these	 cDNA	 bands	 related	 to	 Dectin-1R	 expression	 the	 DNA	fragments	were	 excised	 from	 the	 gel,	 purified,	 sequenced	 and	 BLAST	 analyses	performed.	 Sequencing	 and	 BLAST	 results	 are	 shown	 in	 Figure	 3.3	 A-E.	 The	obtained	 sequences	 (Query)	 were	 aligned	 with	 the	 predicted	 sequences	 of	Dectin-1	gene	CLEC7A	(Sbjct)	and	the	sequencing	data	confirmed	that	the	cDNA	bands	represented	the	Homo	sapiens	Dectin-1R	isoforms	1,	2,	3,	4	and	5.							
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Figure	3.3	Sequence	data	relating	to	the	different	Dectin-1	cDNA	products.	The	sequences	(Query)	were	aligned	with	the	predicted	sequences	of	the	CLEC7a	(Dectin-1R)	isoforms	(Sbjct).		cDNA	1	corresponded	to	a	full	length	CLEC7A	isoform	1,	which	has	a	stalk	region;	cDNA	2	represents	isoform	2,	which	does	not	have	a	stalk;	cDNA	3	–	(isoform	3)	possess	a	stalk	region	but	has	a	shorter	carbohydrate	binding	region;	 	cDNAs	4	and	 5	 (isoforms	 4	 and	 5)	 do	 not	 have	 a	 stalk	 and	 have	 either	 a	 truncated	carbohydrate	region	or	truncated	intracellular	signalling	region	respectively.	As	
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DNA	fragment	4	showed	the	strongest	intensity	on	the	agarose	gel	this	suggested	it	was	the	main	isoform	in	RT4	cells.		These	 data	 confirmed	 the	 CLEC7A	 (Dectin-1R)	 gene	 to	 be	 expressed	 in	 RT4	bladder	epithelial	cells.			
 Protein	synthesis	of	Dectin-1R	isoforms		3.3The	 next	 step	 was	 to	 use	 western	 analyses	 to	 explore	 and	 confirm	 Dectin-1R	protein	synthesis	in	the	RT4	cells.	These	analyses	employed	the	polyclonal	anti-human	Dectin-1	 antibody	 (R&D	 Systems,	 AF1859).	 	 Results	 of	 the	 immunoblot	(Figure	3.4)	revealed	two	strong	bands	of	17	kDa	and	27	kDa	and	weaker	bands	of	25	kDa	and	21	kDa	respectively.	These	corresponded	to	Dectin-1R	isoforms	1,	4	and	2,	3	respectively.	 Interestingly	in	comparison	the	bladder	biopsy	western	indicated	 only	 two	 forms,	 Dectin-1R	 isoforms	 1	 and	 2	 (Figure	 3.1,	 B).	 The	immunoblot	 data	 also	 indicated	 a	 range	 of	 bands	 from	 50	 kDa	 to	 60	 kDa	suggesting	 Dectin-1R	 dimers,	 which	 had	 also	 been	 observed	 in	 the	 bladder	biopsy	sample.	
	
Figure	3.4	Immunoblot	of	Dectin-1R	in	RT4	cells.		M	 -	 molecular	 weight	 marker;	 1-	 RT4	 cell	 proteins	 immunoblotted	 with	 anti-Dectin-1R	 antibody	 (1:50	 dilution).	 The	 gel	 represents	 two	 independent	experiments.	
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These	 molecular	 and	 protein	 data	 validated	 and	 underpinned	 the	 use	 of	 the	immortalised	 RT4	 cell	 line	 to	 further	 investigate	 CLEC7A	 (Dectin-1R)	 gene	expression,	protein	synthesis	and	function	in	urothelial	cells.			
 RT4	bladder	cell	challenge	with	Dectin-1R	ligands		3.4Having	identified	the	synthesis	of	two	potential	Dectin-1Rs	the	next	step	was	to	examine	receptor	functionality.	It	 is	well	documented,	albeit	 in	myeloid	derived	cells,	 that	 β-glucans	 found	 in	 the	 fungal	 cell	 wall	 stimulate	 Dectin-1R	 and	promote	 the	 expression	 of	 a	 number	 of	 pro-inflammatory	molecules	 including	TNF,	 IL1α,	 IL-8	 and	 IL-6	 [121-125].	 This	 information	was	 exploited	 to	 explore	Dectin-1R	functionality	in	the	bladder	RT4	cells.	In	addition	a	range	of	β-glucan	ligands	 were	 tested	 including	 zymosan,	 scleroglucan	 and	 curdlan,	 which	 are	found	 as	 part	 of	 the	 cell	 wall	 material	 of	 Saccharomyces	 cerevisiae,	 Sclerotium	
rolfsii	and	Alcaligenes	faecalis	respectively.		The	 expression	 and	 synthesis	 of	 a	 range	 of	 effector	 molecules	 were	 analysed	using	 molecular	 methodologies	 including	 end-point	 PCR	 and	 qRT-PCR,	 and	ELISA.	Focus	was	on	pro-	and	anti-inflammatory	molecules	including	IL1α,	IL1β,	IL-6,	 IL-8	 and	 IL-10	 although	 genes	 encoding	 antimicrobial	 peptides	 and	proteins,	and	including	DEFB4	and	LCN2	were	also	investigated.	Gene	expression	was	 initially	 investigated	using	End-Point	PCR	 following	a	 zymosan	 (50	μg/ml;	6h)	 challenge.	 The	 resultant	 data	 (Figure	 3.5),	 although	 non-quantitative,	suggested	that	the	gene	expression	of	DEFB4,	encoding	the	antimicrobial	peptide	hBD2	[126];	IL1α	and	CXCL8	encoding	proinflammatory	cytokines	IL-1α	and	IL-8	[121],	 and	LCN2	encoding	 the	 iron	 sequestering	protein	 agent	 LCN2	 [57]	were	increased	 in	 response	 to	 zymosan.	These	data	were	 further	 supported	by	qRT-PCR	analyses,	which	directed	the	use	of	these	effectors	in	future	investigations	of	bladder	Dectin-1R	function	(Figure	3.6).		 	
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Figure	 3.5	 Expression	 of	 genes	 encoding	 pro-inflammatory	 and	 host	
defence	peptides/proteins	in	RT4	cells	following	a	zymosan	challenge.		
IL1α,	IL1β,	IL-10,	IL-8,	DEFB4,	LCN2	and	IL-6	gene	End-Point	PCR	analyses	using	cDNA	prepared	from	confluent	RT4	cells	challenged	with	zymosan	(50	μg/ml;	6	h)	or	PBS.	Expected	band	sizes	were:	IL1A	–	162	bp,	IL1B	–	553	bp,	IL10	–	110	bp,	
CXCL8	–	292	bp,	DEFB4	–	83	bp,	LCN2	–	92	bp	and	IL6	-79	bp.	The	gels	represent	two	independent	experiments.		
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Figure	3.6	Expression	of	 genes	encoding	 IL1A,	CXCL8,	DEFB4,	LCN2	 in	RT4	
cells	following	zymosan	challenge.		cDNA	material	from	RT4	cells	challenged	with	zymosan	(50	μg/ml;	6	h)	was	used	to	 measure	 IL1A,	 CXCL8,	 DEFB4,	 LCN2	 gene	 expression	 using	 qRT-PCR.	 (No	statistics	are	presented	as	data	relate	to	only	one	experiment)	ie	N=1;n=3).			
3.4.1 RT4	cells	challenged	with	zymosan	To	confirm	these	molecular	data	 the	media	bathing	 the	RT4	cells	was	collected	following	 the	 zymosan	 challenges	 and	 the	 IL-8	 and	 LCN2	 concentrations	measured	 by	 ELISA.	 Data	 shown	 in	 Figure	 3.7	 supported	 significant	 increases	(p<0.001	 and	 p<0.01	 respectively)	 in	 these	 two	 effectors,	 which	 reflected	 the	molecular	data	and	suggested	Dectin-1R	functionality.		The	 initial	 RT4	 cell	 challenges	 to	 explore	 the	 Dectin-1R	 responses	 followed	procedures	 published	 in	 the	 literature	 using	 a	 zymosan	 concentration	 of	 50	μg/ml	 and	 challenge	 times	 of	 6,	 16	 and	24	 hours	 respectively	 [124].	However,	this	dose	 and	 the	 challenge	 times	were	 all	 linked	 to	 experiments	performed	 in	myeloid	derived	cells	so	to	confirm	this	concentration	was	optimal	for	urothelial	
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cells	 the	 6h	 time	 challenge	 was	 repeated,	 but	 using	 a	 range	 of	 zymosan	concentrations	 up	 to	 200	 µg/ml.	 Again	 effector	 IL-8	 and	 LCN2	 concentrations	were	measured	using	ELISA	and	data	are	shown	in	(Figure	3.7).			IL-8	concentrations	increased	from	a	mean	of	667	±	122	pg/ml	in	non-challenged	cells	to	1364	±	94	pg/ml,	2919	±	460	pg/ml,	3767	±	526	pg/ml,	4364	±	475	and	4494	±	492	pg/ml	respectively	(Figure	3.7,	A).	Figure	3.7,	B	shows	data	relating	to	the	LCN2	concentrations	measured.	The	mean	LCN2	concentration	was	866	±	9	 pg/ml	 in	 PBS	 challenged	 samples,	which	was	 not	 significantly	 different	 from	the	concentrations	measured	in	the	samples	challenged	with	5	μg/ml	of	zymosan	(825	±	50	pg/ml).	However,	mean	LCN2	concentrations	increased	to	1322	±	72	pg/ml,	 1859	 ±	 159	 pg/ml,	 2156	 ±	 44	 pg/ml	 and	 2519	 ±	 100	 pg/ml	 following	challenges	with	25,	50,	100	and	200	μg/ml	of	zymosan	respectively.		The	 challenge	 experiments	 were	 repeated	 using	 50	 μg/ml	 zymosan,	 but	 using	different	 challenge	 times.	 Figure	 3.7,	 C	 shows	 that	 the	 IL-8	 concentrations	increased	from	a	mean	of	399	±	37	pg/ml	in	PBS	challenged	cells	to	4119	±	425	pg/ml	 (p<0.0001),	 4915	 ±	 422	 pg/ml	 (p<0.0001)	 and	 4387	 ±	 410	 pg/ml	(p<0.0001)	 in	 RT4	 cells	 challenged	 with	 zymosan	 for	 6,	 16	 and	 24	 hours	respectively.	Figure	3.7,	D	demonstrated	a	similar	response	for	LCN2	with	mean	concentrations	 increasing	 from	 2669	 ±	 269	 pg/ml	 in	 PBS	 challenged	 cells	 to	4350	±	468	pg/ml	 (NS	 compared	 to	 control),	 19500	±	1377	pg/ml	 (p<0.0001)	and	22500	±	1948	pg/ml	(p<0.0001)	at	6,	16	and	24	hours	respectively.		Interestingly	the	LCN2	concentrations	presented	in	panels	B	and	D	following	the	50	 μg/ml,	 6h	 challenges	 do	 not	 concur.	 In	 panel	 B	 a	 statistically	 significant	increase	 in	 LCN2	was	 observed	while	 in	 the	 panel	D	 no	 increase	was	 detected	compared	 to	 control.	 The	 reason(s)	 for	 this	 anomaly	 is	 not	 known,	 but	 it	probably	 reflects	 the	 elevated	LCN2	 concentrations	 in	 the	PBS	 challenged	 cells	(panel	 D)	 compared	 to	 panel	 B	 (866	 ±	 9	 pg/ml	 and	 2669	 ±	 269	 pg/ml	respectively).			
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Figure	3.7	RT4	cells	challenged	with	zymosan.		Panels	A	and	B	show	IL-8	and	LCN2	concentrations	in	RT4	cells	challenged	with	5,	25,	50,	100	and	200	μg/ml	of	zymosan	for	6	hours.	Panels	C	and	D	show	IL-8	and	LCN2	concentrations	in	RT4	cells	challenged	with	50	μg/ml	of	zymosan	for	6,	16	or	24	hours.	Data	in	A	and	B	show	mean	±SD	and	N=2,	in	C	and	D	–	mean	±SD	and	N=3.	*	p<0.05,	**	p<0.01,	***	p<0.001,	****	p<0.0001.		
3.4.2 RT4	cells	challenged	with	scleroglucan	and	curdlan	Dectin-1R	function	was	further	investigated	in	RT4	bladder	cells	by	challenging	the	cells	with	two	other	β-glucans	–	scleroglucan	and	curdlan.	Scleroglucan	is	a	polysaccharide,	 which	 consists	 of	 β-(1-3)-linked	 and	 β-(1-6)-linked	 glucose	residues,	while	 curdlan	 comprises	β-(1-3)-linked	glucose	 residues.	 	 It	 has	been	shown	 previously	 that	 these	 β-glucans	 can	 promote	 cytokine	 production	 in	myeloid	derived	cells	[124,	127].	The	 manufacturer	 recommended	 a	 challenge	 concentration	 and	 time	 of	 100	μg/ml	and	24	hours.	However,	 for	 these	experiments	RT4	cells	were	 incubated	with	 100,	 125,	 250	 and	 500	 μg/ml	 of	 scleroglucan	 for	 6,	 12,	 24	 and	 40	 hours.	
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Media	bathing	the	challenged	RT4	cells	were	collected	and	analysed,	using	ELISA,	for	concentrations	of	the	cytokine	IL-8.	Data	are	presented	in	Figure	3.8.	Figure	 3.8,	 A	 shows	 the	 IL-8	 concentrations	 of	 RT4	 cells	 challenged	 with	100µg/ml	 scleroglucan	 for	 6,	 12	 and	 24	 hours	 respectively.	 The	 IL-8	concentrations	 increased	 from	 894	 ±	 20	 pg/ml	 (PBS	 challenge)	 to	 1097	 ±	 54	pg/ml,	1023	±	12	pg/ml	and	1061	±	42	pg/ml	respectively.	Increasing	the	challenge	time	to	40	hours	Figure	3.8,B	did	not	affect	the	data	with	the	concentration	of	IL-8	increasing	from	547	±	8.8	pg/ml	(PBS	challenge)	to	673	±	 33	 pg/ml.	 Increasing	 the	 scleroglucan	 concentrations	 to	 250	 and	 500	 μg/ml	and	 challenging	 for	 40	 hours,	 were	 associated	 with	 increases	 in	 IL-8	concentrations	1040	±	97	pg/ml	and	917	±	67	pg/ml.			 	
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Figure	 3.8	 RT4	 bladder	 cells	 challenged	 with	 either	 scleroglucan	 or	
curdlan.		A:	IL-8	concentrations	in	RT4	cells	following	100	μg/ml	scleroglucan	challenge	at	6,	12	and	24h;	B:	IL-8	concentrations	in	RT4	cells	following	40	hour	scleroglucan	challenge	at	concentrations	of	125,	250	and	500	μg/ml;	C:		IL-8	concentrations	in	RT4	 cells	 following	 100	 μg/ml	 curdlan	 challenge	 at	 6,	 12	 and	 24h;	 D:	 IL-8	concentrations	 in	 RT4	 cells	 following	 40	 hour	 curdlan	 challenge	 at	concentrations	of	5	to	200	μg/ml.	Data	in	A	show	mean	±SD	and	N=2;	B	–	mean	±SD	and	N=2.		Similarly,	confluent	RT4	cells	were	challenged	with	5,	25,	50,	100	and	200	μg/ml	of	curdlan	for	6,	12,	24	and	40	hours	respectively	and	IL-8	concentrations	were	measured	 using	 ELISA	 (Figure	 3.8,	 C-D).	 Media	 IL-8	 concentrations	 did	 not	change	 after	 challenging	 the	 cells	with	 100	 μg/ml	 of	 curdlan	 for	 6,	 12	 and	 24	hours	compared	to	PBS	challenged	the	cells	(Figure	3.8,	C).	Similarly	there	were	no	significant	changes	in	the	IL-8	concentrations	after	challenging	the	cells	with	either	5,	25,	50,	100	or	200	μg/ml	for	40	hours	(Figure	3.8,	D).	These	data	demonstrated	 that	 challenging	 the	RT4	bladder	 cells	with	 zymosan	resulted	 in	 a	 rapid	 innate	 defence	 response	 (6	 hours)	when	 compared	 to	 that	
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seen	using	either	scleroglucan	or	curdlan.	The	experiments	using	zymosan	also	demonstrated	 that	 a	 concentration	 of	 50	 μg/ml	 and	 challenge	 time	 of	 6	 hours	were	 sufficient	 to	 trigger	a	Dectin-1R	 innate	 response	 in	urothelial	 cells.	These	conditions	were	therefore	used	in	subsequent	experiments.			
 CLEC7A	(Dectin-1R)	knockdown	in	RT4	cells	3.5The	results	of	 the	challenge	experiments	provided	novel	data,	which	suggested	that	the	Dectin-1R	protein	plays	a	key	role	in	the	urothelial	 innate	defences.	To	explore	 this	 further	 and	 confirm	 these	 data	 it	 was	 necessary	 to	 knock-down	
CLEC7A	 (Dectin-1R)	 gene	 expression	 and	 repeat	 the	 challenge	 experiments.	 To	reduce	potential	 issues	 linked	 to	 variable	 knock-down	 resulting	 from	 transient	gene	knock-downs	it	was	decided	to	engineer	a	RT4	cell	line	in	which	Dectin-1R	gene	expression	was	stably	knocked-down.		To	achieve	this	knock-down	the	RT4	cells	 were	 stably	 transfected	 with	 a	 commercial	 siRNA,	 psiRNA-Dectin-1	(Invivogen),	which	expresses	siRNA	targeting	CLEC7A	(Dectin-1)	gene	expression	(Figure	3.9).			
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Figure	 3.9	 Plasmid	 vector	 psiRNA	 used	 to	 stably	 knock-down	 CLEC7A	
(Dectin-1R)	gene	expression	in	RT4	cells.		This	plasmid	contains	the	gene	encoding	resistance	to	the	antibiotic	zeocin	(zeo)	used	to	select	stably	transfected	cells	and	the	gene	encoding	GFP.			
3.5.1 Cell	transfection	Before	transfection	of	the	RT4	cells	the	plasmid	psiRNA-Dectin-1	was	amplified	in	 E.	 coli	 and	 purified	 as	 described	 in	 Section	 2.25.	 To	 validate	 the	 purified	plasmid	 it	 was	 restricted	 with	 enzymes	 HindIII	 and	 NcoI,	 which	 as	 predicted	produced	 DNA	 fragments	 of	 2780	 bp	 and	 820	 bp	 (Figure	 3.10,	 A:	 lane	 1)	confirming	the	authenticity	of	the	purified	plasmid.		In	addition	the	Dectin-1	siRNA	fragment	in	the	plasmid	was	amplified	using	End-Point	PCR	and	analysed	on	an	agarose	gel	(Figure	3.10,	A:	lane	2).	The	amplified	DNA	fragment	of	210	bp	was	as	predicted	and	this	was	confirmed	by	sequencing	(Figure	3.10,	B).		
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Figure	3.10	Analysis	of	psiRNA-Dectin-1	plasmid	using	restriction	enzymes,	
End-Point	PCR	and	sequencing.		A:	M-	base	pair	marker;	Lane	1-	Purified	psiRNA-Dectin-1	plasmid	restricted	with	
HindIII	 and	 NcoI	 restriction	 enzymes;	 Lane	 2	 -	 Dectin-1	 target	 sequence	amplified	 using	 End-Point	 PCR.	 B:	 sequence	 data	 confirming	 Dectin-1	 target	sequence.		Once	 the	 plasmid	 was	 verified	 RT4	 cells	 were	 transfected	 with	 the	 plasmid	(Section	2.26)	and	cells	expressing	the	siRNA	selected	using	the	antibiotic	zeocin	(100	 μg/ml).	 Within	 two	 weeks	 zeocin	 resistant	 cells,	 which	 formed	 colonies,	were	 identified	 (Figure	 3.11).	 Surviving	 colonies	 were	 trypsinised,	 pooled,	cultured,	 passaged,	 analysed	 and	 utilised	 in	 challenge	 experiments	 as	 a	 ‘mixed	colony’	 cell-line.	 Control	 RT4	 cells	 were	 stably	 transfected	 with	 the	 psiRNA-Luciferase	plasmid	(siLuc)	(Invivogen)	and	similarly	selected	using	zeocin	(100	μg/ml).		
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Figure	3.11	Colonies	of	RT4	cells	expressing	psiRNA-Dectin-1	and	selected	
using	zeocin	containing	(100	μg/ml)	media.		A:	a	colony	of	surviving	cells	B:	dying	cells.		The	psiRNA-Dectin-1R	plasmid	contains	a	GFP	gene	sequence	(Figure	3.9),	which	is	 expressed	 in	 both	 bacteria	 and	 mammalian	 cells.	 Before	 any	 molecular	 or	protein	 analyses	were	 performed	 this	 property	 ie	 GFP	 expression	was	 used	 to	microscopically	examine	the	pooled	stably	transfected	RT4	cells.	This	approach	was	used	as	the	engineered	cell-line	was	a	mix	of	cell	clones	and	monitoring	the	cells	 visually	 for	 GFP	 variability,	 would	 provide	 information	 relating	 to	 the	reproducibility	of	the	CLEC7A	(Dectin-1R)	knock-down.			To	 achieve	 this	 the	 stably	 transfected	 cells	 were	 cultured	 to	 confluence	 on	coverslips,	 fixed	using	4%	PFA	and	visualised	using	microscopy	 (Section	2.18).	Typical	 data	 are	 shown	 in	 Figure	 3.12.	 Panel	 A	 shows	 control	 RT4	 cells	 stably	transfected	with	psiRNA-Luciferase	plasmid	(siLuc)	and	panel	B	shows	Dectin-1R	knockdown	 RT4	 cells	 (siDct1).	 	 While	 background	 fluorescence	 or	 auto-florescence,	typified	the	control	RT4	cells	(A)	the	intensity	of	the	florescence	was	
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much	 stronger	 in	 the	 knockdown	 cells	 (B)	 confirming	 the	 presence	 and	functioning	 of	 the	 plasmid,	 psiRNA-Dectin-1.	 Visual	 inspection	 suggested	 GFP	expression	was	homogeneous	which	reduced	the	risk	of	variable	Dectin-1R	gene	knock-down	impacting	subsequent	data.		
	
Figure	3.12	Microscopy	of	RT4	cells	transfected	with	psiRNA-Luciferase	and	
psiRNA-Dectin-1.		A:	 Control	 RT4	 cells	 (siLuc),	 B:	 Dectin-1R	 knockdown	 RT4	 cells	 (siDct1)	examined	 for	 GFP	 (green	 colour),	 C:	 DAPI	 stained	 nuclei	 of	 siLuc	 RT4	 cells,	 D:	DAPI	 stained	 nuclei	 of	 siDct1	 RT4	 cells.	 Images	 were	 taken	 	 using	 	 Zeiss		Axioimager	II	fluorescent		microscope	and	400x	magnification.		Once	 the	 cells	 were	 verified	 for	 GFP	 expression	 using	 microscopy	 the	effectiveness	of	the	Dectin-1R	knockdown	in	the	stably	transfected	RT4	cells	was	examined	using	molecular	(qRT-PCR)	and	protein		(western	blot)	approaches.		Figure	 3.13,	 A	 shows	 the	 results	 of	 the	 qRT-PCR	 analyses,	 in	which	 Dectin-1R	mRNA	 levels	 in	 RT4	 cells	 transfected	 with	 psiRNA-Dectin-1	 plasmid	 (siDct1)	were	compared	to	those	in	RT4	cells	transfected	with	control	psiRNA-Luciferase	plasmid	(siLuc).	These	data	showed	that	the	Dectin-1R	mRNA	level	in	the	Dectin-
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1R	 gene	 knock-down	 cells	 was	 71	 ±	 5%	 (mean	 ±	 SEM;	 n=6)	 lower	 than	 that	measured	in	the	control	cells.	Figure	3.13,	B	shows	the	western	data	comparing	Dectin-1R	protein	levels	 in	knock	down	cells	to	those	in	the	control	cells.	Using	the	 anti-Dectin-1R	 antibody	 (AF1859),	 bands	 relating	 to	 Dectin-1R	 protein	isoforms	 1	 and	 4	 (27	 kDa	 and	 17	 kDa)	were	 detected	 in	 the	 control	 RT4	 cells	(siLuc)	 (Figure	 3.13,	 B).	 The	 same	 bands	 were	 detected	 in	 the	 western	 blots	relating	 to	 the	 Dectin-1R	 knockdown	 cells,	 but	 the	 signals	 were	 significantly	reduced,	supporting	effective	receptor	protein	knock-down.	
	
Figure	3.13	Dectin-1R	mRNA	expression	and	protein	synthesis	 in	Dectin-1	
knock-down	RT4	cells.		A:	Fold	change	in	Dectin-1R	mRNA	expression	in	Dectin-1R	knockdown	RT4	cells	(siDct1)	and	control	RT4	cells	stably	transfected	with	psiRNA-Luciferase	plasmid	(siLuc).	B:	 Immunoblot	of	Dectin-1R	proteins	 in	Dectin-1R	knockdown	(siDct1)	and	control	(siLuc)	RT4	cells	using	anti-Dectin-1	antibody	(1:50	dilution).	mRNA	expression	data	shows	mean	±SD	and	N=4.	****	p<0.0001.	The	western	blot	data	represents	two	independent	experiments.		These	 data	 confirmed	 that	 the	 RT4	 cells	were	 stably	 transfected	with	 psiRNA-Dectin-1	plasmid	 and	 showed	decreased	 expression	of	 the	CLEC7A	 (Dectin-1R)	gene	and	synthesis	of	Dectin-1R.	These	data	therefore	suggested	that	this	stably	transfected	cell	 line	was	a	good	model	to	further	investigate	Dectin-1R	function	in	bladder	epithelial	cells.		
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3.5.2 CLEC7A	(Dectin-1R)	knockdown	RT4	cells	challenged	with	
zymosan	The	stably	transfected	Dectin-1R	knockdown	RT4	cells	were	used	to	confirm	the	roles	 of	 the	 Dectin-1R	 protein	 in	 sensing	 and	 responding	 to	 β-glucan	 in	 the	bladder	 epithelia.	 	 These	 knockdown	 cells	 were	 challenged	 as	 previous	 with	zymosan	 (50	 μg/ml;	 6h)	 and	 mRNA	 expression	 of	 DEFB4,	 CXCL8	 and	 LCN2	measured	by	qRT-PCR.	The	resultant	data	demonstrated,	 interestingly,	 that	 the	challenge	was	associated	with	the	increased	expression	of	DEFB4	by	11.5	±	2	and	27.7	 ±	 5.6	 fold	 in	 the	 control	 (siLuc)	 and	 knockdown	 (siDct1)	 RT4	 cells	respectively	(Figure	3.14,	A.			
	
Figure	3.14	DEFB4,	CXCL8	 and	LCN2	mRNA	expression	 in	 siDct1	RT4	 cells	
challenged	with	zymosan.		Panels	show	DEFB4	(A),	CXCL8	(B)	and	LCN2	(C)	mRNA	expression	(fold	change)	in	control	RT4	cells	(siLuc)	and	knock-down	RT4	cells	(siDct1)	challenged	with	zymosan	(50	μg/ml)	for	6	hours.	Data	show	mean	±SD	and	N=2.	
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	Gene	expression	of	CXCL8	increased	65	±	5.8	fold	in	the	control	cells	(siLuc)	and	47	±	4.9	 fold	 in	 the	knock	down	cells	 (siDct1)	 following	 the	zymosan	challenge	(Figure	3.14,	B).	However	the	knock	down	of	CLEC7A	(Dectin-1R)	was	associated	with	a	25%	reduction	in	CXCL8	expression	compared	to	the	control.	In	response	to	the	zymosan	challenge	LCN2	gene	expression	increased	3.7	±	0.4	fold	in	the	control	cells	(siLuc)	but	5.8	±	1.2	fold	in	the	knockdown	cells	(siDct1)	(Figure	3.14,	C).	These	data	indicated	that	the	challenged	Dectin-1R	knock-down	cells	 expressed	60%	more	LCN2	compared	 to	 the	 control	 cells.	However,	 these	data	were	associated	with	large	error	bars.	However,	these	results	demonstrated	that	challenging	the	Dectin-1R	knockdown	RT4	 cells	 with	 zymosan	 impacted	 DEFB4,	 CXCL8	 and	 LCN2	 gene	 expression	patterns.	The	knockdowns	were	associated	with	an	increase	in	DEFB4,	decrease	in	CXCL8	but	no	change	in	LCN2	gene	expression.			Media	 bathing	 the	 cells	 was	 not	 collected	 from	 any	 of	 these	 experiments	therefore	 these	 molecular	 data	 were	 not	 supported	 by	 effector	 protein	measurements.			
 Dectin-1R	blocking	with	antibody	and	challenging	with	3.6
zymosan	To	help	confirm	these	data	a	different	approach	was	taken	using	the	monoclonal	anti-Dectin-1R	antibody	(MAB1859).	This	antibody	was	used	to	inhibit	Dectin-1R	functioning	in	RT4	cells	prior	to	a	zymosan	challenge.	The	blocking	antibody	was	used	 at	 two	 concentrations,	 6	 μg/ml	 and	 3	 μg/ml	 prior	 to	 the	 cells	 being	challenged	 with	 zymosan	 (50	 μg/ml)	 for	 6h.	 Also	 non-specific	 IGG	 antibodies	were	 used	 at	 6	 μg/ml	 in	 the	 control	 samples.	 These	 antibody	 concentrations	were	selected	following	manufacturer	recommendations	that	indicated	100	and	50%	 blocking	 of	 the	 Dectin-1R	 respectively.	 In	 these	 experiments	 the	 media	bathing	 the	 cells	 were	 analysed	 by	 ELISA	 for	 effector	 protein,	 IL-8	 and	 LCN2,	concentrations.		
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The	IL-8	and	LCN2	data	are	shown	in	Figure	3.15,	which	are	presented	as	mean	concentration	and	mean	fold	change.		Panel	A	shows	that	challenging	the	cells	with	zymosan	resulted	in	increase	of	IL8	secretion	 from	 590	 ±	 57	 pg/ml	 to	 3407	 ±	 325	 pg/ml.	 When	 the	 cells	 were	blocked	with	6	or	3	μg/ml	of	 antibody	 this	 response	decreased	 significantly	 to	2384	 ±	 123	 pg/ml	 and	 2290	 ±	 251	 pg/ml	 respectively	 (p<0.01).	 To	 address	potential	variability	between	experiments	the	data	were	also	normalised	to	the	control	cells	challenged	with	zymosan	and	similarly	these	data	showed	statistical	significance	(p=0.001)	(Figure	3.15,	C).		Data	 in	 the	 panel	 B	 demonstrated	 that	 challenging	 the	 cells	 with	 zymosan	increased	LCN2	media	concentrations	from	1126	±	247	pg/ml	to	3612	pg/ml	±	684	pg/ml.	Blocking	Dectin-1R	with	6	or	3	μg/ml	antibody	resulted	in	a	decrease	in	LCN2	concentrations	to	1914	±	495	pg/ml	and	2216	±	530	pg/ml	respectively.	However,	this	change	was	not	statistically	significant	with	p	values	of	p=0.33	and	p=0.17	 respectively.	 When	 the	 data	 were	 normalised	 to	 the	 controls	 cells	challenged	 with	 zymosan	 the	 decrease	 in	 LCN2	 concentrations	 in	 the	 cells	blocked	with	6	μg/ml	was	shown	to	be	statistically	significant	(p=0.05).		
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Figure	3.15	Dectin-1	blocking	in	RT4	cells	and	zymosan	challenge.		A:	 IL-8	 fold	 change	 in	 RT4	 cells	 treated	 with	 Dectin-1R	 blocking	 antibody	 (6	μg/ml	or	3	μg/ml)	and	challenged	with	zymosan	(50	μg/ml)	for	6	hours.	B:	LCN2	fold	change	in	RT4	cells	treated	with	Dectin-1R	blocking	antibody	(6	μg/ml	or	3	μg/ml)	and	challenged	with	zymosan	(50	μg/ml)	 for	6	hours	Data	shows	mean	±SD	and	N=3.	*	p=0.05.		Media	hBD2	concentrations	were	also	measured	using	ELISA,	but	in	all	cases	the	values	measured	were	at	or	below	the	ELISA	detection	limit	and	these	data	have	not	been	presented.		These	 data	 suggested	 that	 blocking	 of	 the	 Dectin-1	 receptor	 protein	 and	challenging	with	zymosan	resulted	in	the	decreased	synthesis	of	IL-8	and	LCN2	by	 the	 urothelial	 cells.	 These	 data	 were	 supportive	 of	 the	 molecular	 data	reported	using	the	Dectin-1R	gene	knockdown	approach	and	validated	a	role	for	Dectin-1R	in	the	innate	response	of	urothelial	cells	to	β-glucan	and	potentially	β-glucan	containing	microbes.		
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 TRL2	synthesis	in	RT4	cells	3.7Previous	 studies	 demonstrated	 that	 zymosan	 could	 stimulate	 TLR2	 in	myeloid	cells	 [74].	 To	 investigate	 if	 TLR2	 is	 present	 in	 RT4	 cells	 a	 western	 blot	 was	performed	 using	 RT4	 cell	 lysate	 and	 anti-TLR2	 antibodies.	 The	 data	 shown	 in	Figure	 3.16	 did	 not	 suggest	 a	 TLR2	 band	 in	 the	 RT4	 sample,	 but	 a	 band	representing	TLR2	(90	kDa)	was	detected		in	the	CHO	cells.	
	
Figure	3.16	TLR2	synthesis	in	RT4	and	CHO	cells.		The	immunoblot	demonstrates	synthesis	of	TLR2	(arrows)	in	RT4	and	CHO	cells.	M	 -	 molecular	 weight	 marker.	 The	 blot	 shown	 is	 representative	 of	 two	independent	experiments.		
 Discussion	3.8The	work	presented	 in	 this	 chapter	 investigated	 the	gene	 (CLEC7A)	 expression	and	Dectin-1R	protein	synthesis	in	human	bladder	material	and	in	RT4	bladder	epithelial	 cells.	 It	 also	 exploited	 gene	 knock-down	 and	 antibody	 blocking	approaches	to	explore	the	gene	expression	and	protein	synthesis	of	host	defence	peptides/proteins	 including	 hBD2,	 IL-8,	 LCN2	 and	 IL1α	 in	 RT4	 bladder	 cells	challenged	 with	 zymosan.	 Zymosan	 is	 a	 Dectin-1R	 agonist,	 which	 contains	 β-
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glucan	and	was	used	to	model	potential	bladder	pathogens	containing	β-glucan	challenging	the	urinary	tract	tissues.		Analysis	of	human	bladder	biopsy	revealed	the	expression	of	CLEC7A	(Dectin-1R)	gene	 transcripts	 with	 a	 strong	 cDNA	 band	 of	 330	 bp	 linking	 directly	 to	 the	synthesis	of	a	25	kDa	receptor	protein	(Figure	3.1,	B).	However,	these	data	were			limited	in	that	only	one	bladder	biopsy	sample	was	analysed.		These	data	would	therefore	be	strengthened	by	analyses	of	additional	bladder	samples	 from	both	male	and	female	donors.	Also	as	there	was	no	clinical	data	to	either	support	or	refute	that	the	donor	was	suffering	a	urinary	tract	infection	it	cannot	be	ignored	that	these	data	actually	reflected	an	infected	state.	However,	this	was	extremely	unlikely	 as	 the	 ethics	 governing	 biopsy	 procedure	 precluded	 any	 sampling	 of	patients	suffering	an	active	infection.		The	 bladder	 biopsy	 data	 did	 however	 support	 Dectin-1R	 synthesis,	 which	inferred	 the	 receptor	 to	 function	 directly	 in	 the	 bladder	 innate	 defences.		Importantly	 however,	 contamination	 of	 the	 bladder	 sample	 with	 blood	 and	therefore	myeloid	derived	cells	such	as	macrophages	and	dendritic	cells,	which	are	 known	 to	 synthesise	 Dectin-1R	 [116,	 128,	 129]	 cannot	 be	 excluded.	Therefore	to	further	explore	the	roles	of	the	Dectin-1R	in	the	bladder	epithelium	an	in	vitro	approach	was	adopted	and	the	RT4	urothelial	cell-line	which	closely	models	the	bladder	was	selected	for	all	further	studies	[119].		Molecular	 analyses	 of	 the	 RT4	 cell	 RNA	 revealed	 five	 Dectin-1	 cDNA	 bands	reflecting	five	different	transcripts	including	those	encoding	Dectin-R	isoforms	1	and	 2	 identified	 in	 the	 bladder	 biopsy	 (Figure	 3.2,	 A).	 The	most	 intense	 band	related	to	cDNA	band	4	although	the	corresponding	encoded	protein	isoform	was	not	detected	in	the	bladder	biopsy.		Interestingly	it	has	been	reported	previously	that	this	isoform	cannot	bind	zymosan	and	regulatory	roles,	comparable	to	other	cell	 receptors	 including	 CD40	 and	 scavenger	 receptor	 type	 A,	 have	 been	attributed	to	its	function	[102].			Interestingly	 immunoblotting	 of	 RT4	 material	 detected	 the	 non-functional	isoform	4	(17	kDa)	protein	band,	but	also	isoforms	1	and	2	(27	kDa	and	25	kDa	respectively)	 that	 link	 to	 functional	Dectin-1Rs.	 	 The	major	difference	between	
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Dectin-1R	 isoform	 4	 and	 isoforms	 1	 and	 2	 is	 that	 isoform	 4	 has	 a	 shorter	carbohydrate	 binding	 domain	 and	 four	 cysteine	 amino	 acids	 compared	 to	 six,	which	 prevents	 it,	 structurally,	 from	 binding	 zymosan.	 None-the-less,	 since	human	bladder	and	RT4	cells	both	synthesised	the	functional	Dectin-1R	isoforms	1	 and	2,	RT4	 cells	were	 chosen	as	 an	 appropriate	 in	vitro	model	 to	 investigate	Dectin-1R	functioning	in	the	innate	protection	of	the	bladder	epithelium.	To	 date	 there	 has	 been	 little	 research	 relating	 to	 Dectin-1R	 synthesis	 and	functionality	 in	 epithelia.	 Dectin-1Rs	 have	 been	 identified	 in	 the	 gut,	 lung	 and	cornea	 [91,	 130,	 131],	which	 like	 the	bladder	 are	 directly	 exposed	 to	 potential	fungal	infections	from	organisms	including	the	yeast	Candida.	However,	most	of	the	 Dectin-1R	 research	 has	 focussed	 on	 the	 innate	 protection	 mechanisms	operating	 in	 myeloid	 derived	 cells	 including	 monocytes,	 macrophages	 and	dendritic	cells	[116,	120,	128,	129,	132].		Eight	 Dectin-1R	 isoforms	 have	 been	 shown	 to	 be	 produced	 in	 human	macrophages	[102],	with	two	major	isoforms	known	as	A	and	B,	corresponding	to	 isoforms	 1	 and	 2	 in	 this	 study.	 These	 data	 suggest	 that	 regardless	 of	 tissue	isoforms	1	and	2	are	key	receptors	functioning	to	help	protect	against	infection	from	β-glucan	containing	microbes.	Isoform	1	is	characterised	by	a	carbohydrate	binding	 domain	 bound	 to	 a	 stalk	 region,	 while	 isoform	 2	 lacks	 the	 stalk.	 	 In	relation	 to	 functionality	 it	 has	 been	 shown	 in	murine	 fibroblasts	 that	 the	 full-length	Dectin-1R	 (isoform	A/isoform	1)	 binds	 β-glucans	with	 higher	 affinity	 at	temperatures	lower	than	37°C	than	the	truncated	isoform	(isoform	B/isoform	2)	[101]	 although	 the	 functional	 significance	 of	 this	 observation	 remains	 to	 be	determined.	Challenging	 RT4	 bladder	 cells	 with	 zymosan,	 which	 is	 a	 natural	 ligand	 of	 the	Dectin1R,	 resulted	 in	 the	 upregulation	 of	 genes	 encoding	 innate	 host	 defence	effector	molecules	including	hBD2,	IL-8	and	LCN2	within	a	six	hour	period.	Gene	knockdown	 and	 antibody	 blocking	 studies	 confirmed	 the	 role	 of	 the	Dectin-1R	and	supported	the	receptor	functioning	as	a	key	player	in	the	innate	protection	of	the	bladder	tissue.	This	probably	extends	to	the	uro-genital	tract	as	previous	work	in	the	 laboratory	showed,	using	the	vaginal	epithelial	cell	 line	VK2	E6/E7	
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that	 hBD2	 synthesis	 is	 increased	 in	 response	 to	 zymosan	 [83].	 Similarly,	 hBD2	and	IL1α	up-regulation	were	reported	in	PK	E6/E7	cells	[123].		HBD2	is	a	potent	microbial	killing	agent	and	activator	of	antigen	presenting	cells	[47,	 133,	 134]	 and	 it	 has	 also	 been	 shown	 to	 be	 synthesised	 in	 response	 to	zymosan	 challenge	 in	 epithelial	 cells	 [40,	 131].	 Similarly	 secretion	 of	 the	 pro-inflammatory	molecule,	 IL-8,	 has	 been	widely	 reported	 in	 various	 cells	 and	 in	response	to	various	β-glucans	[122,	135,	136].	The	data	reported	in	this	study	in	relation	 to	 LCN2	 is	 novel	 although	 upregulation	 of	 LCN2	 gene	 expression	 has	been	shown	in	primary	hepatic	cells	challenged	with	zymosan	[137].	The	scarcity	of	 LCN2	 data	 probably	 relates	 to	 fact	 that	 most	 Dectin-1R	 research	 relates	 to	myeloid	derived	cells,	which	do	not	synthesise	LCN2.		In	 fact	data	 from	studies	 focussed	on	human	DCs,	monocytes	and	macrophages	have	 reported	 that	 zymosan	 can	 stimulate	 the	 secretion	 of	 a	 number	 of	 pro-inflammatory	cytokines	including	IL1β,	IL-6,	IL-12,	TNF-α	and	anti-inflammatory	cytokines	 namely	 IL-10	 [121,	 135,	 138].	 In	 contrast	 data	 from	 this	 study,	focussed	on	bladder	RT4	 cells,	 suggested	no	 change	 in	 the	expression	of	 genes	encoding	 either	 IL1β,	 IL-6	 or	 IL-10.	 These	 data	 suggest	 that	 the	 response	 of	epithelial	 cells	 to	 β-glucan	 containing	 microbes	 may	 differ	 slightly	 when	compared	to	that	of	myeloid	derived	cells	and	that	this	response	may	reflect	the	defence	mechanisms	operating.	 For	 example,	while	macrophages	 and	dendritic	cells	 can	switch	on	phagocytosis	 to	clear	potential	pathogens	 from	an	 infection	site,	epithelial	cells	do	not	have	this	option.	Epithelial	cells	need	to	kill	pathogens	directly	e.g.	 through	 the	synthesis	of	direct	killing	agents	 such	as	 the	defensins	and	 LCN2;	 their	 back-up	 is	 the	 synthesis	 of	 pro-inflammatory	 molecules	 that	attract	 other	 immune	 cells	 to	 the	 infection	 site	 and	 which	 function	 as	reinforcements.	Increasing	the	zymosan	challenge	concentration	from	50	µg/ml	to	200	µg/ml	did	not	significantly	affect	the	IL-8	concentrations	measured	at	6	hours	in	the	media	bathing	 the	 RT4	 cells	 (Figure	 3.7,	 A).	 This	 observation	 contrasted	 to	 the	increased	 IL-8	 concentrations	 observed	 in	 whole	 blood	 cells	 challenged	 with	increasing	 doses	 of	 zymosan	 [124].	 These	 RT4	 bladder	 cell	 data	 therefore	
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suggest	that	either	the	Dectin-1	receptors	on	the	RT4	cells	were	saturated	at	50	
µg/ml	 zymosan	 or	 that	 IL-8	 expression	 was	 regulated	 by	 a	 negative	 feedback	loop	 mechanism	 functioning	 presumably	 to	 control	 inflammation	 and	 prevent	cell	 damage.	 	 The	 fact	 that	 the	 IL-8	 data	 at	 6	 hours	 post	 challenge	 was	 also	comparable	 to	 the	 16	 and	 24	 hour	 data	 (Figure	 3.7),	 supported	 a	 negative	feedback	loop	mechanism.	Interestingly,	it	has	been	shown	in	monocytes	that	the	IL-8	 concentration	 increased,	 but	 then	 stabilised	 after	 8	 hours	 of	 stimulation	with	zymosan	[136],	again	suggesting	that	there	are	factors	operating	to	control	IL-8	production	and	the	inflammatory	response.		This	 pattern	 was	 not	 observed	 with	 LCN2	 as	 increasing	 concentrations	 of	zymosan	 were	 associated	 with	 significantly	 increased	 LCN2	 concentrations	(Figure	3.7,	B).	These	data	probably	reflect	the	killing	mechanism	of	the	effector.	Essentially	LCN2	is	a	potent	microbial	killing	agent	that	directly	targets	microbes.	Therefore	its	synthesis	is	in	direct	response	to	β-glucan	concentrations	which	in	
vivo	reflect	pathogen	numbers.	It	would	have	been	optimal	for	these	LCN2	data	to	 be	 supported	 by	 hBD2	 data.	 However,	 issues	with	 the	 hBD2	 ELISA	 relating	different	batches	of	antibody	meant	these	data	were	not	available.		Interestingly	knock-down	of	 the	CLEC7A	 (Dectin1-	R)	gene	was	associated	with	increased	 DEFB4	 and	 LCN2	 gene	 expression	 (Figure	 3.14,	 A	 &	 C).	 These	observations	 were	 difficult	 to	 explain	 and	 thought	 initially	 to	 reflect	 technical	issues.	However,	focussing	on	LCN2	the	effect	was	also	observed	in	experiments	described	 in	 chapter	 Chapter	 4	 and	 these	 data	 are	 discussed	 further	 in	 the	discussion	accompanying	chapter	Chapter	4.			The	ability	of	RT4	cells	to	respond	to	other	Dectin-1R	ligands	was	investigated	by	challenging	 RT4	 cells	 with	 the	 polysaccharides	 scleroglucan	 and	 curdlan.	Scleroglucan	consists	of	β-(1-3)-linked	and	β-(1-6)-linked	glucose	residues,	while	curdlan	 contains	 β-(1-3)-linked	 glucose	 residues.	 These	 β-glucans	 have	 been	reported	 to	 bind	 to	 Dectin-1	 receptors	 and	 stimulate	 the	 production	 of	 pro-inflammatory	 cytokines	 in	 blood	 cells	 including	 monocytes,	 macrophages	 and	dendritic	cells	 [124,	127,	139,	140].	Scleroglucan,	but	not	curdlan,	 induced	IL-8	synthesis	in	the	RT4	bladder	cells.	This	was	surprising	as	curdlan	comprises	β1-3	
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linked	glucose	residues	and	has	been	shown	in	other	studies	using	macrophages,	dendritic	cells	and	lymphocytes	to	induce	pro-inflammatory	molecules	including	TNFa,	IL6,	IL2,	IL8	and	IL12	[124,	125,	141].	These	data	therefore	indicated	that	either	 the	 size	 and/or	 structure	 of	 curdlan	 did	 not	 facilitate	 Dectin-1R	binding/signalling	in	RT4	cells.		The	 curdlan	 used	 was	 sourced	 commercially	 and	 is	 purified	 from	 the	 soil	bacterium,	Alcaligenes	faecalis.		Unlike	antigen	presenting	cells	circulating	in	the	blood	 the	 bladder	 tissues	 are	 less	 likely	 to	 be	 exposed	 to	 a	 soil	 organism.	Therefore	 it	 is	 feasible	 that	 the	 RT4	 bladder	 Dectin-1R	 proteins	 bound	 the	 β-glucan	 material	 relating	 to	 A.faecalis,	 but	 that	 binding	 did	 not	 result	 in	 a	signalling	cascade	and	an	effector	response.	However,	as	Sclerotium	rolfsii	used	to	 purify	 scleroglucan	 is	 also	 a	 soil	 organism	 this	 seems	 unlikely.	 It	 is	 also	feasible	 that	 the	A.faecalis	 preparation	 was	 not	 pure	 and	 contained	molecules	that	 inhibited	 curdlan	 binding	 to	 the	RT4	bladder	Dectin-1R	proteins	 although	this	 needs	 further	 investigation	 for	 example	 by	 using	 different	 sources	 and	batches	of	curdlan.		It	 is	 acknowledged	 that	 the	 zymosan	preparation	used	 in	 these	 challenges	was	also	not	pure	and	was	probably	 contaminated	with	LPS,	which	stimulates	Toll-like	receptors	2	and	4	[142].	The	argument	could	be	made	therefore	that	it	was	the	LPS	and	not	the	β-glucan	that	triggered	the	effector	response	in	the	bladder	RT4	cells.	However,	it	has	been	shown	previously	that	challenging	RT4	cells	with	LPS	 for	 6	 hours	 does	 not	 stimulate	 a	 significant	 host	 effector	 response	 [40]	suggesting	 that	 LPS	 was	 not	 directly	 responsible	 for	 the	 effects	 observed	following	 the	 zymosan	 challenges.	 Additionally	 incubating	 RT4	 cells	 with	antibody	 to	TLR2	before	 challenging	with	 zymosan	 (50	µg/ml	 for	 eight	 hours)	did	 not	 affect	 the	 NF-κB	 signalling	 response	 [83],	 which	 supports	 a	 direct	zymosan-Dectin-1R	effect.				In	 summary	 these	 data	 demonstrated	 that	 RT4	 bladder	 cells	 expressed	transcripts	encoding	 five	potential	Dectin-1R	 isoforms	and	the	synthesis	of	 two	isoforms	 –	 a	 full-length	 Dectin-1R	 (isoform	 1)	 and	 a	 truncated	 Dectin-1R	(isoform	 4)	 was	 detected.	 The	 Dectin-1R	 ligands	 zymosan	 and	 scleroglucan	
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stimulated	the	expression	of	genes	encoding	the	host	defence	effector	molecules	hBD2,	IL1α,	IL-8	and	LCN2.	Gene	(CLEC7A)	knockdown	and	antibody	blocking	of	Dectin-1R	confirmed	 that	zymosan	stimulated	 the	Dectin-1	receptor	 to	activate	the	 synthesis	 of	 pro-inflammatory	 molecules	 eg	 IL-8	 and	 host	 antimicrobial	agents	 eg	 LCN2.	However,	 it	 is	 not	 known	 from	 the	 knock-down	 and	 antibody	blocking	 data,	 which	 Dectin-1R	 receptor,	 isoform	 1	 or	 2	 or	 both,	 were	responsible	 for	 the	 host	 effector	 response.	 To	 explore	 this	 further	 isoform	specific	knock-down	experiments	will	be	necessary.			 	
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Chapter	4 .	Co-operation	of	Dectin-1R	and	TLR5	in	RT4	
cells	
Data	reported	in	previous	chapter	supported	the	presence	of	 functional	Dectin-1Rs	 on	 urothelial	 cells.	 The	 fact	 that	 these	 receptors	 responded	 to	 β-glucan	(zymosan)	 through	 the	 increased	 synthesis	 of	 host	 defence	 peptides/proteins	suggested	 important	 roles	 for	 the	 receptors	 in	 the	 innate	 defence	 of	 the	urothelial	tissues.	 	Additionally	these	data	predict	that	the	receptors	respond	to	and	help	defend	against	β-glucan	containing	microbes,	specifically	yeasts	which	can	contaminate	the	urinary	tract	through	the	gut-faecal	route.	The	urinary	tract	as	discussed	in	Section	1.2	(page	5)	is	susceptible	to	infection	by	 uropathogenic	 bacteria,	which	 are	 characterised	 by	 the	 presence	 of	 flagella	and	their	motility.	Uropathogenic	bacteria	such	as	uropathogenic	Escherichia	coli	(UPEC)	 are	 detected	 via	 TLR5	 receptors	 located	 on	 host	 bladder	 cells,	 which	respond	to	flagellin	proteins	by	activating	the	innate	host	antimicrobial	defences	[40].	 Interestingly	 previous	 data	 from	 the	 laboratory	 exploring	 TLR5	 NFκB	signalling	 responses	 showed	 that	 blocking	 TLR5	 functionality	 in	 RT4	 bladder	epithelial	 cells	 and	 challenging	with	 zymosan	 reduced	NF-κB	signalling	 (Figure	4.1;	 [83]),	which	 hinted	 at	 potential	 cooperation	 between	Dectin-1R	 and	 TLR5	receptors	 in	 the	 bladder	 epithelial	 cells.	 	 These	 data	 were	 surprising	 as	 the	literature,	 albeit	 focussed	 on	 antigen	 presenting	 cells,	 suggests	 that	 Dectin-1R	cooperates	 with	 TLR2	 and	 TLR4,	 but	 not	 TLR5	 [103,	 104,	 129,	 143]	 and	 that	TLR5	unlike	other	TLRs	only	functions	as	a	homodimer	[78,	118,	144].						
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Figure	 4.1	 NF-κB	 activity	 in	 RT4	 cells	 in	 which	 TLR5	 was	 blocked	 with	
antibody	and	challenged	with	zymosan.	(Lanz,	2013)	[83].		Using	 the	 RT4	 bladder	 cell	 line	 this	 Chapter	 aimed	 to	 further	 explore	 the	potential	TLR5/Dectin-1R	relationship	in	urothelia.			
 Immunostaining	of	Dectin-1	and	TLR5	proteins	in	RT4	cells	4.1Immunocytochemistry,	 using	 antibodies	 raised	 to	 the	 Dectin-1R	 (monoclonal,	R&D	systems,	MAB1859)	and	TLR5	(polyclonal,	Abcam,	ab37071)	receptors	was	initially	 utilised	 to	 confirm	 Dectin-1R	 and	 TLR5	 synthesis	 in	 the	 bladder	 RT4	cells	and	to	explore	potential	co-localisation	of	the	two	receptors	(Section	2.16).		Data	 presented	 in	 Figure	 4.2	 show	 TLR5	 (blue),	 Dectin-1R	 (green)	immunostaining	 in	RT4	 cells	 challenged	with	 zymosan	 (50	μg/ml,	 6h).	 Panel	A	demonstrates	RT4	cell	nuclei	stained	with	propidium	iodide	(red),	panel	B	shows	immuno-staining	 with	 TLR5	 and	 panel	 C	 staining	 with	 Dectin-1R	 antibodies	respectively.	Panels	E	and	F	show	results	of	staining	with	IgG	control	antibodies	and	 secondary	 Alexa	 Fluor	 488	 or	 350	 antibodies.	 Interestingly	 the	 Dectin-1R	immuno-staining	was	 characterised	by	 regions	of	punctate	 staining.	 In	panel	D	the	channels	detecting	Alexa	488	and	Alexa	350	were	merged	with	the	resultant	cyan	colour	indicating	co-localisation	of	TLR5	and	Dectin-1R.		These	 data	 suggested	 co-localisation	 of	 the	 TLR5	 and	 Dectin-1	 receptors	following	a	zymosan	challenge	of	RT4	bladder	cells.		
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Figure	 4.2	 Immunostaining	 of	 Dectin-1R	 and	 TLR5	 in	 RT4	 zymosan	
challenged	cells.		RT4	 cells	 were	 challenged	 with	 zymosan	 (50	 μg/ml,	 6h)	 then	 fixed	 with	 4%	formaldehyde	 and	 incubated	 overnight	 with	 anti-Dectin-1	 and	 anti-TLR5	antibodies	(dilutions	1:50).	A:	nuclei	stained	with	propidium	iodide;	B:	RT4	cells	stained	 with	 anti-TLR5	 antibody;	 C:	 RT4	 cells	 stained	 with	 anti-Dectin-1R	antibody;	D:	merged	red,	blue	and	green	channels;	E	and	F:	RT4	cells	stained	with	IgG	control	antibodies	and	secondary	Alexa	Fluor	488	or	350	antibodies.		
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 Expression	and	synthesis	of	host	defence	peptides/proteins	4.2
in	siTLR5	RT4	cells	challenged	with	zymosan	To	 further	 investigate	co-operation	between	 the	Dectin-1R	and	TLR5	receptors	and/or	 signalling	 response	 siRNA	 knock-down	 methodology	 was	 used.	 This	focussed	 initially	 on	 repeating	 the	 Lanz	 experiment,	 but	 using	 a	 TLR5	 knock-down	 approach.	 Using	 siRNA	 primers	 designed	 to	 TLR5	 (Section	 2.28),	 TLR5	expression	was	transiently	reduced	by	73%	(p	<	0.0001)	in	the	RT4	cells	(Figure	4.3).			
	 	
Figure	4.3	Efficiency	of	TLR5	knockdown	in	RT4	cells.		
TLR5	 was	 knocked	 down	 in	 RT4	 cells	 using	 siRNA	 technology	 and	 TLR5	 gene	expression	measured	using	qRT-PCR.	N=3,	****	p<0.0001.		
4.2.1 Expression	of	DEFB4,	CXCL8,	IL1A	and	LCN2	genes	in	siTLR5	
RT4	cells	challenged	with	zymosan	Following	TLR5	 gene	 knockdown	 the	RT4	 cells	were	 challenged	with	 zymosan	(50	μg/ml)	for	6	hours	and	analysed	using	qRT-PCR	for	the	gene	expression	of	an	array	of	effectors,	specifically	DEFB4	(encodes	hBD2),	CXCL8	(encodes	IL8),	IL1A	(encodes	 IL1α)	 and	 LCN2	 (encodes	 LCN2).	 To	 address	 variability	 between	experiments	 the	 expression	 data	 were	 normalised	 to	 the	 control	 cells	(transfected	with	scrambled	siRNA)	similarly	challenged	with	zymosan	(scr	+	Z).	Data	presented	 in	Figure	4.4,	A	 shows	 that	 reduced	TLR5	 gene	expression	was	
		 79	
associated	 with	 a	 significantly	 reduced	DEFB4	 expression	 (p<0.001).	 Similarly	the	 expression	 of	CXCL8	 (p<0.0001),	 IL1A	 (p<0.0001)	 and	LCN2	 (p<0.01)	were	significantly	reduced.			
	
Figure	4.4	DEFB4,	CXCL8,	IL1A	and	DEFB4	mRNA	expression	in	siTLR5	RT4	
cells	challenged	with	zymosan.		Panels	 A,	 B,	 C	 and	 D	 show	 DEFB4,	 CXCL8,	 IL1A	 and	 LCN2	 mRNA	 expression	synthesis	 in	 control	 RT4	 cells	 (scr)	 and	 RT4	 cells	 in	which	TLR5	 was	 reduced	(siTLR5)	before	and	after	zymosan	(50	μg/ml)	challenge.	Data	shows	mean	±SD	and	N=2.	**	p<0.01,	***	p<0.001,	****	p<0.0001.		These	data	 showing	 reduced	DEFB4,	CXCL8,	 IL1A	 and	LCN2	gene	 expression	 in	
TLR5	 knockdown	RT4	 cells	 challenged	with	 zymosan	 added	 further	 support	 to	the	NF-κB	data	of	Lanz	(2013)	[83].	As	zymosan	is	acknowledged	as	containing	β-glucan,	 a	 ligand	 that	 specifically	 activates	 the	Dectin-1R	 receptor,	 these	 data	again	 suggested	 cooperation	 between	 the	Dectin-1	 and	TLR5	 receptors	 in	 RT4	cells.	
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4.2.2 IL-8	and	LCN2	protein	synthesis	in	siTLR5	RT4	cells	
challenged	with	zymosan	To	further	investigate	cooperation	between	Dectin-1R	and	TLR5	the	synthesis	of	the	 host	 defence	 peptides/proteins	 IL8	 and	 LCN2	 were	 investigated.	 In	 these	analyses	 the	media	 from	 the	 control	 cells	 (transfected	 with	 scrambled	 siRNA)	and	TLR5	 knockdown	RT4	cells	were	collected	and	ELISA	used	 to	measure	 IL8	and	LCN2	concentrations.	Data	 presented	 in	 Figure	 4.5	 panel	 A	 shows	 that	 the	 concentration	 of	 IL8	increased	from	1438	±	304	pg/ml	in	unchallenged	cells	to	4044	±	849	pg/ml	in	the	zymosan	challenged	cells.	However,	in	the	TLR5	knock-down	cells	challenged	with	 zymosan	 the	 IL8	 concentration	 increased	 to	 only	 2158	 ±	 458	 pg/ml.	Essentially	 the	 challenged	 TLR5	 knockdown	 cells	 secreted	 50%	 less	 IL8	compared	to	the	challenged	control	cells.	However,	to	account	for	experimental	variability,	 these	 data	 were	 normalised	 to	 that	 of	 the	 control	 cells	 challenged	with	zymosan	(scr	+	Z)	(Figure	4.5,	B.	
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Figure	4.5	 IL8	and	LCN2	protein	 synthesis	 in	 siTLR5	RT4	cells	 challenged	
with	zymosan	(50µg/ml;	6h).		Panels	A	and	C	show	IL8	and	LCN2	concentrations	in	control	RT4	cells	(scr)	and	
TLR5	 knock-down	 RT4	 cells	 (siTLR5).	 In	 the	 panels	 B	 and	 D	 the	 data	 were	normalised	 to	 the	 challenged	 control	 cells	 (scr	 +	 Z).	 The	 cells	were	 challenged	with	zymosan	(Z)	(50	μg/ml)	and	ELISA	was	used	to	measure	concentration	IL8	and	LCN2	in	growing	medium.	Data	shows	mean	±SD	and	N=2.			Similarly	 the	 results	 in	 Figure	 4.5	 panel	 C	 indicated	 that	 LCN2	 synthesis	 was	affected	 in	 the	 TLR5	 knockdown	 RT4	 cells	 challenged	 with	 zymosan.	 The	concentration	 of	 LCN2	 was	 3640	 ±	 252	 pg/ml	 in	 siRNA	 control	 cells	 which	increased	 to	 5923	 ±	 609	 pg/ml	 in	 the	 zymosan	 challenged	 cells.	 	 In	 the	 TLR5	knockdown	 cells	 LCN2	 synthesis	 increased	 from	 2502	 ±	 173	 pg/ml	 to	 2800	 ±	185	pg/ml	 following	 incubation	with	zymosan.	 Interestingly	LCN2	secretion	by	knockdown	cells	(siTLR5)	was	lower	by	31%	compared	to	the	control	cells	(scr)	however	this	difference	was	not	statistically	significant.		
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These	 data	 indicated	 that	 IL-8	 and	 LCN2	 synthesis	 were	 reduced	 in	 the	challenged	 TLR5	 knockdown	 cells,	 again	 supporting	 cooperation	 between	Dectin-1	and	TLR5	receptors	in	RT4	bladder	cells.			
 CLEC7A	knockdown	cells	challenged	with	flagellin	4.3To	 explore	 co-operation	 further	 the	 reciprocal	 experiment	 was	 performed	 in	which	 the	 CLEC7A	 gene	 (encodes	 Dectin-1R)	 was	 knocked	 down	 in	 RT4	 cells	(siDct1	 –	 stable	 knock-down;	 siLuc	 –	 control	 Section	 2.28)	 and	 the	 cells	challenged	with	flagellin,	the	TLR5	ligand	(100	ng/ml;	6h).	In	these	analyses	only	gene	 expression	was	measured	 and	 using	 qPCR	 targets	 were	 CXCL8,	 IL1A	 and	
LCN2	 respectively.	 DEFB4	 gene	 expression	 was	 measured	 but	 the	 resulting	values	were	below	the	qRT-PCR	detection	limits	and	these	data	are	not	reported.		Flagellin	 challenge	of	 the	Dectin-1R	knock-down	cells	 resulted	 in	 the	 increased	expression	of	CXCL8	 in	siLuc	(control)	and	siDct1	cells,	with	 these	data	(Figure	4.6,	A)	revealing	14	±	0.5	fold	and	11.4	±	0.7	fold	increases	respectively.	However	the	mean	increase	in	CXCL8	was	20	%	reduced	in	the	challenged	Dectin-1	knock-	down	cells	(siDct1	+	F)	compared	to	the	challenged	control	cells	(siLuc	+	F)	and	this	difference	was	statistically	significant	(p	<	0.001).		Expression	 of	 IL1A	 in	 the	 challenged	 control	 (siLuc)	 and	 knockdown	 (siDct1)	cells	increased	by	2.5	±	0.15	fold	and	1.6	±	0.13	fold	respectively	(Figure	4.6,	B).	The	mean	increase	of	IL1A	was	40%	lower	in	Dectin-1	knock	down	cells	(siDct1	+	F)	compared	to	the	control	cells	(siLuc	+	F)	and	this	difference	was	statistically	significant	with	p	<	0.0001.		Flagellin	 challenge	 increased	LCN2	 in	 the	 control	 cells	 	 (siLuc)	 and	knockdown	cells	(siDct1)	by	4.3	±	0.52	fold	and	8	±	1.65	fold	respectively	(Figure	4.6,	C).	The	mean	 increase	 of	LCN2	 in	 the	 knockdown	 cells	 (siDct1	 +	 F)	 increased	 by	 82%	compared	to	the	control	cells	(siLuc	+	F).	The	mean	 increase	of	LCN2	was	75%	lower	in	the	knockdown	cells	(siDct1)	compared	to	the	control	cells	(siLuc),	but	this	difference	was	not	statistically	significant	(p=0.86).	
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Figure	 4.6	 CXCL8,	 IL1A	 and	 LCN2	 mRNA	 expression	 in	 siDct1	 RT4	 cells	
challenged	with	flagellin.		Panels	 A,	 B	 and	 C	 demonstrate	 CXCL8,	 IL1A	 and	 LCN2	 mRNA	 expression	 by	control	RT4	cells	(siLuc)	and	CLEC7A	knock-down	RT4	cells	(siDct1)	challenged	with	flagellin	(100	ng/ml)	for	6	hours.	Data	show	mean	±SD	and	N=4.	*	p<0.05,	***	p<0.001,	****	p<0.0001.			Overall,	 these	 data	 reported	 in	 Figure	 4.6	 showed	 that	 in	 CLEC7A	 knockdown	RT4	cells	 challenged	with	 flagellin	significantly	 less	CXCL8	 and	 IL1A	 expression	were	 observed	 when	 compared	 to	 the	 wild	 type	 cells.	 However	 expression	 of	
LCN2	was	significantly	higher.	Again	these	data	suggested	cooperation	between	Dectin-1R	and	TLR5	receptors.	It	is	acknowledged	that	these	data	relate	to	gene	expression	only	and	as	such	still	need	to	be	supported	by	protein	data	by	measuring	IL8,	IL1α	and	LCN2	protein	concentrations	in	the	challenged	siLuc	and	siDct1	cells.				
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 Proximity	ligation	assay	(PLA)	4.4Immunostaining	 data	 presented	 in	 Section	 4.1	 supported	 co-localisation	 of	 the	Dectin-1R	and	TLR5	receptors,	while	effector	data	shown	in	sections	4.2	and	4.3	suggested	receptor	co-operation/collaboration.		To	investigate	potential	physical	interactions	 between	 the	 Dectin-1R	 and	 TLR5	 receptors	 in	 RT4	 cells	 the	proximity	 ligation	 assay	 approach	 was	 used	 (Figure	 4.7).	 This	 assay	 detects	interactions	between	two	proteins	when	the	distance	between	them	is	less	than	40	nm	[145].	The	technique	utilises	primary	antibodies	to	Dectin-1R	and	TLR5,	and	 unique	 secondary	 antibodies,	 which	 if	 close	 enough	 to	 each	 other	 ligate	resulting	in	a	fluorescent	signal.				
	
Figure	4.7	Proximity	ligation	assay.		(A)	 Primary	 antibodies	 bind	 to	 proteins	 TLR5	 and	 Dectin-1R;	 (B)	 secondary	antibodies	 bind	 to	 the	 primary	 antibodies;	 (C)	 ligation	 of	 the	 secondary	antibodies;	(D)	amplification	of	fluorescent	signal.		
		 85	
The	procedure	 of	 cell	 fixation	 and	 incubation	with	primary	 antibodies	was	 the	same	as	for	immunocytochemistry	(Section	2.16).	Further	steps	are	listed	in	the	Section	2.17.			
4.4.1 Dectin-1	and	TLR5	Receptors	form	heterodimers	in	RT4	
cells		A	 typical	 set	of	 results	 relating	 to	 the	proximity	 ligation	assay	experiments	are	shown	in	Figure	4.8.	Panel	A	demonstrates	proximity	ligation	assay	data	showing	Dectin-1R	and	TLR5	co-localisation	in	non-challenged	RT4	cells	while	Figure	4.8,	panel	 B	 shows	 the	 negative	 control	 data	 i.e.	 cells	 incubated	 with	 secondary	antibodies	only.	The	blue	 colouration	 in	 the	panels	A	and	B	 represent	RT4	cell	nuclei	 stained	with	 DAPI	while	 the	 red	 dots	 reflect	 receptor	 co-localisation.	 In	panel	A	the	red	dots	suggested	random	dimerisation	events	between	the	Dectin-1R	and	TLR5	receptors	indicating	that	the	two	receptors	interact	physically.		
	
Figure	4.8	Dectin-1R	and	TLR5	form	heterodimers	in	RT4	cells.		Panel	 A	 shows	 proximity	 ligation	 assay	 with	 anti-Dectin-1R	 and	 anti-TLR5	antibodies	 and	 secondary	 antibodies	 from	 proximity	 ligation	 assay	 kit.	 Red	coloured	 dots	 suggest	 dimerisation	 between	 two	 receptors.	 Panel	 B	demonstrates	 RT4	 cells	 incubated	 with	 proximity	 ligation	 assay	 secondary	antibodies	and	no	primary	antibodies.	
unchallenged	WT	RT4	 -ve	WT	RT4	
A	 B	
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4.4.2 Zymosan	promotes	clustering	of	Dectin-1	and	TLR5	
heterodimers	To	 investigate	 if	 zymosan	 impacted	 Dectin-1R	 and	 TLR5	 dimerisation	 in	 RT4	cells,	the	cells	were	challenged	with	zymosan	(200	μg/ml)	for	20	and	30	minutes	respectively	and	again	analysed	using	the	proximity	ligation	assay	methodology.	In	 these	 experiments	 a	 higher	 concentration	 of	 zymosan	 was	 used	 (x4)	 to	maximise	Dectin-1R	 stimulation.	 The	 challenge	 times	were	 guided	 by	 previous	publications	that	showed	Dectin-1R	interactions	with	the	TLR2	receptor	at	5	and	10	minutes	respectively	[143].	A	typical	set	of	results	is	shown	in	Figure	4.9.			Panel	A	shows	unchallenged	RT4	cells;	blue	colour	represents	DAPI	stained	cell	nuclei	 and	 red	 dots	 reflect	 random	 dimerisation	 between	Dectin-1R	 and	 TLR5	receptors.	When	the	cells	were	challenged	with	zymosan	for	20	and	30	minutes	(panels	B	and	C	respectively)	significant	numbers	of	Dectin-1R	and	TLR5	dimer	clusters	 were	 observed	 (white	 arrows).	 Panel	 D	 shows	 data	 related	 to	 assay	using	no	primary	antibody	but	incubation	with	secondary	antibodies.		As	 a	 further	 control	 the	 zymosan	 challenge	 experiment	 was	 repeated	 (200	μg/ml;	30	minutes)	and	the	RT4	cells	analysed	using	primary	antibodies	to	TLR5	and	TLR6.	Panel	E	shows	small	numbers	of	red	dots	indicating	that	dimerisation	was	occurring,	but	importantly	no	clustering	was	observed.	Importantly	similar	experiment	 with	 antibodies	 for	 Dectin-1R	 and	 TLR6	 was	 not	 done	 because	primary	antibodies	for	these	receptors	were	of	same	species.	Panel	 F	 demonstrates	 RT4	 cells	 challenged	 with	 flagellin	 (100	 ng/ml)	 for	 30	minutes.	 The	 red	 dots	 represent	 dimerisation	 of	Dectin-1R	 and	TLR5	proteins.	However	no	clustering	of	these	dimers	was	observed.				
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Figure	 4.9	 Zymosan	 stimulates	 clustering	 of	 Dectin-1R	 and	 TLR5	
heterodimers	in	RT4	cells.		A:	non-challenged	RT4	cells;	B	and	C:	–	challenged	RT4	cells	with	zymosan	(200	μg/ml)	 for	20	and	30	minutes	 respectively;	D:	negative	control	where	 the	cells	were	 incubated	with	 IgG2b	 control	 antibody;	 E:	 proximity	 ligation	 of	 TLR5	 and	TLR6	 in	 RT4	 cells	 challenged	 with	 zymosan	 for	 30	 minutes;	 F:	 RT4	 cells	challenged	with	flagellin	for	30	minutes.		
E F 
10	μm 
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These	 proximity	 ligation	 data	 demonstrated	 that	 the	 Dectin-1R	 and	 TLR5	receptors	 interacted	 physically	 in	 RT4	 bladder	 cells	 forming	 heterodimers.	Moreover	 significant	 clustering	 of	 these	 heterodimers	 was	 evident	 following	challenge	of	the	cells	with	zymosan.			
 Discussion	4.5This	 chapter,	 focussing	 on	 RT4	 bladder	 cells,	 investigated	 the	 physical	 and	functional	 cooperation	of	 two	 receptors,	Dectin-1R	and	TLR5,	 in	protecting	 the	bladder	 from	 infection	 by	 potential	 pathogens	 namely	 fungi	 and	 flagellated	bacteria.	 It	 is	 well	 established	 that	 the	 Dectin-1R	 binds	 and	 is	 activated	 by	zymosan	 –	 a	 component	 of	 the	 fungal	 cell	 wall	 [138],	 while	 flagellin,	 a	 key	component	of	flagellum,	is	found	in	bacteria	and	activates	TLR5	signalling	[146].		These	 studies	 exploring	 potential	 co-operation	 of	 the	 two	 receptors	 were	prompted	by	NF-kB	signalling	data	using	RT4	cells	that	showed	NF-kB	signalling	to	be	significantly	reduced	in	such	cells	following	TLR5	blocking	and	challenging	with	zymosan	[83].		Results	 of	 the	 experiments	 reported	 in	 this	 chapter	 and	 involving	immunocytochemical	 staining,	 proximity	 ligation	 assays	 and	 gene	 knock-down	all	 strengthened	 the	NF-kB	 signalling	 story	 and	 further	 supported	 the	 physical	and	 functional	 co-operation	 between	 the	 Dectin-1	 and	 TLR5	 receptors	 in	 RT4	bladder	 epithelial	 cells.	 Additionally	 this	 co-operation	 functioned	 seemingly	 to	protect	the	bladder	cells	from	infection.		It	 is	 known	 that	 in	myeloid	derived	 cells	 the	Dectin-1R	 co-operates	with	 other	Toll-like	 receptors	 including	 TLR2	 and	 TLR4	 in	 the	 fight	 against	 infection.	 For	example,	 in	 macrophages	 and	 dendritic	 cells,	 Dectin-1R	 and	 TLR2	 co-operate	resulting	in	the	production	of	cytokines	including	IL-12	and	TNFα	[103].	Knock-out	mice	 have	 also	 been	 used	 to	 highlight	 co-operation,	with	 the	Dectin-1	 and	TLR2	receptors	functioning	to	activate	a	macrophage	pro-inflammatory	response	following	 a	 mycobacterium	 infection	 [113].	 Similarly	 physical	 and	 functional	collaboration	 of	 Dectin-1	 and	 TLR2	 receptors	 was	 reported	 in	 mouse	
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macrophages	 following	 challenge	with	Mycobacterium	abscessus	 (Mab)	 a	 quick	growing	 non-tuberculous	 mycobacterium	 [143].	 Additionally	 it	 has	 also	 been	shown	 that	 the	 Dectin-1R	 and	 TLR4,	 together	 with	 the	 mannose	 receptor	collaborate	 in	 the	 activation	 and	 expansion	 of	 Th17	 and	 Tc17	 cells	 following	
Paracoccidioides	 brasiliensis	 stimulation	 of	 murine	 dendritic	 cells	 [129].	 All	 of	these	 effects	 function,	 presumably,	 to	 enhance	 the	 innate	 response	 and	potentiate	 the	 host	 defence	 mechanisms	 through	 activation,	 recruitment	 and	expansion	of	effective	immune	cells.	However,	to	date	there	is	no	published	data	that	directly	shows	co-operation	between	the	Dectin-1	and	TLR5	receptors.		TLR5	is	unique	amongst	the	TLRs	in	that	it	only	recognises	flagellin	and	functions	in	host	defence	through	homodimer	formation	[118,	144,	146-148].	There	are	no	reports	of	 it	 forming	heterodimers	with	other	TLRs.	However,	data	reported	 in	this	chapter	indicates	that	in	the	bladder	epithelium	TLR5	co-operates	physically	and	 functionally	with	 the	Dectin-1R	 in	 defending	 the	 bladder	 against	 infection.	Potentially	there	are	hints	in	the	literature	of	this	TLR5/Dectin-1R	relationship.	For	 example	 in	 the	 corneal	 epithelium,	 flagella	 induced	 expression	 of	 CXCL-10	was	 shown	 to	 be	 associated	 with	 fungal	 killing	 and	 Natural	 Killer	 [NK]	 cell	recruitment	in	response	to	a	Candida	albicans	infection	[149].			TLR5	receptors	have	been	reported	in	ocular	cells	[150,	151].	Dectin-1	receptors	have	also	been	reported	in	corneal	epithelial	cells	with	activation	by	Aspergillus	
fumigatus	associated	with	the	production	of	cytokines	and	chemokines	including	IL-1β,	IL-6	and	IL-8	[152].	Therefore	the	data	reported	by	Liu	et	al	(2014)	[152]	,	linked	to	a	Candida	 infection	suggests	a	potential	Dectin-1R/TLR5	collaboration	although	this	was	neither	recognised	nor	discussed	by	the	authors.		Additionally,	Rodland	et	al,	 (2011),	observed	 in	vitro	 that	conidia	 from	Aspergillus	fumigatus	up-regulated	TLR5	gene	expression	in	human	monocytes	[153].	From	this	work	the	authors	proposed	a	role	 for	TLR5	in	A.fumigatus	monocyte	 infections,	but	a	literature	 search	 has	 provided	 no	 further	 publications	 either	 supporting	 or	developing	these	2011	findings.	The	 immunocytochemical	 and	 proximity	 ligation	 assay	 data	 demonstrated	 co-localisation	and	clustering	of	 the	 two	receptors	 following	zymosan	challenge	of	
		 90	
RT4	bladder	cells	(Figure	4.2	and	Figure	4.9).	From	these	observations	it	was	not	possible	 to	 identify	 whether	 receptor	 co-localisation	 was	 associated	 with	 the	membrane	 or	 also	 included	 intracellular	 receptors.	 Such	 analyses	 would	necessitate	 further	 staining	 for	 example	 using	 an	 array	 of	 antibodies	 directed	specifically	to	membrane	localised	proteins.		Receptor	 clustering	was	 an	 interesting	 observation;	 it	 has	 been	 suggested	 that	clustering	functions,	potentially,	to	stabilise	cell	membrane	transporters	and/or	receptors	 as	 well	 as	 to	 facilitate	 signal	 amplification	 [154,	 155].	 Signal	amplification	is	mediated	through	either	better	retention	of	the	receptor	ligands	or	 increased	 ligand	 rebinding.	 While	 in	 this	 study	 the	 factors	 underpinning	receptor	clustering	remain	unclear,	cooperation	between	the	Dectin-1	and	TLR5	receptors	resulting	 in	the	activation	of	shared	intracellular	signalling	molecules	to	maximise	the	effector	response	is	very	plausible.	Interestingly	it	was	reported	in	human	dendritic	 cells	 stimulated	with	curdlan	and	LPS	 that	 the	Dectin-1R	 is	required	 for	 potentiation	 of	 TLR2	 signalling	 and	 cytokine	 IL-10	 and	 IL-12	production	 [111]	 although	 receptor	 clustering	 was	 not	 mentioned.	 Clustering	may	 therefore	be	unique	 to	Dectin-1/TLR5	receptor	 interactions	or	 specifically	bladder	epithelial	cell	Dectin-1/TLR5	receptor	interactions.		The	proximity	 assay	 ligation	data	 indicated	dimerisation	 of	Dectin-1	 and	TLR5	receptors	 in	 response	 to	 flagellin,	 but	 clustering	 similar	 to	 that	 seen	 with	zymosan	 was	 not	 observed.	 This	 suggested	 that	 the	 zymosan	 or	 β-glucan	challenge	 was	 essential	 and	 driving	 the	 receptor	 clustering	 effect.	 Again,	 the	reasons	 for	 this	are	not	known.	 It	 is	known	however,	 that	bladder	cells,	within	hours,	respond	to	 flagellin,	synthesised	by	UPEC	as	a	major	component	of	 their	flagella	and	linked	to	motility,	to	produce	a	strong	innate	response,	which	involve	the	 synthesis	 of	 pro-inflammatory	molecules	 and	 antimicrobial	 agents	 to	 clear	the	bacterial	infection.	In	contrast	yeast	infections	are	more	challenging	to	detect.	During	growth	or	 colonisation	yeasts	 such	as	C.	albicans	hide	 their	β-glucan	by	covering	 it	 in	 a	 coat	 of	 mannan,	 which	 masks	 their	 detection	 by	 Dectin-1	receptors.	 During	 infection,	 which	 involves	 hyphal	 growth	 the	 β-glucan	 is	unmasked,	but	the	concentrations	are	low	[156].	This	means	that	once	β-glucan	is	detected	 the	bladder	cells	need	 to	maximise	 their	 innate	response	 to	quickly	
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clear	 the	 infection.	 Clustering	 of	 the	 Dectin-1	 and	 TLR5	 receptors,	 which	 in	bladder	 are	 the	 major	 TLR	 and	 present	 in	 higher	 concentrations	 than	 either	TLR2	 and	 TLR4	 [157],	 would	 facilitate	 this.	 It	 is	 therefore	 feasible	 that	 the	Dectin-1R/TLR5	 clustering	 mechanism	 observed	 in	 response	 to	 zymosan	 has	specifically	evolved	in	bladder	epithelial	cells	as	a	mechanism	to	defend	against	yeast	infections.		In	myeloid	derived	cells	Dectin-1receptors	have	been	shown	to	co-operate	with	TLR2	and	TLR6	receptors.	Previous	work	 in	RT4	cells	 in	which	TLR2	receptors	were	 blocked	 using	 antibody	 did	 not	 support	 a	 Dectin-1/TLR2	 receptor	collaboration.	It	is	acknowledged	that	this	relationship	should	have	been	further	investigated	by	repeating	the	proximity	ligation	assay	using	Dectin-1R	antibody	and	antibodies	to	TLR2	and	TLR6.		However	as	all	the	available	Dectin-1R,	TLR2	and	TLR6	antibodies	were	raised	in	the	same	species,	 it	meant	the	assay	would	not	work	 and	 therefore	 these	 analyses	were	 not	 performed.	 For	 completeness	these	experiments	need	to	be	completed.		LCN2	 is	a	host	defence	protein	 involved	 in	 the	 innate	protection	of	 the	bladder	epithelium	 from	 fungal	 and	 bacterial	 infections	 as	 observed	 by	 the	 increase	 in	gene	expression	and	protein	synthesis	in	response	to	zymosan	(Figure	3.5-Figure	3.6)	and	flagellin	challenges	[40].	As	expected	TLR5	gene	knockdown	was	linked	to	 a	 significant	 decrease	 in	 LCN2	 gene	 expression	 and	 protein	 synthesis.	However,	the	LCN2	expression	data	associated	with	the	siDct1	treated	ie	CLEC7A	knockdown	cells	was	surprising,	with	expression	actually	significantly	increased	(p<0.05).	 The	 reasons	 for	 this	 increase	 are	 not	 known	 and	 these	 data	 were	compromised	by	the	lack	of	LCN2	protein	measurements	to	help	confirm	and/or	explain	 the	 result.	The	 increased	gene	expression	may	however,	have	 reflected	the	 CLEC7A	 gene	 knockdown	 cells	 compensating	 the	 loss	 of	 Dectin-1R	 by	producing	 more	 LCN-2	 to	 fight	 infection.	 Yet,	 this	 appears	 unlikely	 as	 genes	encoding	the	cytokines	CXCL8	and	IL1A,	which	also	encode	proteins	involved	in	the	 innate	 response	 were	 suppressed.	 However,	 this	 theory	 cannot	 be	 totally	excluded.	Essentially	IL-8	and	IL-1α	are	pro-inflammatory	cytokines	while	LCN2	is	 an	 antimicrobial	 agent	 with	 a	 microbial	 killing	 function.	 Therefore	 a	 direct	consequence	 of	 Dectin-1R	 loss	 may	 be	 the	 increased	 production	 of	 host	
		 92	
antimicrobials	ie	killing	agents,	such	as	LCN2	and	the	defensin	peptides.	Further	in	 vitro	 analyses,	 for	 example	 DEFB4	 gene	 expression	 and	 hBD2	 and	 LCN2	protein	measurements	need	to	be	done	in	CLEC7A	gene	knock-down	RT4	cells	to	investigate	this	further.		Clinical	data	indicates	that	patients	who	are	Dectin-1R	deficient	suffer	persistent	
Candida	infections	[158,	159]	with	monocytes	and	macrophages	recovered	from	such	 patients	 defective	 in	 producing	 IL-6,	 TNFα	 and	 IL-Iβ.	 Mice	 deficient	 in	Dectin-1	also	show	an	increased	susceptibility	to	C.	albicans,	but	it	is	argued	that	
Candida	 killing	 itself	 is	 not	 impacted	 [160,	 161]	 with	 neutrophils	 being	responsible	for	killing	fungi	and	clearing	fungal	infections.				However,	as	none	of	the	 Dectin-1R	 deficient	 patient	 and	 transgenic	 mice	 model	 material	 published	has	examined	 the	mucosal	 concentrations	of	host	defence	agents	 such	as	LCN2	and	 the	 defensins,	 their	 increased	 synthesis	 and	 killing	 roles	 in	 Dectin-1R	defective	patients	cannot	be	ignored.		In	 summary,	 data	 presented	 in	 this	 chapter	 showed	 that	 Dectin-1	 and	 TLR5	receptors	 co-operated	 physically	 and	 functionally	when	 RT4	 bladder	 epithelial	cells	 were	 challenged	 with	 zymosan	 resulting	 in	 an	 innate	 immune	 response	involving	the	synthesis	of	host	cytokines	and	antimicrobial	agents.			 	
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Chapter	5 .	Engineering	overexpression	of	Dectin-1	and	
TLR5	receptors	in	RT4	bladder	cells	
Data	from	experiments	performed	thus	far	indicated	that:	(i) the	RT4	bladder	epithelial	cells	expressed	the	CLEC7A	gene	encoding	the	 Dectin-1R	 and	 that	 transcripts	 encoding	 receptor	 isoforms	 1	(stalk),	2,	3,	4	and	5	(no	stalk)	were	synthesised,		(ii) western	data	supported	the	synthesis	of	isoforms	1,	2	and	4,	and	(iii) the	 Dectin-1	 receptor	 co-operates	 with	 TLR5	 in	 RT4	 bladder	 cells	which	results	in		an	innate	response	to	zymosan.		In	humans	TLR5	is	a	key	pathogen	receptor	protein	of	the	lower	urogenital	tract	tissues	 recognising	 flagellated	 bacteria,	 mainly	 UPEC	 from	 gut-faeces,	 and	orchestrating	an	innate	response	to	prevent	bacterial	ascent	of	the	urinary	tract	[40].	 It	 is	 known	 however,	 that	 approximately	 10%	 of	 population	 carry	 a	truncated	TLR5	receptor	due	to	the	SNP	1174C>	T	which	encodes	a	STOP	codon	and	that	this	correlates	with	susceptibility	to	recurrent	UTIs	[86].	 Interestingly,	however,		a	study	has	also	shown	a	significant	association	between	the	presence	of	 the	TLR5	 SNP	 and	 the	 risk	 of	 developing	 invasive	 aspergillosis	 following	 an	allogenic	stem	cell	transplant	[162],	which	again	provides	support	to	investigate	potential	Dectin1R/TLR5	interactions	further.		Therefore,	 the	 aim	 of	 this	 part	 of	 the	 project	 was	 to	 attempt	 to	 model	 these	Dectin-1R	 isoform/TLR5	wild-type	 and	 truncated	 receptor	 interactions	 in	vitro	to	help	further	understand	the	innate	defences	of	the	urinary	tract.				The	 approach	was	 to	 amplify	DNA	 sequences	 encoding	 the	Dectin-1	 and	 TLR5	receptor	isoforms,	clone	these	DNA	isoforms	into	pVitro2-neo-mcs	(Figure	5.1),	which	 is	 able	 to	 co-express	 two	 DNA	 sequences	 simultaneously,	 (Figure	 5.2),	stably	 transfect	 the	 resultant	plasmids	 into	CHO	cells	 and	 study	 interactions	of	encoded	 receptor	 isoforms	 in	 response	 to	 zymosan,	 flagellin	 and	zymosan/flagellin	challenges.			
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Figure	5.1	pVitro2-neo-mcs	plasmid.		pVitro2	 plasmid	 was	 used	 to	 overexpress	 CLEC7A	 and	 TLR5	 genes	simultaneously.			
	
Figure	5.2	Co-expression	of	wild	type	or	SNP	TLR5	with	Dectin-1R	isoforms	
1,	2	or	4.		
TLR5	wild	type	or	SNP	cDNAs	were	inserted	into	plasmid	pVitro2	together	with	
CLEC7A	(encoding	Dectin-1R)	isoform	1,	2	or	4.	Six	combinations	of	the	genes	in	the	plasmids	were	envisaged.		
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 Construction	of	plasmids	expressing	CLEC7A	and	TLR5	5.1The	process	of	 plasmid	 construction	 included	gene	 amplification,	 separation	of	cDNA	products	on	an	agarose	gel,	purification	of	the	cDNA	fragments,	restriction	of	 cDNA	 fragments	 and	 vector	 plasmid	 pVitro2,	 and	 ligation	 of	 the	 cDNA	fragments	 into	 the	 plasmid	 vector.	 Step	 1	 (Figure	 5.3)	 involved	 ligating	 the	
CLEC7A	and	TLR5	cDNA	fragments	into	separate	plasmid	vectors	and	then	in	step	2	the	second	cDNA	was	ligated	in.				
	
Figure	 5.3	 Schematic	 representation	 of	 CLEC7A	 and	 TLR5	 cloning	 into	
pVitro2	plasmid.		pVitro2	plasmid	and	amplified	CLEC7A	and	TLR5	DNA	sequences	were	restricted	with	appropriate	enzymes	and	ligated	to	engineer	final	plasmid	construct.			Complementary	DNA	sequences	of	CLEC7A	 isoforms	1,	2	and	4,	wild	 type	TLR5	and	 truncated	 TLR5	 were	 amplified	 from	 RT4	 cDNA	 material.	 Primers	 were	designed	 to	 contain	 3’	 and	5’	 restriction	 sites	 (BglII	 and	XhoI	 for	CLEC7A)	 and	(BamHI	 and	 SalI	 for	TLR5)	 to	 facilitate	 cloning	 of	 the	 resultant	 cDNAs	 into	 the	plasmid	vector	pVitro2	plasmid	(Figure	5.4).		 	
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Figure	5.4	Primers	designed	for	insertion	of	CLEC7A	and	TLR5	into	plasmid	
pVitro2.		A:	Primers	 to	amplify	all	 isoforms	of	CLEC7A	with	sequences	 for	BglII	and	XhoI	restriction	 sites.	 B:	 Primers	 to	 amplify	 full	 length	 or	 truncated	 TLR5	 with	sequences	for	BamHI	and	SalI	restriction	sites.			 	
5’-ATGGAATATCATCCTGATTTAGAAAATTTGGATGAAGATGGATATACTCAATTACACTTCGACTCTCAAAGCAATACCAGGATAGCTGTTGTTTCAGAGAA…	
	
…AACCCATCTCCAAATTGTGTATGGATTCACGTGTCAGTCATTTATGACCAACTGTGTAGTGTGCCCTCATATAGTATTTGTGAGAAGAAGTTTTCAATGTAA-3’	
5’-TAAGCAAGATCTATGGAATATCATCCTGAT-3’		
5’-GAGAAGAAGTTTTCAATGTAACTCGAGTGAGCA-3’	
BglII	
XhoI	
A	CLEC7A	
5’-ATGGGAGACCACCTGGACCTTCTCCTAGGAGTGGTGCTCATGGCCGGTCCTGTGTTTGGAATTCCTTCCTGCTCCTTTGATGGCCGAATAGCCTTTTATCG…	
	
	
...GCAATAATTCAAGACCAAACATTCAAATTCCTGGAAAAATTACAGACCTTGGATCTCCGAGACAATGCTCTTACAACCATTCATTTTATTCCAAGCATACCC…	
	
	
…CTGGTTTCTTCATAAACTCTCTCAACAGATACTAAAGAAAGAAAAAGAAAAGAAGAAAGACAATAACATTCCGTTGCAAACTGTAGCAACCATCTCCTAA-3’	
5’-CGAGCAGGATCCATGGGAGACCACCTGGACC-3’		
5’-CAGACCTTGGATCTCTGAGTCGACGCAGCA-3’	
BamHI	
SalI	
5’-GTAGCAACCATCTCCTAAGTCGACGCAGCA-3’	
SalI	
B	TLR5	
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End-point	 PCR	 resulted	 in	 cDNA	 bands	 of	 2750	 bp	 and	 1250	 bp	 representing	
TLR5	 wild	 type	 and	 TLR5	 truncated	 sequences	 and	 750,	 620	 and	 500	 bp	representing	CLEC7A	 isoform	1,	 2	 and	 4	 (Figure	 5.5).	 These	 cDNA	bands	were	excised	and	purified	for	cloning	into	pVitro2.			
	
Figure	 5.5	 Amplification	 of	 TLR5	 and	 CLEC7A	 DNA	 sequences	 for	 cloning	
into	plasmid	pVitro2.		
TLR5	wild	type,	TLR5	SNP	and	CLEC7A	sequences	were	amplified	for	cloning	into	pVitro2.	 End-point	 PCR	 produced	 cDNA	 bands	 of	 2750	 bp	 and	 1250	 bp	representing	TLR5	 wild	 type	 and	TLR5	 truncated	 sequences	 and	 750,	 620	 and	500	 bp	 representing	 CLEC7A	 isoform	 1,	 2	 and	 4	 (white	 arrows).	 M:	 base	 pair	marker.			The	purified	 cDNA	 sequences	 and	pVitro2	 vector	plasmid	were	 restricted	with	appropriate	 restriction	 enzymes	BglII	 and	XhoI	 (for	CLEC7A	 sequences)	 or	Sall	and	BamHI	(for	TLR5	sequences)	and	the	DNA	sequences	ligated	into	the	vector	plasmid	(Figure	5.6).			
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Figure	5.6	Restriction	and	 ligation	of	pVitro2	vector	plasmid,	CLEC7A	 and	
TLR5	DNA	sequences.	Vector/DNA	combinations.			The	 engineered	 plasmids	 (Figure	 5.6,	 C)	 were	 transformed	 into	 bacteria,	transformants	selected	and	the	plasmids	purified.		Each	plasmid	was	checked	by	restriction	analyses	ie	BglII	and	XhoI	for	CLEC7A	sequences,	and	Sall	and	BamHI	for	 TLR5	 sequences	 to	 confirm	 that	 the	 cDNAs	were	 inserted	 successfully	 and	correctly.	 	These	data	are	shown	 in	Figure	5.7.	Panel	A	 lane	1	shows	a	band	of	750	bp	 representing	CLEC7A	 isoform	1.	Panel	B,	 lanes	2	 and	3	 reveal	 bands	of	620	and	500	bp	representing	isoforms	2	and	4	respectively.	Restricted	plasmids	containing	 wild	 type	TLR5	 and	 truncated	TLR5	 cDNA	 sequences	 are	 shown	 in	Figure	5.7	panel	C	(lanes	4	and	5)	at	2700	bp	and	1200	bp	respectively.		 	
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Figure	 5.7	 Analyses	 of	 pVitro2	 plasmids	 with	 CLEC7A	 and	 TLR5	 cDNA	
insertions.		cDNAs	 of	 interest	 indicated	 with	 an	 arrow.	 Panel	 A	 shows	 CLEC7A	 isoform	 1	(lane	1)	at	750	bp;	panel	B	–	isoforms	2	and	4	(lanes	2	and	3)	at	650	bp	and	500	bp	respectively;	panel	C	–	TLR5	wild	type	gene	and	truncated	form	(lanes	4	and	5)	at	2700	bp	and	1200	bp	respectively.	M:	base	pair	marker.			The	 next	 step	was	 to	 clone	 the	TLR5	 cDNAs	 into	 the	 relevant	 vector	 plasmids	containing	 CLEC7A	 cDNAs.	 For	 example	 the	 pVitro2	 containing	 an	 CLEC7A	insertion	was	restricted	with	Sall	and	BamHI	and	the	wild	type	cDNA	sequence	ligated	into	it		(Figure	5.8).			
	
Figure	5.8	Scheme	of	cloning	TLR5	into	pVitro2	Dectin-1	plasmid.			
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Initially	two	plasmids	were	successfully	engineered	–	pVitro2-(CLEC7A	isoform	1	+	 TLR5	 WT)	 and	 pVitro2-(CLEC7A	 isoform	 1	 +	 TLR5	 SNP).	 Data	 presented	 in	Figure	5.9	 show	pVitro2	plasmids	 containing	CLEC7A	 isoform	1	 and	TLR5	wild	type	(lanes	1	and	2)	or	truncated	TLR5	sequences	(lane	3	and	4).	Plasmid	vector	acted	 as	 the	 control	 (lane	 5).	 The	 2.7	 Kbp	 bands	 in	 the	 lanes	 1	 and	 2	corresponded	to	the	TLR5	wild	type	cDNAs.	The	3.2	Kbp	bands	in	the	lanes	1	-	4	corresponded	to	vector	DNA	plus	CLEC7A	isoform	1	sequences.	This	band	in	the	control	lane	5	was	2.5	Kbp	reflecting	lack	of	CLEC7A	cDNA.	The	3.7	Kbp	bands	in	lanes	1	-	4	represent	a	vector	DNA	and	are	of	comparable	size	in	lane	5.			
	
Figure	5.9	pVitro2	engineered	to	contain	CLEC7A	and	TLR5	cDNAs.		
TLR5	wild	 type	 or	 SNP	 cDNA	 sequences	were	 inserted	 into	 pVitro2	 containing	
CLEC7A	 isoform	1	 cDNA.	The	plasmids	were	digested	with	 restriction	enzymes	
BamHI,	BglII	and	SalI.	Lanes	1	and	2	–	enzyme	restricted	pVitro2	with	 inserted	
CLEC7A	 isoform	 1	 and	 a	 wild	 type	 TLR5;	 Lanes	 3	 and	 4	 –	 enzyme	 restricted	pVitro2	with	inserted	CLEC7A	isoform	1	and	a	truncated	TLR5.	Lane	5	–	enzyme	restricted	pVitro2.	M:	base	pair	marker.			
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Before	 the	 transfection	 procedures	 were	 initiated	 the	 CLEC7A	 and	 TLR5	insertions	 were	 all	 sequenced	 and	 aligned	 to	 predicted	 sequences	 of	 both	receptors	 using	 the	 BLAST	 alignment	 tool.	 These	 alignments	 	 (Figure	 5.10)	confirmed	that	the	CLEC7A	and	TLR5	sequences	in	the	plasmids	were	correct.			
	
Figure	 5.10	 Confirmation	 of	 CLEC7A	 isoform	 1	 and	 TLR5	 insertions	 by	
sequencing	and	alignment.		
CLEC7A	 and	 TLR5	 insertions	 were	 sequenced	 in	 two	 different	 pVitro2	recombinant	 plasmids	 and	 aligned	 to	 predicted	 sequences	 using	 the	 BLAST	alignment	tool.	A	and	B:	alignment	to	a	predicted	sequence	(Sbjct)	of	sequenced	
CLEC7A	and	TLR5	fragments	(Query)	from	plasmid	pVitro2-(CLEC7A	isoform	1	+	
TLR5	WT).	C	and	D	demonstrated	alignment	 to	a	predicted	 sequence	 (Sbjct)	of	sequenced	CLEC7A	and	TLR5	fragments	(Query)	 from	plasmid	pVitro2-(CLEC7A	isoform	1	+	TLR5	SNP).			These	 data	 indicated	 the	 successful	 construction	 of	 a	 recombinant	 plasmid	containing	CLEC7A	and	a	wild	type	or	truncated	TLR5	gene.		
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The	 next	 stage	 was	 to	 repeat	 these	 manipulations	 but	 insert	 a	 wild	 type	 or	truncated	TLR5	 cDNA	 into	 the	 pVitro2	 construct	 containing	CLEC7A	 isoform	4.	Again	two	different	plasmids	were	created		–	pVitro2-(CLEC7A	isoform	4	+	TLR5	WT)	and	pVitro2-(CLEC7A	 isoform	4	+	TLR5	SNP).	Plasmids	were	prepared	and	purified	 as	 previously	 described	 and	 subjected	 to	 analyses	with	 the	 restriction	enzymes	BamHI	and	SalI.	Data	in	Figure	5.11,	lanes	1	and	2	revealed	bands	of	1.2	Kbp	and	2.7	Kbp	bands	that	corresponded	to	the	TLR5	SNP	and	TLR5	WT	cDNAs.	These	 data	 confirmed	 the	 successful	 insertion	 of	 the	 TLR5	 cDNA	 sequences.	cDNA	bands	of	8	Kbp	in	lanes	1	and	2	represented	pVitro2	plasmid	plus	CLEC7A	isoform	4	cDNA.	
	
Figure	5.11	pVitro2	engineered	to	contain	CLEC7A	and	TLR5	cDNAs.		
TLR5	 wild	 type	 or	 TLR5	 SNP	 sequences	 were	 inserted	 into	 pVitro2	 plasmid	containing	CLEC7A	 isoform	4	gene.	The	plasmids	were	digested	with	restriction	enzymes	 BamHI	 and	 SalI.	 Lane	 1	 –	 enzyme	 restricted	 pVitro2	 with	 inserted	
CLEC7A	isoform	1	and	a	truncated	TLR5.	Lane	2	–	enzyme	restricted	pVitro2	with	inserted	CLEC7A	isoform	4	gene	and	a	wild	type	TLR5.			
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The	 purified	 plasmids	 pVitro2-(CLEC7A	 isoform	 4	 +	 TLR5	 WT)	 and	 pVitro2-(CLEC7A	isoform	4	+	TLR5	SNP)	were	verified	by	sequencing	and	these	data	are	presented	in	Figure	5.12.	
	
Figure	 5.12	 Confirmation	 of	 CLEC7A	 isoform	 4	 	 (A	 &	 C)	 and	 TLR5	 cDNA	
insertions	by	sequencing	and	alignment	(B	&	D).		A	 and	 B:	 alignment	 to	 a	 predicted	 sequence	 (Sbjct)	 of	 sequenced	 CLEC7A	 and	
TLR5	fragments	(Query)	from	plasmid	pVitro2-(CLEC7A	isoform	4	+	TLR5	WT).	C	and	 D	 demonstrated	 alignment	 to	 a	 predicted	 sequence	 (Sbjct)	 of	 sequenced	
CLEC7A	and	TLR5	fragments	(Query)	from	plasmid	pVitro2-(CLEC7A	isoform	4	+	
TLR5	SNP).		At	this	point	a	decision	was	taken	to	transfect	the	CLEC7A	isoform	1	and	4/TLR5	plasmids	and	depending	on	the	subsequent	data	 then	decide	whether	or	not	 to	engineer	the	CLEC7A	isoform	2	constructs.				
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 Transfection	of	the	pVitro2	plasmids	into	CHO	cells	5.2CHO	 cells	were	 selected	 to	 overexpress	 and	 examine	 interactions	 between	 the	Dectin-1R	 and	 TLR5	 proteins	 in	 eukaryote	 cells.	 The	 selection	 marker	 was	geneticin	(G418)		(Figure	5.1)	so	before	any	transfections	were	initiated	the	cells	were	 incubated	 with	 increasing	 concentrations,	 50,	 100,	 200,	 300,	 400,	 500	μg/ml	 of	 the	 antibiotic	 G418.	 Fresh	 antibiotic	 was	 added	 every	 two	 days.	However	 the	CHO	cells	 selected	 for	use	were	not	affected	by	 the	antibiotic	and	did	not	die.	These	data	suggested	that	the	CHO	stocks	held	were	mislabelled	as	wild-type	 cells	 and	 had	 previously	 been	 transfected	 with	 a	 plasmid	 carrying	resistance	to	G418.			
 RT4	cells	stably	transfected	with	pVitro2	constructs	5.3
containing	Dectin-1	and	TLR5	cDNAs		Since	 the	CHO	 cells	 available	were	 resistant	 to	G418	 it	was	 decided	 to	 use	 the	bladder	RT4	 cells	 to	overexpress	 the	Dectin-1R	and	TLR5	proteins.	These	 cells	unlike	 CHO	 cells	were	 known	 to	 support	 the	 two	 different	 receptors	 naturally	and	 contain	 all	 the	 signalling	 apparatus	 relating	 to	 the	Dectin1/TLR5	 receptor	collaboration.	These	cells	were	incubated	with	70	μg/ml	of	the	antibiotic	G418	to	select	 transfected	 cells.	 An	 optimal	 concentration	 of	 the	 antibiotic	 was	determined	previously	in	our	laboratory	[157].		In	reporting	subsequent	experiments	and	data	the	plasmid	constructs	containing	the	 cDNAs	 were	 named	 as	 follows:	 pVitro2-(CLEC7A	 isoform	 1	 +	 TLR5	 WT)	 –	“D1T1”;	 pVitro2-(CLEC7A	 isoform	 1	 +	 TLR5	 SNP)	 –	 “D1T2”;	 pVitro2-(CLEC7A	isoform	4	+	TLR5	WT)	–	“D4T1”	and	pVitro2-(CLEC7A	 isoform	4	+	TLR5	SNP)	–	“D4T2”.	The	plasmids	were	stably	transfected	into	RT4	cells	using	attractene	as	described	in	 Section	 42.	 Non-transfected	 RT4	 cells	 died,	 while	 transfected	 cells	 survived	(Figure	5.13).	A	mixture	of	individual	colonies	was	used	for	further	analysis.			
		 105	
	
Figure	5.13	Selection	of	stably	transfected	RT4	cells	with	G418	antibiotic.		RT4	cells	were	transfected	with	pVitro2	plasmid	constructs	and	after	three	days	G418	 antibiotic	 (70	 μg/ml)	 was	 added.	 Transfected	 RT4	 cells	 survived,	 while	non-transfected	–	died	(white	arrows).			Once	stocks	of	the	pooled	transfected	RT4	cells	had	been	banked	genomic	DNA	was	 isolated	(Section	2.7)	to	verify	that	the	plasmid	DNA	had	been	successfully	incorporated	into	the	eukaryote	DNA.	To	facilitate	this	primers,	which	amplified	DNA	 fragments	 at	 the	 junctions	 between	 pVitro2	 and	 the	 receptor	 cDNA	sequences	 were	 used	 (Figure	 5.14	 &	 Table	 5).	 These	 primers	 were	 used	 to	amplify	 plasmid/insertion	 sequences	 from	 the	 genomic	 DNA	 using	 end-Point	PCR	and	the	DNA	products	were	analysed	on	an	agarose	gel.		
200	μm	
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Figure	 5.14	 Schematic	 representation	 of	 End-Point	 PCR	 approach	 to	
confirm	plasmid	insertion	into	RT4	cell	DNA.		A:	Primers	1	R	and	F	were	used	to	amplify	DNA	at	pVitro2/CLEC7A	junction.	B:	Primers	2	R	and	F	were	used	to	amplify	DNA	at	pVitro2/TLR5	junction.			The	 end-point	PCR	data	presented	 in	 Figure	5.15	 lanes	1	 –	4	 shows	 fragments	(400	bp)	amplified	using	Primers	1	F	and	R	(Figure	5.14,	A).	The	expected	size	of	the	 fragments	was	399	bp.	DNA	templates	 in	 lanes	1	and	2	were	genomic	DNA	from	the	cells	transfected	with	D1T1	and	D1T2	respectively,	while	in	the	lanes	3	and	4	the	DNA	templates	were	the	purified	plasmids	D1T1	and	D1T2.		Lanes	6	-	9	show	DNA	bands	(380	bp)	amplified	using	Primers	2	F	and	R	(Figure	5.14,	B).	The	expected	size	of	 the	bands	was	347	bp.	DNA	 templates	 in	 lanes	6	and	 7	 were	 genomic	 DNA	 from	 the	 cells	 transfected	 with	 D1T1	 and	 D1T2	respectively,	while	 in	 lanes	8	–	9	 the	 templates	were	plasmids	D1T1	and	D1T2	respectively.		
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Figure	 5.15	 pVitro2	 plasmids	 containing	 CLEC7A	 and	 TLR5	 genes	 in	
genomic	DNA	of	RT4	cells.		Lanes	1	 –	 4	 shows	 fragments	 (400	bp)	 amplified	using	Primers	1	 F	 and	R	 and	lanes	6	 -	 9	 show	 fragments	 (380	bp)	 amplified	using	Primers	2	F	 and	R.	 	DNA	templates	in	lanes	1,	2,	6	&	7	were	genomic	DNA	from	the	cells	transfected	with	D1T1	and	D1T2	 respectively,	while	 in	 the	 lanes	3,	 4,	 8	&	9	 the	DNA	 templates	were	plasmids	D1T1	and	D1T2.	Lanes	5	and	10	no	 template	DNA.	M:	base	pair	marker.			These	PCR	data	confirmed	that	the	engineered	pVitro2/CLEC7A/TLR5	constructs	were	incorporated	into	the	genomic	DNA	of	the	bladder	RT4	cells.			
 Immunocytochemical	staining	of	transfected	RT4	cells	5.4To	confirm	the	gene	expression	data	and	explore	protein	‘overexpression’	of	the	Dectin-1	and	TLR5	receptors	in	the	transfected	RT4	bladder	cells,	the	cells	were	cultured	 to	 confluence	 and	 immunostained	with	 anti-Dectin-1R	 (R&D	 Systems,	MAB1859)	 and	 anti-TLR5	 (Abcam,	 ab3701)	 primary	 antibody	 Section	 2.16	(Table	3).		Dectin-1R	immunostaining	data	are	presented	in	Figure	5.16.	Panel	A	shows	RT4	cells	 transfected	 with	 empty	 pVitro2	 plasmid;	 panels	 B	 and	 C	 show	 RT4	 cells	transfected	 with	 plasmid	 D1T1	 (B)	 or	 D1T2	 (C)	 respectively	 and	 panel	 D	demonstrates	 RT4	 cells	 transfected	 with	 control	 plasmid	 and	 stained	 with	secondary	antibody	only.	Strong	Dectin-1R	staining	was	observed	in	panel	B	compared	to	panel	A	(control)	suggesting	 that	 the	 D1T1	 transfected	 cells	were	 overexpressing	 the	 Dectin-1R.		However,	Dectin-1R	signal	intensity	in	the	panel	C	cells,	which	were	transfected	
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with	 D1T2	 was	 similar	 to	 that	 of	 panel	 A	 suggesting	 that	 these	 cells	 did	 not	overexpress	the	Dectin-1R.		
	
Figure	5.16	Dectin-1R	immunostaining	of	transfected	RT4	cells.		RT4	cells	transfected	with	pVitro2	plasmids	overexpressing	Dectin-1R	and	TLR5	were	 fixed	 with	 4%	 paraformaldehyde	 and	 incubated	 with	 anti-Dectin-1R	antibody	(1:50)	and	Alexa	Fluor	488	secondary	antibody	(green	colour).	A:	RT4	cells	 transfected	 with	 pVitro2	 plasmid;	 B:	 RT4	 cells	 transfected	 with	 D1T1	plasmid;	 C:	 RT4	 cells	 transfected	with	 D1T2	 plasmid;	 D:	 RT4	 cells	 transfected	with	empty	plasmid	but	stained	with	secondary	antibody	only.		The	 comparable	 transfected	 cells	 immunostained	with	 anti-TLR5	 antibody	 are	presented	in	the	Figure	5.17.	The	cells	in	panel	A	stained	green	indicating	TLR5	receptor	 protein.	 Staining	 of	 panels	 B	 and	 C	 was	 similar	 to	 A	 suggesting	 that	there	was	 no	TLR5	 overexpression	 in	 the	RT4	 cells	 transfected	with	 the	D1T1	and	D1T2	plasmids.	
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	Figure	5.17	TLR5	immunostaining	of	transfected	RT4	cells.		RT4	cells	transfected	with	pVitro2	plasmids	overexpressing	Dectin-1R	and	TLR5	were	 fixed	with	 4%	paraformaldehyde	 and	 incubated	with	 anti-TLR5	 antibody	(1:50)	 and	 Alexa	 Fluor	 488	 secondary	 antibody	 (green	 colour).	 A:	 RT4	 cells	transfected	with	pVitro2	plasmid;	B:	RT4	cells	transfected	with	D1T1	plasmid;	C:	RT4	 cells	 transfected	with	 D1T2	 plasmid;	 D:	 RT4	 cells	 transfected	with	 empty	plasmid	but	stained	with	secondary	antibody	only.		Overexpression	of	CLEC7A	gene	in	the	transfected	cells	was	analysed	using	qRT-PCR.	Data	in	Figure	5.18	shows	that	in	D1T1	cells	CLEC7A	expression	increased	by	3%	±	20%	compared	to	the	control	cells	but	decreased	by	40%	±	20%	in	the	D1T2	cells.	However	the	difference	was	not	statistically	significant	(p=0.5).		
A B 
C D 
Empty	plasmid	 Dct1	isoform	1	+	TLR5	WT	
Dct1	isoform	1	+	TLR5	SNP	 -ve	
50	μm	50	μm	
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Figure	5.18	CLEC7A	expression	in	transfected	RT4	cells	D1T1	and	D1T2.		qRT-PCR	 was	 used	 to	 analyse	 CLEC7A	 expression	 in	 the	 transfected	 RT4	cells.Data	show	mean	±SEM	and	N=2,	n=6.	
	These	 results	 were	 disappointing.	 The	 constructs	 had	 been	 checked	 carefully	before	 their	 transfection	 into	 the	RT4	cells	 therefore	 these	data	 suggested	 that	the	approach	of	using	the	pVitro2	plasmid	to	overexpress	the	Dectin-1	and	TLR5	receptors	 to	examine	Dectin-1R	and	TLR5	physical	and	 functional	 co-operation	was	flawed.	It	was	therefore	decided	not	to	transfect	the	RT4	cells	with	the	D4T1	and	 D4T2	 constructs.	 Additionally	 as	 the	 immunostaining	 was	 comparable	 to	wild-type	RT4	cells	it	was	decided	to	focus	on	using	the	non-transfected	RT4	cell	model	to	examine	the	Dectin1R	signalling	pathways.		
 Discussion	5.5Previous	data	 supported	human	bladder	RT4	 cells	 to	 express	 the	CLEC7A	 gene	and	 synthesise	 Dectin-1R	 proteins	 (Figure	 3.2	 and	 Figure	 3.4)	 particularly	isoforms	 1,	 2	 and	 4.	 Isoform	 1	 represents	 the	 full	 length	 Dectin-1R;	 isoform	 2	does	not	have	an	extracellular	stalk	domain	while	isoform	4	lacks	a	stalk	and	has	a	shorter	carbohydrate	binding	domain	(Figure	1.10).		In	contrast	human	bladder	epithelial	 cells	 express	 one	 TLR5	 isoform	 although	 approximately	 10%	 of	population	carry	a	SNP	1174C>	T	which	encodes	a	STOP	codon	and	results	in	the	synthesis	 of	 a	 truncated	 TLR5.	 Data	 presented	 in	 Chapter	 4	 demonstrated	
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physical	 and	 functional	 co-operation	between	 the	Dectin-1	and	TLR5	receptors	and	 showed	 that	 zymosan	 promoted	 formation	 of	 Dectin-1R/TLR5	 clusters	 in	RT4	epithelial	 cells.	Key	questions	arising	 therefore	related	 to	which	Dectin-1R	isoforms,	either	1,	2,	4	or	all	three	isoforms	participated	in	this	cooperation	and	clustering,	and	whether	carrying	a	truncated	TLR5	receptor	impacts	significantly	on	 this	 co-operation.	 To	 further	 explore	 this,	 stably	 transfected	 RT4	 cell	 lines	overexpressing	 the	 Dectin-1R	 isoform	 1	 and	 either	 the	wild-type	 or	 truncated	TLR5	were	engineered.	
The	 expression	 vector	 chosen	 for	 this	 work	 was	 pVitro2,	 which	 facilitates	 the	universal	and	constitutive	co-expression	of	two	genes	or	cDNAs	of	interest.	The	plasmid	 contains	 two	 human	 ferritin	 promoters,	 FerH	 (heavy	 chain)	 and	 FerL	(light	 chain)	with	 the	 endogenous	 5’UTRs	 replaced	 by	 the	 5’UTR	of	 the	mouse	and	 chimpanzee	 EF-1α	 genes.	 This	 adjustment	 prevents	 any	 interference	 or	regulation	of	expression	due	to	iron.	Driving	the	choice	of	this	promoter	was	the	need	 to	 express	 two	 different	 genes	 at	 same	 time	 and	 initially	 at	 the	 same	concentrations.	The	advantage	of	this	system	was	that	the	resultant	transfected	cell	 model	 would	 carry	 comparable	 numbers	 of	 Dectin-1	 and	 TLR5	 receptors	facilitating	the	interpretation	of	subsequent	data.	The	disadvantage	was	that	the	model	may	not	 reflect	 the	 in	vivo	 situation	although	 there	 is	no	 in	vivo	 data	 to	either	support	or	disprove	equal	numbers	of	receptors	in	bladder	cells.	
It	was	decided	 to	 focus	on	creating	a	 stable	cell	model	 to	provide	reproducible	and	robust	data.	The	original	choice	of	cells	was	CHO	cells	as	 these	are	easy	 to	transfect	 and	 culture.	 However	 as	 these	 proved	 resistant	 to	 the	 selection	antibiotic	G418	it	was	decided	to	utilise	the	original	RT4	cells	for	the	transfection	studies.	The	advantages	of	using	these	cells	were	that	they	transfected	easily.	In	fact	 stable	 transfectant	 lines	 had	 been	 engineered	 in	 the	 laboratory	 previously	[83].	 Additionally	 using	 bladder	 derived	 cells	meant	 the	 cells	 contained	 all	 the	required	endogenous	signalling	apparatus	to	examine	potential	Dectin-1R/TLR5	interactions.	The	disadvantage	was	these	cells	synthesised	endogenous	Dectin-1	and	 TLR5	 receptors	 and	 therefore	 forcing	 over-expression	 of	 these	 receptors	could	stress	and	kill	 the	cells,	which	was	a	significant	risk.	Previous	work	used	mouse	fibroblasts	to	successfully	overexpress	eight	different	Dectin-1R	isoforms	
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[102].	It	could	be	argued	therefore	that	human	fibroblasts	should	have	been	used	to	 overexpress	 the	 human	Dectin-1	 and	 TLR5	 receptors	 although	 as	with	 CHO	cells	 it	 was	 not	 possible	 to	 predict	 whether	 these	 cells	 also	 contained	 the	appropriate	 signalling	 systems	 to	 examine	 potential	 Dectin-1R/TLR5	interactions.		Although	 a	 series	 of	 Dectin1/TLR5	 DNA	 constructs	 were	 engineered	 the	transfection	 experiments	were	 limited	 to	 using	 the	 Dectin-1R	 isoform	 1/TLR5	and	 TLR5SNP	 constructs.	 These	 transfections	 were	 successful	 although	 it	 was	noted	 that	 many	 of	 the	 original	 transfectant	 cell	 clones	 grew	 poorly,	 did	 not	expand	in	cell	numbers	and	died	out.			Molecular	 analyses	 and	 immunostaning	 of	 the	 stably	 transfected	 cell	 lines	supported	 increased	Dectin-1R	expression	 in	 the	Dectin1/TLR5	cells	but	not	 in	the	Dectin1/TLR5SNP	cells.	In	fact	Dectin-1R	signal	intensity	in	the	latter	cell	line	was	 comparable	 to	wild	 type	 cells.	 These	 data	 suggested	 that	 co-expression	 of	truncated	TLR5	 gene	 impacted	on	CLEC7A	 expression	 and	Dectin-1R	 synthesis,	meaning	 that	 the	surviving	cells	selected	and	used	 to	expand	the	cell	 line	were	flawed	experimentally	as	they	had	actually	down-regulated	CLEC7A	expression.	If	this	was	the	case	then	it	probably	explained	the	early	cell	death	of	a	number	of	transfectant	clones.		Interestingly	immunostaining	did	not	support	elevated	levels	of	TLR5	protein	in	either	 cell	 line.	 There	 were	 no	 measurements	 of	 TLR5	 gene	 expression	performed,	which	was	an	experimental	flaw,	and	it	is	recognised	that	this	lack	of	molecular	data	has	impacted	the	ability	to	fully	interpret	and	explain	the	results.	However	the	immunostaining	data	as	presented	suggested	no	overexpression	of	TLR5	 receptors.	 However	 it	 should	 be	 noted	 that	 the	 cells	 when	 stained	 with	antibody	were	not	permeabilised	therefore	increased	intracellular	localisation	of	receptors	may	have	been	missed.		Overall,	these	data	were	disappointing	and	indicated	that	engineering	eukaryote	cell	 models	 to	 explore	 the	 Dectin1/TLR5	 receptor	 interactions	 was	 more	challenging	 than	 originally	 anticipated.	 Simultaneous	 over	 expression	 of	 two	plasma	membrane	receptors	while	defendable	experimentally	probably	needed	
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additional	 finer	 control	mechanisms.	For	example,	 the	pVitro2	promoters	were	constitutive	meaning	the	expression	of	both	genes	was	switched	on	continuously,	therefore	 using	 regulated	 promoters	 e.g.	 T-REx	 may	 have	 provided	 a	 better	experimental	option.		The	 TLR5	 gene	 has	 been	 successfully	 expressed	 in	 eukaryote	 cells.	 Early	experiments	 investigating	 TLR5/Flagellin	 interactions	 involved	 COS-1	 cells	transfected,	 albeit	 transiently,	 with	 the	 TLR5	 gene	 [163].	 Later	 work	 has	 also	shown	 functionally	 active	 TLR5	 receptors	 in	 HEK293	 [164].	 In	 addition	 stably	transfected	TLR5	HEK	cells	are	available	commercially	(Invivogen).	This	suggests	that	 potential	 issues	 linked	 to	 receptor	 protein	 synthesis	 and	 trafficking	 were	probably	not	a	problem	in	this	study	although	the	use	of	different	cells	lines	and	DNA	constructs	means	this	concern	cannot	be	ignored	totally.		In	summary	the	construction	of	DNA	plasmids	engineered	to	allow	co-expression	of	 genes	 encoding	 Dectin-1	 isoform	 1	 or	 4	 and	 wild	 type	 or	 truncated	 TLR5	receptor	proteins	in	eukaryote	epithelial	cells	was	successful.	However,	following	stable	 transfection	 of	 RT4	 bladder	 cells	 only	 overexpression	 of	 the	 Dectin-1	receptor	 ie	 Dectin-1R	 isoform1	 was	 detected.	 Therefore	 new	 approaches	 are	needed	to	create	a	eukaryotic	cell	model	that	allows	dissection	and	further	study	of	Dectin1/TLR5	receptor	interactions.		 	
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Chapter	6 .	Dectin-1R	signalling	in	RT4	cells	
Results	 from	 the	 gene	 knockdown	 and	 proximity	 ligation	 assay	 experiments	presented	 in	 Chapter	 4	 supported	 the	 physical	 interaction	 and	 cooperation	 of	Dectin-1R	 and	 TLR5	 in	 the	 innate	 defence	 of	 the	 urothelium.	 To	 attempt	 to	investigate	 this	 cooperation	 further,	 particularly	 intra-cellular	 signalling	 events	following	 stimulation	 of	 the	 cells	 with	 zymosan,	 in	 vitro	 cell	 models	overexpressing	 the	wild	 type	 and/or	Dectin-1R	 isoforms	 and	wild	 type	 and/or	truncated	 TLR5	 receptors	 were	 engineered.	 However,	 as	 the	 resultant	 RT4	bladder	 cell	 models	 were	 only	 partially	 successful	 it	 was	 decided	 to	 use	 the	original	RT4	cells	to	explore	downstream	signalling	events	focussing	initially	on	the	response	to	a	zymosan	challenge.		It	 is	 known	 from	 work	 using	 myeloid	 derived	 cells	 including	 monocytes,	macrophages	and	dendritic	cells,	that	Dectin-1R	stimulation	results	in	a	number	of	different	effects,	including	phagocytosis,	ROS	production	and/or	the	secretion	of	 pro-inflammatory	 cytokines	 that	 play	 key	 roles	 in	 innate	 defence	 [165].	 As	discussed	 in	 Section	 1.10	 (page	 17)	 studies	 have	 shown	 that	 Dectin-1R	intracellular	signalling	underpinning	such	effects	involves	a	number	of	different	intracellular	 pathways	 (Figure	 1.11),	 with	 the	 canonical	 signalling	 pathway,	 in	these	 antigen	 presenting	 cells,	 being	 Syk	 dependant	 [166].	 In	 this	 pathway	stimulation	 of	 Dectin-1R	 results	 in	 phosphorylation	 of	 tyrosine	 protein	 kinase	Syk	 leading	 to	 the	 activation	 of	 either	 the	 CARD9	 complex	 or	 NF-κB-inducing	kinase	 (NIK),	 both	 of	which	 are	 associated	with	 activation	 of	 the	 IKK	 complex.	Phosphorylation	and	degradation	of	IκBα	releases	NF-κB,	which	translocates	into	the	nucleus	and	activates	the	transcription	of	genes	associated	with	the	Dectin-1R	response.		Signalling	 can,	 however,	 also	 occur	 via	 a	 non-canonical	 pathway,	 or	 Syk	independent	 pathway,	 which	 involves	 activation	 of	 the	 protein	 kinase	 Raf-1	(Figure	 1.11).	 Although	 less	 common	 it	 has	 been	 shown	 that	 activation	 of	 the	Dectin-1R/Raf-1	 signalling	pathway	 in	dendritic	 cells	promotes	 secretion	of	 IL-12	leading	to	the	differentiation	of	T-helper	cells	[111].			
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Previous	work	in	our	laboratory	showed	that	zymosan	challenges	of	vaginal	VK2	E6/E7	and	bladder	RT4	cells	 stimulated	NF-κB	activity	 [83].	Additionally	using	zymosan	challenged	vaginal	VK2	E6/E7	cells	and	western	blotting	of	the	isolated	proteins	 using	 an	 anti-phospho-Syk	 antibody,	 activation	 of	 the	 canonical	 Syk	phosphorylation	intracellular	signalling	pathway	was	proposed	[83].	The	aim	of	this	chapter	was	to	confirm	these	signalling	data	 in	RT4	bladder	epithelial	cells	and	 further	 investigate	 the	 signalling	 cascade	 in	 relation	 to	 Dectin-1R/TLR5	cooperation.		
 	Syk-P	and	Dectin-1R	signalling	cascade		6.1At	the	onset	it	was	predicted	that	the	Dectin-1R	signalling	mechanism	in	the	VK2	E6/E7	 cells,	 in	which	 Syk	 phosphorylation	was	 identified	 following	 a	 zymosan	challenge,	would	also	function	in	the	RT4	bladder	epithelial	cells.	To	confirm	this	the	VK2	E6/E7	zymosan	challenge	experiment	was	repeated	[83],	but	using	RT4	bladder	 cells.	 Essentially	 RT4	 bladder	 cells	were	 challenged	with	 zymosan	 (50	μg/ml)	for	0,	15,	30,	45,	90	and	150	minutes.	The	protein	samples	were	extracted	and	blotted	onto	nitrocellulose	 (Section	2.13)	and	 the	membranes	probed	with	antibody	to	Syk	and	two	anti-phospho-Syk	antibodies	each	directed	against	two	different	phosphorylation	sites	Tyr525/526	and	Tyr323	(Table	2).			Data	shown	in	Figure	6.1	A	&	B	indicated	that	no	phospho-Syk	protein	bands	were	detected	(72	kDa)	following	the	zymosan	challenge.	However,	following	probing	with	antibody	to	Syk	a	72kDa	band	was	detected	in	all	the	samples	(72	kDa).				 	
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Figure	6.1	Immunoblot	of	phosphorylated	Syk	in	RT4	cells	challenged	with	
zymosan	(50	μg/ml).		M	–	molecular	weight	marker.	 Lanes	were	 each	 loaded	with	30	ug/ml	protein.	Lanes	1	and	2	–	non-challenged	RT4	cells;	 lanes	3	and	4	–	RT4	cells	challenged	with	zymosan	(50	μg/ml)	for	15	mins;	lanes	5	and	6	–30	min	challenge,	lanes	7	and	8	–45	min	challenge;	lanes	9	and	10	–	90	min	challenge;	lanes	5	and	6	–150	min	challenge.	A:	phospho-Syk	Tyr525/526;	B:	phospho-Syk	Tyr323;	C:	total	Syk.			
6.1.1 SYK	gene	knockdown	with	siRNA	These	data	were	unexpected	but	the	immunoblots	were	reproducible.	These	data	therefore	 suggested	 that	 Syk	 was	 not	 involved	 in	 the	 Dectin-1R	 intra-cellular	signalling	pathway	 in	RT4	cells.	To	explore	 this	 further	a	knockdown	approach	was	 taken.	 In	 these	 experiments	 SYK	 gene	 expression	 was	 reduced	 via	 siRNA	knockdown	and	the	zymosan	(50	μg/ml)	challenge	experiments	repeated.	ELISA	was	 used	 to	measure	 the	 concentration	 of	 an	 effector,	 in	 this	 case	 IL-8,	 in	 the	bathing	 media.	 Figure	 6.2A	 demonstrated	 that	 expression	 of	 SYK	mRNA	 was	decreased	 by	 95	%	 ±	 2	%	 (p<0.001)	 following	 SYK	 gene	 knock-down	 (siSYK)	when	compared	to	RT4	cells	transfected	with	a	scrambled	siRNA	(scr).	
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Following	 the	 zymosan	 challenge	 the	 concentration	 of	 IL-8	 (effector)	 in	 the	bathing	media	of	 the	wild	 type	RT4	cells	 treated	with	scr	 siRNA	was	 increased	significantly	from	1119	±	141	pg/ml	to	2247	±	95	pg/ml	(p<0.0001)	(Figure	6.2,	B).	 Similarly	 the	 concentration	 of	 IL-8	 in	 the	 media	 bathing	 the	 SYK	 gene	knockdown	cells	increased	significantly	from	898	±	64	pg/ml	to	2474	±	124	pg/	ml	 (p<0.0001).	 These	 data	 suggested,	 therefore,	 that	SYK	 gene	 knockdown	did	not	 impact	 the	 synthesis	 of	 IL-8	 following	 Dectin-1R	 activation	 and	 did	 not	support	 the	 hypothesis	 that	 Syk	 was	 involved	 in	 Dectin-1R	 signalling	 in	 RT4	bladder	epithelial	cells.	These	gene	knock-down	data	supported	the	western	blot	results	reported	in	Figure	6.1.			
	
Figure	6.2	SYK	gene	knockdown	in	RT4	cells.		(A)	The	SYK	gene	was	knocked	down	using	an	siRNA	approach	in	RT4	cells	and	
SYK	 expression	 measured	 using	 qRT-PCR.	 (B)	 siRNA	 treated	 RT4	 cells	 were	challenged	with	zymosan	(50	μg/ml)	for	6	hours	and	ELISA	was	used	to	measure	IL-8	 concentrations	 in	 the	 bathing	 media	 Data	 shows	mean	 ±SD	 and	 N=2.	 ***	p<0.001;	****	p<0.0001		
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6.1.2 Inhibition	of	Syk	with	piceatannol	To	 further	verify	 these	 results	a	 third	approach	was	 taken	 involving	use	of	 the	Syk	 inhibitor	 piceatannol	 [167-170].	 In	 these	 experiments	 RT4	 bladder	 cells	were	pre-treated	with	 the	 inhibitor	at	 concentrations	of	0	μg/ml,	10	μg/ml,	20	μg/ml,	 30	 μg/ml	 and	 100	 μg/ml	 for	 30	 minutes	 and	 then	 challenged	 with	zymosan	(50	μg/ml)	for	6	hours.	These	inhibitor	concentrations	were	chosen	as	they	 had	 been	 shown	 previously	 to	 inhibit	 Syk	 activity	 in	 bronchi,	 endothelial	and	breast	cancer	cells	[167-170].		Media	 bathing	 the	 cells	 was	 collected	 and	 the	 IL-8	 concentrations	 measured	using	ELISA	(Figure	6.3).	Zymosan	challenge	of	the	wild-type	cells	resulted	in	an	increase	in	IL-8	from	911	±	66	pg/ml	in	unchallenged	cells	to	2742	±	394	pg/ml	in	 challenged	 cells.	 IL-8	 bathing	media	 concentrations	 in	 RT4	 cells	 pre-treated	with	piceatannol	concentrations	of	100,	30,	20	and	10	μg/ml	were	2380	±	577,	3008	±	484,	2952	±	324	and	2778	±	419	pg/ml	respectively.		
	 	
Figure	6.3	RT4	cells	challenged	with	Zymosan	following	Syk	inhibition	with	
Piceatannol.		RT4	cells	were	pre-treated	with	Piceatannol	(P)	concentrations	of	10,	20,	30	and	100	μg/ml	 for	30	minutes.	The	cells	were	challenged	with	zymosan	(50	μg/ml)	for	 6	 hours	 and	media	 IL-8	 concentrations	measured	 using	 ELISA.	 Data	 shows	mean	±SD	and	N=2.	
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These	 three	 sets	 of	 data	 using	 western	 blot,	 SYK	 gene	 knockdown	 and	 Syk	inhibitor	 approaches	 all	 suggested	 that	 Syk	was	 not	 involved	 in	 the	 Dectin-1R	signalling	 cascade	 in	RT4	bladder	 cells	 challenged	with	zymosan.	These	 results	contradicted	the	Lanz	data	[83].		
6.1.3 Further	analyses	of	Syk	phosphorylation	in	RT4	cells	It	was	deduced	that	the	signalling	data	was	cell	specific	and	that	the	VK2	E6/E7	data	was	unique	 to	 the	vaginal	 cell	 line.	To	 investigate	 this	 conundrum	 further	the	 zymosan	 challenge	 experiment	 of	 Lanz	 (2013),	 was	 repeated	 exactly	 as	described	 [83],	 but	 also	using	 a	 higher	 concentration	 (200	ug/ml)	 of	 zymosan.	The	 higher	 concentration	 of	 zymosan	 was	 used	 in	 an	 attempt	 to	 trigger	 a	stronger	 signal	 for	 easier	 detection	 of	 phosphorylated	 Syk.	 The	 cells	were	 also	lysed	 in	 RIPA	 lysis	 buffer	 as	 used	 by	 Lanz,	 the	 lysed	 samples	 separated	 using	SDS-PAGE,	 transferred	 to	 a	 nitrocellulose	membrane,	 incubated	overnight	with	anti-phospho-Syk	antibodies	(Table	3),	1	hour	with	secondary	antibody	and	the	membrane	visualised	using	the	Licor	Odyssey	imaging	system.	Data	presented	in	Figure	6.4A	(lanes	1,	2	and	3)	demonstrated,	conclusively,	 that	no	phospho-Syk	was	detected	either	in	non-challenged	or	zymosan	challenged	RT4	cells.		Furthermore,	additional	experiments,	using	pervanadate	treated	RT4	cells,	2	mM	and	 5	 mM	 for	 15	 minutes,	 showed	 the	 detection	 of	 protein	 bands	 relating	 to	phospho-Syk	 Y323	 (72	 kDa)	 (Figure	 6.4,	 A	 lanes	 4	 &	 5).	 Pervanadate,	 is	 an	accepted		stimulant	of	Syk	phosphorylation	[171].	Bands	relating	to	Syk	protein	(72	kDa)	and	β-actin	(42	kDa)	were	also	detected	in	all	samples	(Figure	6.4,	B	&	C).		
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Figure	6.4	Immunoblot	of	Syk	in	RT4	cells	challenged	with	zymosan.		RT4	cells	were	challenged	with	200	μg/ml	of	 zymosan	 for	0,	30	or	60	minutes	(lanes	 1-3)	 and	 pervanadate	 (2	mM	or	 5	mM)	 (lanes	 4	 and	 5)	 for	 15	minutes.	Western	 analyses	 used	 anti-phospho-Syk	 Y323	 antibody.	 The	 immunoblot	represents	two	independent	experiments	(N=2).		In	 summary	 these	 data	 did	 not	 support	 the	 results	 of	 Lanz	 (2013).	 Moreover	these	data	indicated	that	Dectin-1R	signalling	in	RT4	bladder	cells	was	probably	functioning	 via	 a	 Syk	 independent	 pathway,	 which	 suggested	 a	 non-canonical	signalling	pathway.			
 Involvement	of	Raf-1	kinase	in	Dectin-1	signalling		6.2The	non-canonical	pathway	 is	a	Syk	 independent	Dectin-1R	signalling	pathway.	This	 involves	 phosphorylation	 of	 Raf-1,	 NF-κB	 activation	 and	 effector	 gene	expression.	To	investigate	this	pathway	in	zymosan	challenged	RT4	cells	a	siRNA	knock-down	approach	was	taken	in	which	RAF-1	gene	expression	was	targeted.		In	these	experiments	RAF1	gene	expression	was	reduced	via	siRNA	knockdown	and	the	zymosan	challenge	experiments	repeated	(50	μg/ml	for	6	hours).	ELISAs	were	used	 to	measure	 the	concentration	of	 two	effectors,	 IL-8	and	LCN2	 in	 the	bathing	media.	
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Figure	6.5	Raf-1	knockdown	using	siRNA.		The	 RAF1	 gene	 was	 knocked	 down	 using	 an	 siRNA	 in	 RT4	 cells	 and	 SYK	expression	measured	using	qRT-PCR.	Data	shows	mean	±SD	and	N=1.			Knock-down	data	are	shown	in	Figure	6.5	and	revealed	reduction	in	RAF-1	gene	expression	by	53	%	±	11%.	Data	resulting	from	the	challenges	of	the	knock-down	cells	 are	 shown	 in	 Figure	6.6.	 Panel	A	 shows	 the	 IL-8	 concentrations	 following	
RAF-1	 gene	 knockdown	 and	 a	 6h	 zymosan	 challenge.	 The	 mean	 IL-8	concentration	of	the	RT4	cells	treated	with	scr-siRNA	was	937	±	402	pg/ml	and	this	increased	4	fold	to	4148		±	1445	pg/ml	when	challenged	with	zymosan.	The	mean	IL-8	concentration	of	 the	RAF-1	knockdown	RT4	cells	(siRAF-1)	cells	was	858	±	384	pg/ml	and	following	zymosan	challenge	this	increased	3	fold	to	3047	±	848	 pg/ml.	 When	 the	 data	 were	 normalised	 to	 eliminate	 variability	 between	experiments,	the	error	bars	were	decreased	(Figure	6.6	B).	Data	 presented	 in	 Figure	 6.6C	 shows	 the	 LCN2	 data.	 The	 mean	 LCN2	concentration	 in	 the	 non-challenged	wild	 type	RT4	 cell	media	 (scr-siRNA)	was	1365	±	103	pg/ml	and	this	increased	to	2120	±	506	pg/ml	when	the	cells	were	zymosan	 challenged.	 Non-challenged	 RAF-1	 knockdown	 RT4	 cells	 (siRAF-1)	produced	806	±	129	pg/ml	of	LCN2,	which	increased	to	1370	±	211	pg/ml	in	the	challenged	 cells	 (siRAF-1	 +	 Z).	 The	 mean	 LCN2	 concentration	 in	 the	 zymosan	challenged	control	cells	(scr	+	Z)	was	significantly	increased	(p	<	0.01)	compared	
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to	 the	 challenged	 knockdown	 cells	 (siRAF-1	 +	 Z).	 To	 eliminate	 variability	between	experiments	the	data	were	normalised	(Figure	6.6	D).		
	
Figure	6.6	RAF1	knockdown	in	RT4	cells	and	zymosan	challenge.		
RAF1	 was	 knocked	 down	 with	 siRNA	 (siRAF-1)	 and	 the	 cells	 challenged	 with	zymosan	 (50	 μg/ml)	 for	 6	 hours.	 	 IL-8	 and	 LCN2	 media	 concentrations	 were	measured	using	ELISA.	Data	show	mean	±SD	and	N=2.			Interestingly	 the	 mean	 LCN2	 concentration	 in	 the	 non-challenged	 knockdown	cells	 (siRAF-1)	was	 lower	 (40%)	 compared	 to	 the	 non-challenged	 control	 cells	(scr)	 (Figure	6.6,	 C-D).	 These	data	 suggested	 that	RAF-1	 knockdown	decreased	the	constitutive	synthesis	of	LCN2.	These	data	analysing	IL-8	and	LCN2	effector	concentrations	in	RAF1	knockdown	RT4	 bladder	 epithelial	 cells	 supported	 a	 Syk	 independent	 Dectin-1R	 signalling	pathway	functioning	in	RT4	bladder	cells	in	response	to	a	zymosan	challenge.			
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 IkBa	and	Dectin-1R	signalling	6.3Previous	data	from	our	laboratory	using	a	RT4	bladder	NF-κB	reporter	cell	 line	indicated	 that	 zymosan	 challenge	 of	 RT4	 cells	 stimulated	 NF-κB	 signalling	activity	 (Figure	4.1)	 [83].	 In	 the	 absence	of	 a	 stimulus	NF-κB	 is	 bound	 to	 IκBα	which	 inhibits	 or	 blocks	 any	 NF-κB	 activity	 (Figure	 6.9,	 page	 129)	 [172,	 173].	However,	 following	a	stimulus	phosphorylation	of	IκBα	leads	to	 its	degradation	[174,	 175]	 allowing	 NF-κB	 to	 translocate	 into	 the	 nucleus	 and	 activate	 gene	transcription	 [172,	 173].	 To	 further	 investigate	 this	 pathway	 operating	 in	bladder	 epithelia	 in	 response	 to	 zymosan/Dectin-1R	 activation	 confluent	 RT4	cells	were	challenged	with	zymosan	(200	μg/ml)	for	30	and	60	minutes,	the	cell	lysates	 collected,	 electrophoresed	 via	 SDS-PAGE	 and	 western	 blots	 used	 to	analyse	IκBα	and	phospho-IκBα	proteins.	The	antibodies	used	in	these	analyses	are	shown	in	Table	3.	The	resultant	data	are	shown	in	Figure	6.7.	Phospho-IκBα	data	is	shown	in	A.	No	phospho-IκBα	 bands	 were	 detected	 in	 the	 PBS	 challenged	 RT4	 cells	 (lane	 1).	However,	 strong	 bands	 of	 39	 kDa	 were	 detected	 in	 the	 cells	 challenged	 with	zymosan	 for	 30	 or	 60	 minutes	 (lanes	 2	 &	 3).	 Phospho-IκBα	 bands	 were	 also	detected	 in	RT4	 cells	 challenged	with	 flagellin,	 a	 classic	 activator	 of	 the	NF-κB	pathway	(lanes	5	&	6)	[147,	148,	176].				
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Figure	 6.7	 Immunoblot	 of	 IκBα	 and	 phosphorylated	 IκBα	 in	 RT4	 cells	
challenged	with	zymosan.		RT4	cells	were	challenged	with	PBS	(lane	1),	200	μg/ml	of	zymosan	for	30	or	60	minutes	(lane	2	and	3)	or	with	50	ng/ml	of	flagellin	for	30	and	60	minutes	(lane	4	and	5).	SDS-PAGE	was	used	to	separate	proteins	and	immunoblotting	was	used	to	detect	phospho-IκBα	 (A),	 IκBα	 (B)	 and	β-actin	 (C)	proteins.	Data	 shown	are	representative	of	two	independent	and	reproducible	experiments.		These	 western	 blots	 were	 re-probed	 using	 anti-IκBα	 antibody	 (Figure	 6.7B).	These	data	showed	that	IκBα	bands	were	detectable	in	PBS	challenged	cells	(lane	1)	 and	 cells	 challenged	 with	 zymosan	 (50	 ng/ml)	 for	 30	 minutes	 (lane	 2).	However,	when	the	cells	were	incubated	with	zymosan	for	60	minutes	the	IκBα	bands	 were	 weaker	 suggesting	 protein	 degradation	 (lane	 3).	 Similarly	 the	intensity	 of	 the	 IκBα	 bands	was	 also	 reduced	 in	 the	 RT4	 cells	 challenged	with	flagellin	compared	to	PBS	challenged	cells	(lanes	4	&	5).	These	 western	 analyses	 revealed	 that	 zymosan	 challenge	 of	 RT4	 bladder	 cells	stimulated	 phosphorylation	 and	 consequently	 degradation	 of	 IκBα,	 which	supports	 this	 protein	 being	 part	 of	 the	 Dectin-1R	 activated	 intracellular	signalling	cascade.		These	data	provided	 further	 evidence	 that	 in	 zymosan	 challenged	RT4	bladder	cells	 Dectin-1R	 signalling	 involves	 a	 Raf-1	 -	 IκBα	 -	 NF-κB	 pathway,	 which	supports	a	non-canonical	signalling	mechanism.			
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 Discussion	6.4This	 chapter	 investigated	 Dectin-1R	 signalling	 pathways	 in	 immortalised	 RT4	bladder	epithelial	cells.	It	has	been	shown	in	myeloid	derived	cells	that	activation	of	 the	 Dectin-1R	 promotes	 Syk	 phosphorylation,	 which	 promotes	 a	 signalling	cascade	 involving	 NF-κB	 translocation	 into	 the	 nucleus	 and	 transcription	 of	effector	 genes	 involved	 in	 innate	 defence	 [107].	 Defence	 mechanisms	 include	cytokine	synthesis,	ROS	production	and	phagocytosis	[165].	This	is	known	as	the	canonical	 signalling	 pathway.	 However,	 a	 second	 pathway,	 known	 as	 the	 Syk	independent	 or	 non-canonical	 signalling	 pathway	 has	 also	 been	 reported	 in	dendritic	cells.	For	this	pathway	it	has	been	shown	that	Dectin-1R	stimulation	by	in	 response	 to	 curdlan	 and/or	 Candida	 albicans	 phosphorylates	 the	 serine-threonine	protein	kinase	Raf-1,	which	activates	NF-κB	to	promote	the	synthesis	and	 secretion	 of	 cytokines	 including	 IL-12	 that	 facilitates	 T	 helper	 cell	differentiation	 [111].	 This	 suggests	 the	 pathway	 functions	 to	 bridge	 the	 innate	and	adaptive	immune	systems	in	protecting	the	body	against	fungal	infections.			Previous	data	from	our	laboratory,	but	using	vaginal	VK2	E6/E7	cells	suggested	that	 the	 Dectin-1R	 ligand,	 zymosan,	 activated	 the	 tyrosine	 kinase	 Syk	phosphorylation	pathway	[83].	Interestingly	data	exploring	antifungal	immunity	in	 human	 corneal	 cells	 [152]	 and	 intestinal	 cells	 	 [91]	 likewise	 indicated	 Syk	activation	 to	 play	 a	 key	 role	 in	 regulating	 inflammatory	 responses	 to	 fungal	 β-glucans	 in	epithelia.	Therefore	the	aim	of	this	work	was	to	confirm	comparable	Syk	 signalling	 in	 the	 RT4	 bladder	 epithelial	 cells	 and	 explore	 the	 signalling	responses	relating	to	TLR5/Dectin-1R	co-operation.		However,	 despite	 significant	 efforts	 involving	 three	 different	 approaches	 -	western	analyses,	SYK	siRNA	knockdown	and	the	Syk	inhibitor	piceatannol,	used	at	 the	 same	 concentrations	 that	 inhibited	 the	 secretion	 of	 pro-inflammatory	proteins	in	epithelial	cells	[167,	168]	-	the	resultant	data	strongly	suggested	that	Syk	 phosphorylation	 was	 not	 involved	 in	 Dectin-1R	 signalling	 in	 RT4	 bladder	cells.		Lanz,	 in	 his	 work,	 reported	 phospho-Syk	 bands	 on	 immunoblots	 containing		protein	samples	prepared	from	VK2	E6/E7	cells	challenged	with	zymosan	for	15	
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minutes	or	 longer	 and	probed	with	antibody	 to	phospho-Syk	 (Figure	6.8)	 [83].		As	 vaginal	 and	 bladder	 epithelial	 cells	 are	 part	 of	 urogenital	 tract	 these	 data	suggested	that	a	common	signalling	mechanism	may	operate.	However,	the	RT4	data	 presented	 here,	 particularly	 the	 evidence	 using	 pervanadate	 (2	 mM	 or	 5	mM)	a	well-known	activator	of	Syk	phosphorylation	[168],	did	not	support	this.	In	fact	these	data	argued,	strongly,	that	zymosan	treatment	does	not	promote	Syk	phosphorylation	in	RT4	bladder	cells.	To	address	this	enigma	the	original	data	ie	the	 immunoblot	 from	 2013	 was	 retrieved	 and	 reviewed.	 Re-analyses	 of	 the	western	blot	established	that	 the	blot	data	had	been	misinterpreted.	 In	 fact	 the	sizes	of	the	phospho-Syk	bands	detected	were	smaller,	approx.	55	kDa,	than	the	actual	expected	size	of	72kDa.			
	
Figure	6.8	Immunoblot	of	phosphorylated	Syk	in	VK2	cells	challenged	with	
zymosan	[83].		The	size	of	phospho-Syk	bands	presented	in	the	blot	was	misinterpreted	and	was	actually	55	kDa	(p-Syk	is	72kDa).			Re-analysing	 these	 data	 therefore	 helped	 to	 confirm	 that	 Dectin-1R	 activation	and	 signalling	 in	 RT4	 bladder	 (and	 presumably	 VK2	 E6/E7	 vaginal)	 epithelial	cells	does	not	involve	Syk	phosphorylation.	Moreover,	these	new	data	indicated	that	the	non-canonical	signalling	pathway	functions	in	uro-genital	epithelial	cells	in	response	to	a	zymosan	(fungal)	challenge.		Searches	of	the	literature	did	not	reveal	many	reports	of	Raf-1	signalling	during	fungal	 infections,	 although	 one	 paper	 was	 of	 interest.	 This	 paper	 reported	research	 involving	 Candida	 and	 β-1-3	 glucans	 challenges	 of	 human	 primary	
		 127	
mononuclear	 cells	 [177].	 The	 authors	 concluded	 that	 such	 treatments	 can	function	 to	 prime	 these	 cells,	 with	 priming	 leading	 to	 enhanced	 cytokine	production	 when	 the	 cells	 are	 further	 stimulated	 with	 TLR	 ligands,	 LPS	 and	lipopeptides	 eg	 Pam3Cys4,	 and	 intestinal	 bacterial	 commensals	 including	
Bacteroides	fragilis,	Staphylococcus	aureus	and	E.coli	ATCC	35218.	It	is	significant	that	 priming	 involves	 the	 Dectin-1R	 and	 is	 facilitated	 by	 the	 non-canonical	pathway	involving	Raf-1.	However,	the	data	actually	supporting	the	involvement	of	the	Raf-1	pathway	is	weak	as	the	experimental	information	mentions	only	that	a	Raf-1	inhibitor	was	used,	but	does	not	actually	name	the	inhibitor.	This	raises	serious	questions	relating	to	inhibitor	specificity.	Still	these	data,	while	focussed	on	 TLR2/4	 ligands	 and	 myeloid	 derived	 cells,	 are	 comparable	 to	 the	 results	reported	 in	 this	 thesis	 using	 epithelial	 cells	 and	 flagellin.	 However,	 the	 key	difference	is	that	Dectin-1R	signalling	in	response	to	β-1-3	glucan	in	RT4	bladder	epithelial	cells	appears	purely	Raf-1	dependent.	Interestingly,	data	published	by	Trinath	et	al.	(2014),	suggests	that	activation	of	Dectin-1R	 and	 TLR	 pathways	 in	 fungal	 infected	macrophages	 can	 result	 in	 the	inflammatory	 responses	 being	 inhibited	 [178].	 The	 authors	 propose	 a	mechanism	involving	Syk	and	WNT5A	pathways,	and	suggest	that	such	pathways	can	 be	 exploited	 by	 virulent	 fungi	 to	 limit	 and	 therefore	 overcome	 the	 host	responses	to	infection.		More	recent	work	although	again	focussed	on	dendritic	cells	has	shown	Dectin-1R	stimulation	by	curdlan	to	involve	Syk,	Raf-1	and	NF-κB	signalling,	and	result	in	 factors	 TNFSF15	 and	 OX40L	 that	 function	 as	 agonists	 and	 promote	differentiation	 of	 naïve	 CD4	 T	 cells	 into	 anti-tumour	 Th9	 cells	 [127].	 These	authors	 suggest	 a	 role	 for	 the	 Dectin-1Rs	 in	 triggering	 anti-tumour	 activity	although	the	use	of	dendritic	cells	suggests	this	property	may	be	unique	to	such	cells.		Another	 C-type	 lectin	 receptor,	 DC-SIGN,	 has	 been	 shown	 to	 stimulate	 Raf-1	phosphorylation	via	Ras	protein	activation	as	part	of	the	innate	defences	[95].	As	in	 this	 pathway	 NF-κB	 is	 activated	 by	 phosphorylation	 and	 acetylation	 of	 p65	
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subunit	 it	 would	 be	 interesting	 to	 explore	 potential	 roles	 for	 Ras	 protein	activation	in	the	RT4	zymosan/Dectin-1R	signalling	cascade.			Issues	 linked	 to	 confirming	 Syk	 phosphorylation	 in	 the	 RT4	 bladder	 cells	challenged	 with	 zymosan	 meant	 that	 further	 analyses	 exploring	 the	 signalling	events	 relating	 to	 Dectin-1R/	 TLR5	 co-operation	 were	 not	 explored.	 Future	experiments	are	needed	to	examine	these	events.	For	example,	data	reported	by	Lanz	 [83]	 showed	 that	 Dectin-1R	 activation	 stimulated	 NF-κB	 activity.	 In	 the	canonical	 NF-κB	 activation	 pathway	 IkBa	 is	 phosphorylated	 to	 allow	translocation	 of	 NF-κB	 from	 cytoplasm	 into	 the	 nucleus	 to	 activate	 DNA	transcription.	 Western	 blot	 data	 presented	 in	 this	 chapter	 confirmed	 that	zymosan	 stimulation	 of	 the	 Dectin-1R	 in	 RT4	 bladder	 cells	 promoted	phosphorylation	and	degradation	of	IkBa.	However,	these	data	conflict	with	the	data	 linked	 to	 dendritic	 cells,	 which	 showed	 that	 Raf-1	 dependant	 NF-κB	activation	was	due	to	acetylation	of	its	p65	subunit	[111].	These	data	suggest	the	functioning	 of	 different	 Dectin-1R	 intracellular	 signalling	 pathways	 in	 antigen	presenting	and	epithelial	cells,	probably	related	to	the	different	functions	of	the	cells	the	defence	of	the	host,	and	which	need	to	be	unravelled.			In	 summary	 the	 data	 presented	 in	 this	 chapter	 suggests	 a	 novel	 signalling	cascade	 functioning	 following	 zymosan	 activation	 of	 the	 Dectin-1R	 in	 RT4	bladder	epithelial	cells.		To	date	this	cascade	appears	to	be	Syk	independent	and	involves	 the	 protein	 kinase	 Raf-1,	 IkBa	 phosphorylation	 and	 NF-κB	 signalling	(Figure	6.9).		
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Figure	 6.9	 Dectin-1R	 signalling	 in	 bladder	 epithelial	 cells	 is	 Raf-1	
dependent.		Dectin-1R	 upon	 triggering	 with	 zymosan	 activates	 Raf-1,	 which	 initiates	 IκBα	phosphorylation	and	degradation.	This	allows	NF-κB	to	translocate	into	nucleus	and	initiate	transcription	of	defence	molecules.		 	
NF-κB	
NF-κB	
Cytplasm	
Nucleus	
IκB	
P	
degrada7on	
Raf-1	
Dec7n-1	
Zymosan	
P	
		 130	
Chapter	7 .	Summary	and	Final	Discussion	
Approximately	25	to	50%	of	women	will	suffer	an	urinary	tract	 infection	(UTI)	during	 their	 life-time	 and	 many	 of	 these,	 especially	 in	 their	 post-menopausal	years,	 will	 experience	 recurrent	 infections.	 These	 infections	 are	 often	 treated	with	 prophylactic	 antibiotics,	 but	 this	 raises	 significant	 clinical	 and	environmental	issues	due	to	the	development	of	antibiotic	resistant	strains.	As	a	result	there	have	been	significant	efforts	to	understand	bacterial	infections	of	the	human	urinary	tract	with	much	research	centred	on	understanding	the	virulence	factors	that	enable	uropathogenic	E.	coli	(UPEC)	to	ascend	the	urinary	tract	and	cause	disease.	 	The	arguments	 supporting	such	research	are	 that	knowledge	of	bacterial	 virulence	 allows	 the	 development	 of	 novel	 antimicrobial	 therapies.	While	 research	 has	 also	 focussed	 on	 dissecting	 the	 relationship	 between	 host	urothelial	cells	and	UPEC	the	use	of	the	mouse	model	has	complicated	the	story.	Data	from	mice	work	suggest	TLR4	to	be	the	key	receptor	in	detecting	UPEC	[80-82]	 while	 work	 using	 human	 cells	 strongly	 suggests	 TLR5,	 which	 recognises	flagellin,	 to	 be	 the	 key	 pathogen	detector	 operating	 in	 lower	 urinary	 tract	 [83,	84].		The	 importance	 of	 TLR5	 is	 supported	 by	 clinical	 studies	 that	 show	 patients	carrying	 the	 TLR5	 SNP	 C1174T	 synthesise	 a	 truncated	 receptor	 that	 cannot	signal	and	are	more	susceptible	to	recurrent	(r)UTIs		[40,	86].	In	fact,	because	of	the	 truncated	 receptor	 the	 innate	defences	 of	 such	patients	 are	 reduced	which	helps	 to	 explain	 their	 increased	 susceptibility	 to	 rUTIs.	One	 therapeutic	 option	for	such	patients	is	to	try	and	boost	their	own	bladder	innate	defences,	and	one	potential	 mechanism	 in	 females	 involves	 use	 of	 a	 topical	 hyaluronic	 acid	treatment	[155].	Previous	work	in	our	laboratory	suggested	that	urothelial	cells	cultured	in	vitro	expressed	 the	CLEC7A	 gene	 encoding	 the	Dectin-1(R)	 receptor,	which	 binds	 β-glucans,	 a	 component	 of	 fungal	 cell	 wall.	 This	 was	 interesting	 as	 most	 of	 the	published	 Dectin-1R	 literature	 relates	 to	 studies	 performed	 using	 myeloid	derived	 cells	 including	 monocytes,	 macrophages	 and	 dendritic	 cells	 [98,	 120,	129].	At	present	only	a	handful	of	published	papers	reporting	on	this	receptor	in	
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epithelial	 cells	 exist,	 and	which	 relate	 to	 the	 lung,	 gut	 and	 corneal	 tissues	 [90,	130,	 179].	 Work	 in	 the	 laboratory	 also	 hinted	 at	 a	 co-operative	 relationship	between	 the	 Dectin-1	 and	 TLR5	 receptors	 in	 the	 bladder	 that	 enhanced	 the	innate	 response	 of	 the	 urothelial	 cells	 to	 a	 fungal	 challenge.	 This	 observation	therefore	suggested	 that	 the	 innate	response	of	 rUTI	patients	could	be	boosted	using	novel	β-glucan	based	therapies	that	specifically	targeted	the	Dectin-1R.	To	explore	this	further	the	expression	and	function	of	the	Dectin-1R	in	bladder	cells	were	investigated	in	vitro	using	the	immortalised	RT4	bladder	cell	line.				Data	 presented	 in	 chapter	 3,	 analysed	 CLEC7A	 gene	 expression	 and	 Dectin-1R	synthesis	 initially	using	a	human	bladder	biopsy	and	 then	 in	 immortalised	RT4	bladder	 epithelial	 cells.	 These	 data	 revealed	 the	 synthesis	 of	 two	 Dectin-1R	isoforms	in	the	bladder	biopsy,	known	as	isoform	1	and	isoform	2.	Interestingly	in	the	RT4	cells	three	isoforms	1,	2	and	4	were	detected.	The	roles	of	isoform	4	in	fungal	 defence	 are	 not	 known	 although	 work	 using	 myeloid	 derived	 cells	suggests	 that	 only	 isoforms	 1	 and	 2	 are	 able	 to	 bind	 ligands	 [102].	 Closer	inspection	 of	 the	 isoform	 4	 sequence	 suggested	 that	 it	 encoded	 a	 smaller	carbohydrate	 binding	 domain	 and	 a	 shorter	 signalling	 intracellular	 motif	compared	 to	 the	 isoforms	 1	 and	 2.	 Experiments	 attempting	 to	 explore	 the	potential	roles	of	isoform	4	in	the	innate	response	were	designed	and	reported	in	chapter	Chapter	5.	Data	from	the	biopsy	and	in	vitro	work	suggested	that	the	RT4	bladder	cells	were	an	 appropriate	model	 of	 the	 human	 urothelium	 and	were	 used	 in	 subsequent	analyses.	 	Dectin-1R	activation	used	zymosan,	a	yeast	cell	wall	preparation,	and	essentially	this	mimicked	a	fungal	infection.	The	immune	response	was	explored	by	measuring	gene	expression	and	 synthesis	of	 an	array	host	defence	peptides	and	 proteins.	 The	 challenge	 data	 clearly	 showed	 that	 such	 molecules	 to	 be	increased	 in	 the	 challenged	 cells,	 and	 this	 finding	mirrored	 results	 reported	 in	myeloid	cells	[124,	130,	131,	179].	These	results,	together	with	previous	work	in	our	 laboratory	 and	 CLEC7A	 gene	 knockdown	 data	 presented	 in	 chapter	 4,	demonstrated	that	activation	of	the	Dectin-1R	could	evoke	an	immune	response	in	bladder	 epithelial	 cells.	 Importantly	 these	data	 also	 suggested	 that	 targeting	
		 132	
the	 bladder	 Dectin-1R,	 for	 example,	 with	 agents	 mimicking	-glucans	 could	potentially	 boost	 the	 bladder	 innate	 defences	 and	 be	 exploited	 as	 a	 new	 non-antibiotic	based	therapy	to	help	treat	recurrent	UTIs.	However,	 exploitation	 of	 the	 Dectin-1R	 in	 rUTI	 therapy	 for	 all	 rUTI	 patients	remains	 questionable	 because	 of	 data	 suggesting	 co-operation	 between	 the	Dectin-1	and	TLR5	receptors	[83].	This	co-operation	was	confirmed	in	chapter	4	using	 gene	 knock-down	 and	 proximity	 ligation	 assay	 techniques.	 Scientifically	these	 data	 are	 novel	 as	 previous	 studies	 in	 macrophages	 and	 dendritic	 cells	demonstrated	 Dectin-1R	 co-operation	 with	 TLR2	 and	 TLR4	 receptors,	 but	 not	TLR5	 [129,	 180].	 However,	 clinically	 these	 data	 suggest	 that	 knockdown	 or	blocking	 of	 TLR5	 decreases	 the	 potency	 of	 the	 Dectin-1R	 immune	 response.	Therefore	 in	 patients	 carrying	 the	 TLR5	 SNP	 C1174T	 it	 can	 be	 argued	 that	treating	with	a	β-glucan	therapeutic	to	help	boost	the	host	innate	response	will	probably	have	a	reduced	effect.	The	 proximity	 ligation	 assay	 data	 demonstrated	 that	 the	 Dectin-1R	 and	 TLR5	receptors	 interacted	physically	 in	 zymosan	challenged	RT4	epithelial	 cells.	 It	 is	reported	that	TLR5	receptors	bind	flagellin	and	function	by	forming	homodimers	[78,	79]	so	the	idea	of	TLR5	forming	a	‘heterodimer’	with	the	Dectin-1R	is	novel.		It	 is	 known	 that	 TLR1,	 TLR2,	 TLR4	 and	 TLR6	 can	 form	 heterodimers	 in	stimulated	macrophages	 [181],	 and	 that	Dectin-1	 receptors	 form	heterodimers	with	TLR2	 in	macrophages	 following	a	 fungal	challenge	 [182].	 	The	outcome	of	this	co-operation	is	still	debatable,	but	is	known	to	potentiate	the	host	response.	For	example	Dectin-1R	co-operation	with	TLR2	results	 in	an	amplified	 immune	response	 in	 curdlan	 challenged	 dendritic	 cells	 [111].	 The	 Dectin-1	 and	 TLR5	receptors	 were	 also	 observed	 to	 cluster	 (Figure	 4.9).	 Dectin-1R/TLR2	 clusters	have	 been	 shown	 to	 have	 a	 role	 in	 the	 formation	 of	 a	 phagocytic	 synapse	 in	macrophages	[182].	However,	as	bladder	epithelial	cells	do	not	have	a	phagocytic	function	clustering	must	play	a	different	role.		It	 is	 possible	 that	 clustering	 increases	 the	 affinity	 and	 sensitivity	 of	 ligand	binding	and	 is	needed	 to	 initiate	a	 signalling	cascade	as	was	shown	with	T-cell	receptors	 in	 T	 cells	 [183,	 184].	 	 However,	 clustering	 may	 relate	 to	 the	 fungal	
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infection	 per	 se.	 Fungi	 such	 as	 yeasts	 can	 colonise	 tissues	 without	 causing	infection	and	in	such	conditions	the	β-glucan	of	the	fungal	cell	wall	is	masked	by	mannan	(Figure	1.8,	B).	During	infection	hyphae	are	produced	that	expose	the	β-glucan	 of	 the	 fungal	 cell	wall,	which	 is	 detected	 by	 the	Dectin-1	 receptors	 and	triggers	 an	 innate	 defence	 response.	 It	 can	 be	 hypothesised	 that	 the	concentrations	 of	 β-glucan	 during	 the	 initial	 infection	 stages	 are	 low	 therefore	activated	 Dectin-1	 receptors	 clustering	 with	 TLR5	 receptors,	 which	 are	 major	TLR	 receptors	on	 the	bladder	 epithelium,	would	 amplify	 the	 signalling	 cascade	significantly.	 This	 in	 turn	would	 result	 in	 a	 very	 strong	 host	 defence	 response	that	 rapidly	 clears	 the	 infecting	 fungi	 (Figure	 7.1).	 Interestingly,	 molecular	analyses	of	RT4	bladder	cell	RNA	did	not	identify	the	expression	of	the	CLEC4N	gene,	 encoding	 Dectin-2	 receptors,	 even	 following	 a	 α-mannan	 challenge	 (data	not	shown).				Experiments	 to	 explore	 this	 idea	 further,	 in	 addition	 to	 investigating	 the	individual	 roles	 of	 Dectin-1	 receptor	 isoforms	 1,	 2	 and	 4	 in	 the	 co-operation/signalling	events,	were	designed	and	presented	in	chapter	Chapter	5.	These	involved	engineering	a	suite	of	cell	lines	each	over-expressing	the	Dectin-1	receptor	 isoforms	 and	 either	 TLR5	 full-length	 or	 TLR5	 truncated	 receptors.	However,	 the	 outcomes	 were	 disappointing	 as	 the	 over-expression	 approach	appeared	 to	 stress	 the	 cells,	 resulting	 in	 the	 cell	 lines	 being	 selected	 and	passaged	 that	 did	 not	 over-express	 the	 Dectin-1	 and	 TLR5	 receptors.	 This	experimental	 approach	 used	 a	 vector	 that	 co-expressed	 the	 two	 different	receptor	 genes	 simultaneously.	 It	 could	 be	 argued	 therefore	 that	 the	 increased	number	 of	 receptors	 synthesised	 by	 the	 cell	 over-loaded	 the	 urothelial	 cell	membranes	causing	gene	silencing	and/or	cell	death.			Several	other	approaches	have	been	discussed	 to	continue	 this	work	 involving	either	 the	use	of	different	expression	 vector	 systems	 and/or	 the	 use	 of	 isoform	 specific	 knockdowns	 and	isoform	specific	antibodies.		The	 final	part	of	 this	project	presented	 in	chapter	Chapter	6	was	 to	 investigate	the	Dectin-1R	signalling	pathway	in	RT4	epithelial	cells	in	response	to	a	zymosan	challenge.	 Studies	 in	 monocytes,	 macrophages,	 dendritic	 cells	 and	 corneal	epithelial	cells	all	identified	a	Syk-dependent	pathway	as	the	canonical	signalling	
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pathway	[131]	that	activated	NF-κB	mediated	gene	transcription	of	host	defence	peptides	 and	 proteins.	 However,	 western	 analyses	 using	 anti-phospho-Syk	antibodies,	 use	 of	 the	 Syk	 inhibitor	 piceatannol	 and	 SYK	 gene	 knock-down	 all	suggested	that	the	Syk	canonical	pathway	did	not	mediate	Dectin-1R	signalling	in	RT4	 bladder	 epithelial	 cells.	 Instead	 the	 data	 supported	 a	 non-canonical	signalling	pathway	involving	Raf-1	and	similar	to	that	reported	in	dendritic	cells	[111].		This	 result	 was	 not	 expected,	 but	may	 reflect	 differences	 in	 bladder	 epithelial	cells	compared	to	myeloid	derived	cells.	For	example	macrophages	and	dendritic	cells	 are	migratory,	 can	 perform	phagocytosis	 and	 often	 bridge	 the	 innate	 and	adaptive	 immune	 systems.	 In	 contrast	 epithelial	 cells	 are	 fixed	 and	 as	 a	 first	defence	mechanism	 need	 to	 synthesise	 and	 secrete	 host	 defence	 peptides	 and	proteins	that	kill	microbes	directly	and	attract	antigen	presenting	cells	to	the	site	of	 infection.	 It	 is	 therefore	 probable	 that	 the	 signalling	 cascade	 using	 Raf-1	 is	activated	 in	 direct	 response	 to	 fungal,	 β-glucan,	 ligands.	 The	 data	 in	 this	 study	suggested	 that	 physical	 interaction	 of	 Dectin-1R	 with	 TLR5	 enhances	 the	response	(Figure	7.1).	However	composition	of	Dectin-1R/TLR5	complex	has	not	been	 revealed.	Moreover	 although	 it	 has	been	 shown	 that	Dectin-1R	physically	interacts	 with	 other	 toll-like	 receptors	 [143],	 no	 data	 has	 been	 published	demonstrating	stoichiometry	of	the	complexes.	Interestingly,	challenging	the	RT4	urothelial	 cells	 with	 pervanadate,	 which	 is	 associated	 with	 the	 production	 of	reactive	oxygen	species	(ROS),	resulted	 in	production	Syk-P.	 It	has	been	shown	that	 ROS	 affect	 kinases	 and	 phosphorylation	 of	 various	 targets	 in	 the	 NF-κB	signalling	 pathway	 [185].	 Therefore	 these	 data	 suggest,	 potentially,	 that	 ROS	produced	 during	 a	 fungal	 infection	 work	 independently	 of	 Dectin-1R/TLR5	complex	and	are	detected	via	a	Syk-P	signalling	pathway,	which	in	turn	helps	to	amplify	the	epithelial	host	defence	response	(Figure	7.1).	Future	experiments	are	needed	to	explore	these	hypotheses	further.			
		 135	
	
Figure	7.1	Dectin-1R	in	bladder	epithelial	cells.		
-glucans	 stimulate	 Dectin-1R	 and	 activate	 Raf-1	 signalling	 pathway,	 which	activates	 NF-κB	 to	 stimulate	 host	 immune	 response.	 Physical	 interaction	 of	Dectin-1	 with	 TLR5	 strengthens	 the	 response.	 ROS	 activates	 Syk	 pathway	independently	of	Dectin-1R	and	toll-like	receptors	and	amplifies	the	response	to	a	fungal	infection.			In	 conclusion	 data	 presented	 in	 this	 thesis	 suggest	 that	 Dectin-1Rs	 are	synthesised	 by	 urothelial	 cells	 and	 play	 a	 significant	 role	 in	 the	 defence	 of	urothelium	 against	 fungal	 infection.	 Dectin-1R	 signalling	 involves	 a	 Raf-1	signalling	 cascade	 and	 the	 receptors	 appear	 to	 co-operate	 in	 the	 signalling	process	with	TLR5	receptors.	These	data	 are	 exciting,	 but	 further	 analyses	 of	 the	Dectin-1	 receptor	 isoforms	synthesised	by	the	bladder	epithelia,	their	co-operation	with	TLR5	receptors	and	the	signalling	cascades	that	underpin	the	observed	host	responses	are	necessary	to	help	unravel	the	roles	these	receptors	play	in	defending	the	uro-genital	tract	from	 infection.	 These	 data	 also	 suggest	 that	 a	 future	 β-glucan	 based	 therapy	might	be	 successful	 in	boosting	 the	host	defence	 response	of	patients	 suffering	rUTIs,	 although	 it	 may	 be	 less	 effective	 in	 patients	 carrying	 the	 TLR5	 SNP	C1174T.		 	
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